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ABBREVIATIONS
Abbreviations used in this thesis are those recommended in the 
Biochemical Journal Instructions to Authors (revised 1978), with the 
following additions :
General
ABC Antigen binding cell(s)
BL Burkitt's Lymphoma
BSA Bovine serum albumin
CHO Carbohydrate, Carbohydrate Moiety
EC, IC Extracellular, Intracellular
fl Fluorescent
H-2 Murine Major Histocompatibility Complex
HLA Human Major Histocompatibility Complex
LPS Lipopolysaccharide (B-cell mitogen)
MLR Mixed lymphocyte reaction
NP-40 Nonidet P-40 (nonionic detergent)
PAGE Polyacrylamide gel electrophoresis
PBS , Phosphate buffered saline
poly (A)^ RNA RNA species containing poly(A) sequences 
at their 3' termini, functionally equiv­
alent to mRNA in this study
RER, SER Rough, Smooth endoplasmic reticulum
SDS Sodium dodecyl sulphate
T,G,A-L A synthetic polypeptide antigen
3D-TKM 3-Detergent, Tris-potassium-magnesium 
buffer
Chemicals
DATD
DEAE
DEP
DMSO
DNP
DTT
EACA
HEPES
lAA, lAM
PCA
PMSF
PPO
TCA
TEMED
TLCK
Diallyltartardiamide
Diethylamino ethyl
Diethyl pyrocarbonate
Dimethyl sulphoxide
Dinitrophenyl
D ,L-Dithiothreitol
e-Amino-n-caproic acid
N-2-Hydroxyethylpiperazine-N'-2- 
ethanesulphonic acid
lodoacetic acid, lodoacetamide
Pyrrolidone carboxylic acid
Phenylmethylsulphonyl fluoride
Diphenyloxazole
Trichloroacetic acid
N,N,N’,N'-Tetramethyl-ethylenediamine 
N-Tosyl-L-lysine chlororaethyl ketone
Serological
Ig, cig, sig
IgX
H, L-chain 
V, C-region 
C, N-terminal
F(ab), F(ab)', F(ab)^, 
Fc, Fd
GARIgG, GARIg 
NoRIgG
RAHIgA, RAHIgG, 
RAHIgM
Immunoglobulin, cytoplasmic Ig, 
cell surface Ig
Immunoglobulin of a nonspecified class
Immunoglobulin Heavy, Light chains
Immunoglobulin Variable, Constant regions
Carboxy, Amino terminal ends of a 
polypeptide chain
Immunoglobulin H-chain or H+L-chain 
fragments produced by specific proteolytic 
cleavage
Goat anti rabbit immunoglobulin G 
Normal rabbit immunoglobulin G 
Rabbit anti human IgA, IgG, IgM
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SUMMARY
Considerable interest is attached to the biochemical events which 
characterize B-lymphocyte gene expression and differentiation. The 
expression of Ig is central to these processes. Among the events 
which are important for an understanding of Ig expression are: 1) the
mode of integration of H-chain V and C-region genes, 2) the expression 
of Ig H-chain genes during isotype diversification, 3) the mode of 
surface binding and signal transmission of the several receptor isotypes, 
4) the pathways which regulate the expression of cell surface and 
secretory Ig, and 5) the mechanisms involved in amplification of Ig 
synthesis. Many of these processes can be studied at the level of the 
unstimulated B-lymphocyte. However, model systems of homogeneous 
B-lymphocyte cell lines have only recently been considered for detailed 
biochemical analyses.
The aim of this thesis work was first to characterize a series of human 
lymphoma and lymphoblastoid cell lines with respect to Ig expression. It 
was hoped that these cell lines would be characteristic of a series of 
early stages in B-cell differentiation. Secondly, using these cell lines 
as model systems, an investigation was undertaken to determine the cell 
surface binding and biosynthetic pathway of cell surface associated Ig.
Many of the lymphoma cell lines investigated were found to synthesize 
predominantly cell surface IgM (sIgM), with varying degrees of IgM 
secretion as well. One lymphoma cell line (U698M) coexpressed cell 
surface IgM and IgD. Another cell line (Raji) synthesized IgM, but 
secreted none, and deposited very little on the cell surface. The
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lymphoblastoid cell lines synthesized and secreted IgM, with very little 
surface deposition. One lymphoblastoid cell line (Bec-11) secreted IgG 
and retained a significant quantity of IgG on the cell surface. It was 
concluded that these cell lines were analogous in their Ig expression to 
many of the cell types described in B-cell ontogeny and during mitogen 
stimulation.
SDS-PAGE analysis of cell surface and secretory IgM jJ-chains revealed 
a reproducible relationship in the molecular sizes of the isolated chains. 
Cell surface y-chains were found to be larger than either secretory or 
intracellular y-chains from IgM secreting cells. Cell surface IgG from 
Bec-11 cells was also found to have a larger y-chain than its secreted 
counterpart.
The basis for the y-chain size differences was further investigated in 
light of previous reports of the same phenomenon, and of a current 
hypothesis that cell surface y-chains may have a C-terminal extra hydro- 
phobic sequence for integral membrane binding. Evidence was obtained 
which strongly supports this hypothesis. Thus, the higher molecular 
weight y-chain (putative surface form) was shown by carboxypeptidase 
digestion to have a different C-terminal amino acid residue than secretory 
y-chain. This was the first actual correlation of a C-terminal diff­
erence with the higher molecular weight form of y-chain.
A working hypothesis, that retention of the putative N-terminal precursor 
sequence on surface y-chains was involved in membrane binding, was also 
tested. This hypothesis was disproved on the basis of N-terminal micro­
sequencing analysis (performed in collaboration with Dr. Donald Capra),
xxri
which indicated the presence of unblocked N-terminal sequences
on both Daudi and Raji cell surface y-chains. However, evidence was 
obtained which suggested a less efficient processing of N-terminal 
precursors in nonsecretory cells.
Further analysis of the Ig H-chains (and L-chains) from nonsecretory 
and secretory cells was carried out by comparative SDS-PAGE of the 
mature cellular products, and their nonglycosylated and cell-free 
synthesised counterparts. This analysis revealed that the size 
difference which related to surface deposition or secretion was the 
property of the polypeptide chains, and not the carbohydrate moieties. 
However, evidence for variable glycosylation of the nonsecretory y-chains 
was obtained. There was no reason to conclude that this variable 
glycosylation was involved in surface deposition or secretion of the 
IgM molecules.
SDS-PAGE analysis of nonglycosylated surface y-chains from Daudi and 
Raji cells revealed both the surface and secretory forms to be present 
in a characteristic ratio for each cell line. I^ vitro synthesis of 
y-chains from these cell lines also revealed the two forms in similar 
relative proportion. It was concluded that these y-chain forms are 
encoded by separate messenger RNA species, differing from one another 
by the presence or absence of a sequence coding for the C-terminal 
extra peptide. An hypothesis is proposed which integrates this concept 
into the current understanding of the biosynthetic pathways leading to 
Ig secretion and surface deposition.
Routine radioiodination and immunoprécipitation of sIgM from Daudi cells
X X l l l
revealed the presence, by SDS-PAGE, of a polypeptide chain (p33) in 
an unusual covalent association with the sIgM. Analysis of the size, 
radioiodination characteristics, SDS-PAGE behaviour, cysteine content, 
and isoelectric focusing spectrum of this polypeptide was carried out. 
The results clarified earlier reports which considered this component 
to be an unusual E-chain. Instead, it has been proposed based on these 
findings that p33 may represent the Daudi antigen heavy chain. Some 
preliminary serological evidence is cited in support of this proposition. 
The idea of the Daudi I antigen heavy chain being in covalent assoc­
iation with its sIgM is discussed in the light of the known aberrant 
expression of HLA molecules by this cell line.
X X I V
INTRODUCTION
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1. CELL SURFACE IMMUNOGLOBULIN AS THE B-LYMPHOCYTE ANTIGEN RECEPTOR
1.1. Clonal Selection and the Receptor Hypothesis
Ehrlich (1900) first proposed the idea that precursors of antibody 
secreting cells possessed a specific receptor for antigen.
Ehrlich's model further proposed that this antigen receptor was a 
cell surface bound form of the antibody molecule itself. It was not 
until over fifty years later, however, that Ehrlich's original concepts 
were returned to. The selection theories (Jerne, 1955; Talmage, 1957) 
were the earliest attempts to restate and amplify Ehrlich's original 
hypothesis in the light of the existing experimental evidence. The 
Clonal Selection Theory of Acquired Immunity (Burnet, 1959) was the 
first comprehensive statement of these ideas. According to the theory, 
each precursor cell, or small lymphocyte, is precommitted to the synthesis 
of only one specific antibody. This precommittment is expressed by the 
lymphocyte in that it possesses surface receptors of only this one 
specific type, which are capable of binding to a complementary antigen. 
Upon interaction of these receptors with antigen, the precursor cell 
becomes stimulated to rapid clonal expansion and the progeny cells in 
the clone undergo differentiation to increased synthesis and secretion 
of the specific antibody molecule. Ehrlich's model indicating the Ig 
nature of the antigen-specific receptor was amplified into the 
Receptor Hypothesis (Mitchison, 1969).
Clonal Selection and the Receptor Hypothesis are now supported by ample 
■evidence. They explain in a general sense the process by which 
B-lymphocytes, which are the subset of small lymphocytes responsible 
for the production of humoural antibody (Claman & Chaperon, 1969;
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Miller & Mitchell, 1959), respond to foreign antigens. The evidence 
supporting clonal selection and the receptor hypothesis has developed 
along several lines. Thus, it has been shown that: 1) B-lymphocytes
possess receptors for antigen, 2) B-lymphocytes have readily detect­
able sig, and 3) the sig and the antigen receptor are the same 
molecule. In addition, it has been shown that interactions which 
affect antigen receptors or sig also affect immune system function 
in ways which would be predicted from the Clonal Selection Theory.
1.2. Detection of Antigen Binding Cells
To investigate the nature of lymphocyte-antigen interaction, early 
efforts were directed at the detection of antigen binding cells (ABC) 
and the elucidation of their functional roles in the immune system.
1.2.1. The Use of Particulate Antigens
The adherence of large particulate antigens to lymphoid cells was the 
earliest recognized method of directly visualising antigen binding. 
These studies used as antigens either bacteria (Hayes et al., 1951; 
Mâkelâ & Nossal, 1961; Russel & Diener, 1970) or erythrocytes (Nota 
et al., 1964; Zaalberg, 1964); the latter technique, referred to as 
'rosette formation', found by far the most general application. Thus, 
rosette forming cells (RFC) could be detected in the lymphoid tissues 
of both immunised and unimmunised animals, using either heterologous 
erythrocytes or homologous erythrocytes coated with various soluble 
antigens, including proteins, polysaccharides and haptens (reviewed 
by Bach, 1973).
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1.2.2. The Use of Radiolabelled Antigens to Enumerate ABC
The use of radiolabelled soluble antigens to detect ABC has been 
extensively studied in several laboratories (Byrt & Ada, 1969; 
Sulitzeanu & Naor, 1969; Ada et al., 1970; Dwyer & Mackay, 1970; 
Humphrey & Keller, 1970). In the original studies of Naor &
Sulitzeanu (1967), radiolabelled BSA and autoradiography were used 
to enumerate BSA-reactive cells in normal mouse splenocytes. It was 
found that 0.3/1000 cells bound the radiolabelled antigen. Other 
studies using similar techniques have established the proportion in 
the lymphoid tissues of ABC for a variety of antigens (reviewed by 
Warner, 1974). The low amounts of specifically antigen-reactive cells 
in the normal lymphoid tissues, i.e. 0.002 to 0.07% or an average of 
about 25,000/spleen (Warner, 1974), are consistent with the predictions 
of the Clonal Selection. Theory.
1.2.3. Other Methods of ABC Detection
Several alternative methods of detecting ABC have been developed. 
Enzyme antigens, such as g-galactosidase, have been used and the 
ABC detected by the action of the enzyme on its substrate (Miller 
et al., 1971; Sercarz et al., 1971). Columns of antigen-coated beads 
have been used to selectively deplete ABC from lymphoid cell 
populations (Wigzell & Andersson, 1969; Wigzell, 1970).
1.2.4. Significance of ABC in the Immune Response
In addition to the detection and enumeration of ABC, studies using 
either the RFC technique or radiolabelled soluble antigens have 
demonstrated that these techniques are: 1) antigen specific, 2) that
binding can be blocked by excess unlabelled antigen, 3) that one cell
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binds only one antigen, and 4) that immune animals often show a 
pronounced increase in numbers of ABC (reviewed by Roelants, 1972).
It has been further demonstrated that at least some ABC are precursors 
of antibody secreting cells. Thus, in the original experiments of 
Ada & Byrt (1969), it was shown that normal splenocytes which were 
previously subjected to highly radioactive (125-1) flagellin were 
unable to produce a specific anti-flagellin response when transferred 
to syngeneic lethally-irradiated mice. It was concluded that the 
antigen-reactive lymphocytes had been killed by radioactive damage, 
by virtue of their having bound the labelled antigen. Similar such 
'antigen suicide' experiments were performed in other laboratories 
using, for example, fowl y-globulin (Basten et al., 1971) or the 
synthetic antigen T,G,A-L (Humphrey & Keller, 1970; Humphrey et al., 
1971). Unanue (1971 ) showed that antigen suicide could be induced 
with bone marrow cells as well, indicating the presence of some ABC in 
this less-differentiated lymphocyte population.
1.3. Detection of sig on Lymphoid Cells
The readily detectable presence of sig on antigen binding cells 
provided early circumstantial evidence for postulating the antigen 
receptor to be sig. Various methods, both direct and indirect, have 
established the presence of sig on lymphoid cells. At the core of 
these methods is the use of specific anti Ig reagents to bind to the 
sig. This approach has required careful consideration of the follow­
ing sources of erroneous results: 1) lack of antiserum specificity,
2) binding of aggregated Ig to cellular receptors, and 3) the 
possibility that the sig detected was cytophilic Ig and not native 
to the cells it was detected on. Many methods have been used to
-5-
detect sig on lymphoid cells (Warner, 1974). In the following 
sections, only the use of fluorescent antibody will be reviewed, as 
this method has become widespread and has contributed greatly to the 
characterisation of sig.
1.3.1. Direct Visualisation by Fl-anti Ig Binding
The use of fluorescent (fl) labelled antibody was first introduced 
by Moller (1961) in studies of the mouse H-2 surface antigens.
Moller noticed the staining of some cells with fl-anti mouse Ig even 
in the absence of sandwiched anti H-2, and suggested that this was 
due to the presence of sig on the mouse lymphocytes. Raff and 
coworkers (Raff et al., 1970) characterised the technique with respect 
to the quantitative and qualitative factors which influence fl-anti­
body binding. Subsequently, fl-antibody has been used in many 
studies to determine both the proportion of sig-bearing cells and 
the class distribution of sig in the lymphoid tissues. In addition, 
f1-antibody has been used to: 1) detect the presence of different
classes of sig and cytoplasmic Ig (Pernis et al., 1970) or sig only 
(Pernis et al., 1971) on the same cell; 2) to demonstrate the 
membrane distribution and movement of sig molecules (see below);
3) to show that sig H and L-chains are associated (Takahashi @t all , 1971) 
and 4) to show that sig and antigen-specific receptors co-cap in 
the lymphocyte membrane (Raff et al., 1973).
1.3.2. Detection of Patch and Cap Formation with Fl-anti Ig
The reaction of fl-anti Ig on mouse lymphoid cells was observed to 
yield a characteristic 'patch* formation caused by apparent clumping 
of Ig determinants in the plasma membrane (Pernis et al., 1970).
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This was originally thought to reflect the distribution of sig in 
the membrane, however further investigations in which monovalent 
fl-F(ab) antibodies were used (Loor et al., 197 2; Taylor et al.,
1971; dePetris & Raff, 1973) showed only a diffuse pattern of labelling. 
These latter findings were interpreted to indicate that the distribution 
of sig was in fact diffuse, and that patching was only induced by the 
crosslinking effect of divalent antibody. The patching of sig 
determinants was shown, in metabolically active cells, to be followed 
by 'capping' of these determinants to one pole of the cell (Raff, 1970). 
Investigations from many laboratories (Taylor et al., 1971; Loor et al., 
1972; dePetris & Raff, 1972; Unanue et al., 1973) have established 
that capping is linked to microfilament activity. The 'patching 
to capping' phenomenon is one of the most important observations to 
be considered in concepts of lymphoid cell membrane dynamics 
(Singer, 1974).
1.3.3. Lymphocyte Stimulation with anti Ig
In an important series' of experiments, it was first demonstrated 
that blast transformation and stimulation of DNA synthesis occurred 
in lymphocytes treated in vitro with antiserum to Ig determinants.
The original studies showed that either anti L-chain allotype 
(Sell & Gell, 1955) or anti class specific heteroantisera (Sell,
1967) could stimulate rabbit lymphocytes in culture. These and 
other similar studies not only indicated the presence of sig on 
lymphocytes, but also demonstrated important aspects about the class 
representation on sig and the requirements for lymphocyte stimulation. 
Thus, anti L-chain antisera was shown to stimulate human lymphocytes 
(Greaves et al., 1969) and to be generally more effective than class
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specific anti H-chain antisera (Greaves, 1970). In both human and 
rabbit cultures, F(ab) or F(ab)' fragments of anti Ig antibody do not 
stimulate (Greaves et al., 1969; Fanger et al., 1970), whereas P(ab)'2 
fragments do stimulate (Fanger et al., 1970; Froland & Natvig, 1970), 
indicating a requirement for multipoint binding or crosslinking in 
the membrane.
1.3.4. Quantitation of sig
Various methods of quantitating sig on homogeneous populations of 
lymphoid cells have been developed. The technique of haemagglutination 
inhibition was first applied by Klein et al. (1970) to quantitate
sIgM on human lymphoid cell lines. This technique was developed into 
a useful routine method for the qualitative and quantitative determin­
ation of sig on lymphoblastoid cell lines (Steel et al., 1974). 
Radioimmunoassay techniques have also been used on human (Lerner 
et al., 1971) and mouse (Rabellino et al., 1971) lymphoid cells. Cell 
surface iodination by the lactoperoxidase technique (Marchalonis et al., 
1971) has also been used to quantitate sig, but has found much wider 
application in the biochemical analysis of isolated sig (discussed 
below).
1.4. Correlation of sig with the Antigen Specific Receptor
The ABC detecting techniques described above demonstrated the presence 
of antigen receptors on lymphoid cells, and the various techniques 
using anti Ig binding have demonstrated the presence of Ig on the 
surface of these cells. One major approach to determining whether 
the antigen receptor and sig are the same molecule has been to attempt 
to interfere with antigen binding or B-lymphocyte function using 
anti Ig antisera.
1.4.1. Blocking of Antigen Binding with anti Ig
Pretreatment of ABC with anti Ig has generally shown that virtually 
all ABC are inhibited (Byrt & Ada, 1969; Warner et al., 1970; Dwyer & 
Mackay, 1970 and reviewed by Warner, 1974), In contrast, pretreatment 
with anti lymphocyte serum (Ada, 1970; Walters & Wigzell, 1970;
Roelants et al., 1973) or anti H-2 serum (Hammerling & McDevitt, 1974) 
does not inhibit antigen binding. Studies of this kind also provided 
early evidence for the H-chain class of antigen receptors. Thus it was 
shown (Warner et al., 1970; Dwyer & Mackay, 1970) that only anti L-chain 
or anti y gave significant blockage of antigen binding, indicating that 
the major class of cell surface antigen-binding Ig was IgM.
Anti Ig blocking of ABC was open to the criticism that it may be 
detecting mere steric hinderance of the antigen receptor, and not 
indicating that surface Ig and the receptor are the same molecule 
(Marchalonis, 1975). However, the demonstration that receptors and 
surface Ig co-capped in the lymphocyte membrane (Raff et al,, 1973), whereas 
most other surface molecules move independently, provided convincing 
evidence against steric hinderance as an explanation of blocking.
1.4.2. Blocking of B-Lymphocyte Function with anti Ig
The binding of anti Ig to ABC has also been shown to interfere with 
the transfer of immunity into lethally irradiated syngeneic mice 
simultaneously injected with antigen (Mitchison, 1967; Warner et al.,
1970; Takahashi et al., 1971). In addition, inhibition with anti Ig 
sera of primary in vitro responses to sheep erythrocytes has been 
reported by various groups (Fuji & Jerne, 1969; Greaves, 1970; Lesley 
& Dutton, 1970; Warner & Dwyer, 1971). In other investigations of
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anti Ig blocking Pierce et al. (1972a, 1972b, 1973) showed that
treatment of unprimed cells with anti y suppressed responses of all 
Ig classes, whereas anti and y^ suppressed only IgG^ and 
responses, and anti a suppressed only IgA responses. In primed cells, 
anti y suppressed only IgM and IgA responses and anti y^ and y^ 
suppressed only IgG^ and IgG^ responses. Experiments such as these 
have led to a clearer understanding of the sequential expression of 
sig classes in lymphocyte differentiation. This subject is reviewed in 
greater detail below (section 5).
1.4.3. Direct Visualisation of sIg-Antigen Binding
In one investigation (Rolley & Marchalonis, 1972), direct visualisation 
of sig-antigen binding was achieved in the following way. Spleen cells 
from unimmunised mice were radioiodinated by the lactoperoxidase 
method in order to label their sig. These cells were then incubated 
with 125-1 labelled DNP-haemoglobin. The authors then immunoprecipitated 
complexes of receptor plus sig using either antibody to the antigen 
(DNP-haemoglobin) or antibody to the sig. It had been previously 
shown (Lawrence et al., 1973) that a high percentage (0.1-1%) of 
unimmunised splenocytes bind this antigen, and so limitations normally 
imposed by the vanishingly small amounts of specific antigen-reactive 
cells available for analysis could be overcome in this system- It was 
shown that labelled sig was present in the anti DNP-haemoglobin 
precipitate, and vice versa, indicating that sig was directly inter­
acting with the antigen on the lymphocyte cell surface.
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2. PHYSICAL CHARACTERISTICS OF sIgM AND ITS MEMBRANE ASSOCIATION
2.1. Molecular Size of Cell Surface IgM
The earliest biochemical analysis of cell surface IgM (sIgM) consisted
of G-200 chromatography and centrifugation studies of the sIgM from
a human Burkitt's lymphoma (BL) cell line, Daudi (Eskeland & Klein, 1970}
These studies showed the sIgM molecule to be an 8S structure. The
observation that sIgM was an 8S monomeric molecule was confirmed on
BL cells and extended to mouse splenocytes by lactoperoxidase iodination
(Baur et al., 1971; Klein & Eskeland, 1971; Vitetta et al., 1971;
Marchalonis et al. , 1972; Sherr et al., 1972) or biosynthetic labelling
(Melchers & Andersson, 1973) and SDS-PAGE analysis of unreduced sIgM
isolated by immunoprécipitation. In a more systematic investigation.
Kennel & Lerner (1973) showed that SDS-PAGE of iodinated sIgM from a
human lymphoblastoid cell line (Wil2~A3) gave an apparent molecular
+
weight of 265,000 - 15,000. This value was considerably higher than
the expected value of 180 - 200,000 for monomeric IgM, a point which
the authors considered, and which has not yet been adequately explained.
2.2. The Polypeptide Chain Structure of Monomeric IgM
As reviewed in the proceeding section, there is very strong evidence 
that cell surface IgM is essentially identical to the monomeric form 
of secretory IgM. Thus, to understand the biosynthesis and membrane 
presentation of sIgM, it is of value to review a few features of the 
structure of monomeric IgM.
The basic structure of the human IgMs polypeptide chains is reviewed
by Putnam et al. (1973), who also presented the first complete sequence
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of the y-chain (from macroglobulinemia protein Ou). The subunit 
consists of two y heavy chains and two light chains (K or X). One 
disulphide bond connects the C-terminal cys of each light chain to 
cys 140 of each y-chain. Two disulphide bonds (cys 337 and cys 575) 
connect the y-chains to one another. Another sulphydryl (cys 414), 
which interconnects the subunits into the 19S pentamer, is thought to 
be reversibly blocked in the monomeric sIgM molecule, based on 
observations of in vitro polymerisation reactions (Askonas & Parkhouse, 
1971) . In this context, Stott & Feinstein (1973) have reported that 
two y-chain sulphydryls are free in the intracellular IgMs subunit 
and suggest that a rearrangement of free sulphydryls may occur upon 
polymerisation. In addition, the y-chain has 10 cysteine residues which 
form 5 intrachain disulphide bridges —  one in each of the 5 homology 
regions (V^, ^y4^ ’ ^®9ion ends and the region
begins at approximately position 125. The Fd' segment of Faby terminates 
at Lys-213 and the Fey begins at Gly-326. The region in between is 
degraded to small peptides by trypsin cleavage at 60°C, and includes 
most of C^2 a]^ d the area identified as the y-chain ’hinge* region. The 
C-terminal end of the y-chain has a nonadecapeptide 'tail' as shown 
below, for which there is no counterpart in y- or E-chains, but an 
identical counterpart in a-chains (Kehoe et al., 1973; Moore & Putnam,
1973).
CHO (C5)
560 570
Lys-Pro-Thr-Leu-Tyr-Asn-Val-Ser-Leu-Val-Met-Ser-ASp-Thr-Ala-Gly-Thr-
576
Cys-Tyr-COOH
  S —  S —  inter-heavy chain
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As can be seen from the amino acid sequence, the tail portion is not 
particularly hydrophobic. The tail sequence (and the entire y-chain 
sequence) terminates with Tyr-576.
2.3. Structure and Location of Carbohydrate Moieties
Human monomeric IgM has been shown to contain carbohydrate attached at 
5 sites (Cl - C5) in the constant region of each y-chain (reviewed by 
Metzger, 1970). The oligosaccharides are of two types: complex and 
simple. The complex oligosaccharides are present in glycopeptides Cl,
C2 and C3, and the simple oligosaccharides in glycopeptides C4 and C5 
(Spragg & Clamp, 1969). Shimizu et al. (1971) and Putnam et al. (1973) 
have determined the oligosaccharide compositions and locations, 
respectively, on the sequenced y-chain Ou. The glycopeptide Cl is in 
the Fd' fragment of the y-chain at position 120. C2 was first reported 
near position 230 in the 'hinge' region (Shimizu et al., 1971) but was 
later localised to position 332 in the C^^ domain immediately carboxy- 
terminal to the beginning of the Fey (Putnam et al., 1973). This
discrepancy was not explained in the latter paper which came from the
same laboratory as the earlier report. C3 and C4 are also located within
the C^2 domain, at positions 395 and 402 respectively, which makes this
domain particularly rich in carbohydrate (i.e. two complex and one 
simple oligosaccharide in a space of 70 amino acid residues). Both 
the C3 (complex) and C4 (simple) oligosaccharides are within the intra­
chain disulphide loop in C^^' and are close to the inter-subunit and 
one of the inter-heavy chain disulphide bridges. C5, a simple oligo­
saccharide, is located in the C-terminal 'tail' region, at position 563.
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The complex oligosaccharides (Cl, C2 and C3) contain one residue of 
fucose, 2-3 of mannose, 2 of galactose, 3-5 of N-acetylglucosamine and 
0-2 of sialic acid in a highly branched structure. The simple oligo­
saccharide C4 contains 5 residues of mannose and 2 of N-acetylg3ucosamine, 
whereas C5 contains considerably more mannose residues (8-11) and 2-3 
residues of N-acetylglucosamine. Both of the simple oligosaccharides 
are linear (unbranched) structures.
2.4. Attachment of sIgM to the Lymphocyte Membrane
Hypotheses concerned with the mode of attachment of sIgM to the lympho­
cyte membrane must address the critical problem of how a basically 
hydrophilic molecule like monomeric IgM can be adapted to the hydrophobic 
membrane environment.
Early explanations of this interaction envisaged an unusual folding of 
the sIgM molecule, perhaps mediated by a specific pattern of carbohydrate 
attachment, in which hydrophobic regions of the polypeptide chains were 
exteriorized forming loops which could interact with the membrane 
bilayer (Vitetta & Uhr, 1975 b) . This model would predict a rather weak 
binding, and support for this was found in the apparent ease of 'shedding' 
of sIgM as opposed to cell surface H-2 (murine alloantigen) molecules 
(Vitetta & Uhr, 1973).
More recent hypotheses have considered sIgM as either an integral or 
peripheral membrane protein respectively, according to the definitions 
proposed by Singer & Nicolson (1972). Integral membrane proteins, for 
example glycophorin '(Segrest et al. , 1972) , cytochrome b^ (Spatz & 
Strittmatter, 1971) and probably HLA (Springer & Strominger, 1976),
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possess C-terminal hydrophobic sequences in their polypeptide chains 
which extend into, and often through, the membrane lipid bilayer.
Secretory IgM y chain contains no such hydrophobic peptide. However, 
to examine the possibility that surface y-chains do_ have such an extra 
anchoring peptide, Melcher & Uhr (1973) compared the size of surface 
iodinated and secreted y-chains by SDS-PAGE. Their results showed hetero­
geneous but lower molecular weights for surface y-chains, which instead 
was interpreted as favouring the conformational change model; conform­
ational change being induced by under-glycosylation of the surface y-chain 
(Vitetta & Uhr, 1975b) . Subsequent similar investigations by the same 
and other workers, however, arrived at the opposite conclusion. Thus, 
Lisowska-Bernstein & Vassalli (1975) and Melcher & Uhr (1976) both 
found murine splenic cell surface y-chains to migrate more slowly than 
secreted y-chains, with a molecular weight difference of 1700 reported 
by the latter group. This finding was consistent with an extra hydro- 
phobic peptide on surface y-chains capable of integral membrane binding.
Further investigations of cell surface IgM were also consistent with a 
partial hydrophobic nature of the molecule relative to secreted IgM. 
Melcher et al. (1976) showed that when nonionic detergent (NP-40) was
removed from a cell lysate containing labelled murine sIgM, a proportion 
of the sIgM molecules became insoluble. In contrast, secreted IgM 
remained totally soluble in the absence of detergent. These results 
suggested that sIgM has hydrophobic portions which require detergent 
for solubility. Moreover, it was shown (Melcher & Uhr, 1977) that 
sIgM has a lighter buoyant density (by isopycnic centrifugation in 
caesium chloride gradients) in the presence of nonionic detergents than 
secreted IgM, consistent with the firm binding of detergent molecules to 
the sIgM.
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Recent hypotheses which view sIgM as a peripheral membrane protein, 
point to the possible interaction of sIgM with an 'anchor' protein. No 
such anchor protein has been definitively identified, although a protein 
similar to the Fc-receptor (Ramasamy et al., 1974) has been implicated. 
New, if somewhat dubious, impetus for this hypothesis has come from the 
studies of Mcllhinney et al. (1978), who failed to find a difference in
the C-terminus of surface versus secreted IgM y-chains by carboxypeptidase 
analysis. These studies are open to objection, however, principally 
due to the lack of convincing evidence that they were indeed analysing 
actual surface IgM. In contrast to the above findings, Williams & Grey 
(1978) have investigated by similar methods the well-established 
sIgM-producing human lymphoma cell Daudi, and reported a distinct 
C-terminus difference relative to secreted y-chain.
2,5. Topography of Cell Surface IgM on the Membrane 
IgM is a relatively soluble molecule with 5 carbohydrate moieties 
attached to each y-chain (Metzger, 1970; Shimizu et al., 1971). Based 
on thermodynamic considerations (Singer & Nicolson, 1972), these carbo­
hydrate moieties restrict the portions of the y-chain that could be 
buried in the plasma membrane. In addition, good evidence that sIgM 
y-chains have a C-terminal hydrophobic sequence for membrane binding 
(reviewed above) eliminates the need to postulate any close interaction 
between the major portion of sIgM and the plasma membrane.
Evidence indicating the orientation and exposure of sIgM on the lympho­
cyte membrane derives from experiments testing the susceptibility of 
sIgM to iodination, proteolysis, and to anti Ig reagents. Uhr & Vitetta 
(1973) reported that the ratio of y to L-chain labelling of sIgM
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was the same whether the cells were labelled by iodination in the 
membrane or in solution, implying nearly complete exposure of the sIgM 
on the cell membrane. However, it was pointed out by Marchalonis & 
Cone (1973), based on the findings of Bayse & Morrison (1971), that 
iodination by diffusable short-lived iodine free radicals or molecular 
iodine can occur in lactoperoxidase-catalysed reactions. This would 
therefore make relatively buried parts of the sIgM molecule accessible 
to iodination.
In contrast to the above discussion, a series of well-documented 
experiments has shown that fl-anti Fey antibodies do not stain slgM- 
containing lymphocytes very effectively (Pernis et al., 1970; Froland 
& Natvig, 1972). Fu & Kunkel (1974) showed that the last 50 residues 
(C-terminal) of sIgM from human leukemia cells were blocked to fl-anti 
Fey antibody. These findings imply that the Fc portion of the sIgM y- 
chains are not available for antibody binding.
Evidence examining the relative susceptibility of sIgM to proteolysis 
also argues in favour of considerable protection of the sIgM molecule. 
It has been shown that sIgM on intact cells is much more resistant 
than secretory IgM to degradation by papain (Vitetta & Uhr, 197 6), 
trypsin, Ot-chymotrypsin and pronase (Hough et al., 1977), although one 
report from Ferrarini et al. (1976) claims that pronase treatment does
result in the loss of cell surface IgM. Hough et al. (1977) found 
that the sIgD Fcô fragment, which is normally stable to further 
degradation (Jefferis, 1975) , was removed from intact cells by treat­
ment with papain (in agreement with Vitetta & Uhr, 1976) , a-chymo- 
trypsin and pronase; whereas sIgM was left intact. This implies
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that only sIgM, and not sIgD, may be 'protected' by the plasma membrane.
Taken as a whole, the present evidence would seem to indicate that 
while sIgM is probably not deeply buried in the plasma membrane, a 
large portion of the molecule is nonetheless protected from interaction 
with large macromolecules such as antibodies or enzymes. The possible 
modes of protection have been discussed previously (Vitetta & Uhr, 1976) 
Thus, protection could be rendered by conformational changes in the 
sIgM molecule to secretory IgM or by interaction of the sIgM with other 
membrane proteins,
3. BIOSYNTHESIS, ASSEMBLY AND TRANSPORT OF IMMUNOGLOBULIN
3.1. Synthesis on Membrane-Bound Polyribosomes
It is now widely accepted that the endoplasmic reticulum is the subcell- 
ular organelle responsible for the processing of secretory and plasma 
membrane associated proteins (reviewed by Palade, 1975; Shore & Tata, 
1977). Accordingly, proteins of this type are considered to be synth­
esised primarily on polyribosomes bound to rough ER membranes (reviewed 
by Sabatini & Kreibich, 1976). The first demonstration of this was 
with the pancreas secreted protein, a-chymotrypsin (Siekevitz & Palade, 
1960). Other examples of secretory proteins include rat serum albumin, 
thyroglobulin, major fractions of milk proteins from mammary glands, 
chick embryo collagen, egg-white proteins synthesised in the hen 
oviduct, and immunoglobulins synthesised in plasma cells (reviewed by 
Shore & Tata, 1977).
A variety of approaches have been used to demonstrate synthesis of
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Ig H and L-chains on membrane-bound polyribosomes, including 1) auto­
radiography coupled with electron microscopy (Scharff & Laskov,.1970;
Uhr, 1970) 2) analysis by immunoprécipitation of polypeptides isolated
with free or membrane-bound polyribosome fractions (Sherr & Uhr, 1970; 
Cioli & Lennox, 1973) 3) analysis of in vitro synthesised products
from fractionated polyribosomes (Lisowska-Bernstein et al., 1970) or 
from mRNA derived from fractionated polyribosomes (Blobel & Dobberstein, 
1975a and 1975b). Several of these studies also demonstrated significant 
synthesis associated with free polyribosomes (Lisowska-Bernstein et al., 
1970; Sherr & Uhr, 1970), which has been attributed to either artifactual 
disruption of polyribosomes or alternatively to an occurrence of 
physiological significance, having to do with the signal hypothesis of 
polyribosome-membrane attachment (see below).
3.2. Polyribosome-Membrane Interactions in Ig Synthesis 
What is the mechanism (s) by which secretory and cell surface proteins 
become selected for synthesis on membrane-bound polyribosomes? Studies 
of Ig biosynthesis have complemented numerous similar investigations 
in other systems to provide a partial understanding of the mechanisms 
involved. Three types of probable binding interactions have been 
identified: 1) direct binding of the ribosomal 60S subunit to the rough
ER membrane, mediated either by ribosomal proteins, ribosomal RNA, 
membrane receptor sites, or all of these, 2) binding of the nascent 
chains to membrane sites, and 3) binding of the mRNA (3'end) to 
membrane sites.
Polyribosomes can either be completely membrane bound (i.e. each ribo­
some on the messenger is membrane-bound) or 'dangling' (some but not all
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of the ribosomes on the messenger are membrane-bound). This distinction 
was made by Rosbash & Penman (1971a, 1971b). Rat liver polyribosomes 
are an example of the completely bound type, since limited digestion 
(of only mRNA) with pancreatic ribonuclease removes only 10% of the 
ribosomes from liver rough microsomal fractions (Blobel & Potter, 1967). 
Adelman et al. (1973b) have further shown that puromycin treatment,
which dissociates nascent chains from the ribosome, releases a negligible 
amount of 60S subunits. This approach shows that direct ribosomal 
binding is occurring in rat liver microsomes, but does not rule out the 
possibility that nascent chain - mediated binding is also occurring.
Investigations using myeloma cells have led to the conclusion that Ig 
synthesizing polysomes are of the 'dangling' type (Harrison et al.,
1974a, 1974b), and have further shown that the tightly bound ribosomes 
are anchored by a nascent chain - membrane interaction (Harrison et al., 
1974b). The distinction between this type of interaction and one in 
which only direct binding is involved is based on the development of 
a method for removing 60S subunits (Adelman et al., 1973a, 1973b;
Harrison et al., 1974a, 1974b) using puromycin and high concentrations 
of KCl. Thus, ribosomes bound by nascent chains are removed with 
puromycin and KCl treatment, but not KCl alone. Harrison et al. (1974b)
have also demonstrated that KCl/puromycin treatment removes almost 
all the poly(A)^ Ig mRNA from the rough ER, which argues against 
direct binding of Ig mRNA to the membrane in myeloma cells. Based on 
their results with ribosome binding, Harrison et al. (1974b) have
suggested that loosely bound ribosomes associated with Ig mRNA are 
precursors of the tightly bound fraction. In support of this idea,
Me chier & Vassalli (1975) have shown that loosely bound myeloma cell
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ribosomes (i.e. those released by limited ribonuclease digestion) 
contain nascent polypeptide chains which are on average 2-3 times 
shorter than chains associated with the tightly bound fraction.
3.3. The 'Signal Hypothesis' and Vectorial Release 
The implication that nascent chain binding to rough ER membranes is 
a mechanism of polyribosome attachment was supported by the original 
observation of Milstein et al. (1972) that Ig L-chains synthesised
in vitro had an hydrophobic extra peptide at the N-terminus.
Schmeckpeper et al. (1975) showed that a product the same size as the 
L-chain precursor could be isolated from the intact myeloma cells, but 
only with very short labelling periods and in the presence of the 
protease inhibitor, TLCK. This indicated that the precursor was not 
an artefact of in vitro synthesis, and that it was probably removed 
during or immediately after translation. Similar hydrophobic pre­
cursors of Ig L-chains (Blobel & Dobberstein, 1975; Schechter &
Burstein, 1976) and more recently H-chains of the mouse a (Jilka &
Pestka, 1977) and type (Singer & Williamson, in preparation) 
have been detected and sequenced. Examples of precursors detected on 
other secreted proteins include: insulin (Chan et al., 1976; Duguid
et al., 1976), a-lactalbumin (Craig et al., 1976), melittin (Suchanek, 
1975), parathyroid hormone (Kemper et al., 1976) and pancreatic 
secretory proteins (Devillers-Thiery et al., 1975).
The 'signal hypothesis' as originally proposed, (Blobel & Sabatini,
1971; Milstein et al., 1972) and in its more elaborated form (Blobel 
& Dobberstein, 197 5a, 197 5b), incorporates many of the above 
observations into an attractive model. According to the model, initiation
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of translation occurs on messenger RNAs free in the cytoplasm. Binding 
of the messenger-ribosome complexes occurs as the growing N-terminus, 
with its hydrophobic segment, interacts with the membrane. Evidence 
that this interaction may be through special receptor proteins has 
been taken from investigations showing that mild treatment of rough 
microsomal membranes with trypsin either releases ribosomes or 
interferes with binding of ribosomes to previously stripped membranes 
(Shires et al., 1973; Bailleyet al., 1974; Jothy et al., 197 5). The 
model is also consistent with the evidence of Rosbash (1972) that 
newly-synthesised mRNA was arrested in small cytoplasmic polyribosomes 
upon treatment with the translation inhibitor, cycloheximide. Upon 
removal of the cycloheximide, the small polyribosomes could be 
'chased' into a fraction of larger, membrane associated polyribosomes.
An important feature of the 'signal hypothesis' is that the hydrophobic 
signal sequence which initially binds the polyribosome to the rough 
ER membrane is also thought to lead the growing nascent chain through 
the membrane and into the microsomal compartment (cisternal space).
Such a transfer across the microsomal membrane has been termed 
'vectorial release', and is an essential element in the intracellular 
life-history of secretory or cell surface molecules such as Ig. It has 
been possible to test this hypothesis by the use of cell-free trans­
lation systems incorporating exogenously added polyribosomes and 
native or stripped microsomes. Thus, Blobel & Dobberstein (1975a, 
1975b) have demonstrated that L-chain mRNA directs the synthesis of 
mature L-chains in a cell-free system containing microsomes. This 
L-chain could not be degraded by exogenous proteases, indicating that 
it had been segregated into the microsomal cisternae. In contrast.
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globin mRNA translated in the same system was not resistant to proteo­
lysis. The authors were able .to conclude from these experiments that 
the information for microsomal binding and vectorial release of nascent 
polypeptides was encoded by the mRNA (i.e. the N-terminal hydrophobic 
sequence) and was not inherent in the protein synthetic machinery.
Previous results with a similar in vitro microsomal system (Vassalli 
et al., 1971) also indicated that newly synthesised L-chain is 
segregated into the cisternal space of microsomes.
3.4. Ig Assembly and Early Events in the Microsomal Compartment 
Williamson & Askonas (1967) first showed that Ig H and L-chains are 
synthesised on separate polyribosomes. As reviewed above, ample 
evidence established that these H and L-chain synthesising polyribo­
somes 1) become bound to the cytoplasmic side of the microsomal membrane; 
2) that this binding is mediated by the hydrophobic N-terminal pre­
cursor segment on the nascent chains; 3) that the growing nascent chains 
are transferred vectorially through the membrane and into the micro­
somal lumen, perhaps through a 'pore' created by the prior passage of 
the precursor segment; and 4) that inside the lumen the polypeptide 
chains fold into their native soluble conformation and, once this 
occurs, they cannot be transferred back through the membrane.
Are the rates of synthesis of H and L-chains coordinated, or is one 
polypeptide chain type synthesised in excess? Studies from different 
laboratories and using different cell types (i.e. myeloma tumours or 
lymph node cells) give somewhat varying results. It is clear that 
small L-chain pools exist in both tumour (Askonas & Williamson, 1966) 
and lymph node cells (Askonas & Williamson, 1967a), and that the
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L-chain pool is involved in the assembly of Ig in both cell types 
(Williamson & Askonas, 1968; Stott, 1972). Very little, if any, free 
H-chain has been detected in intracellular pools (Askonas & Williamson, 
1966; Scharff et al., 1967; Schubert, 1968). However, these findings 
are not inconsistent with a balanced synthesis of H and L polypeptide 
chains (Askonas & Williamson, 1967a). To the contrary, the apparent 
steady-state nature of the L-chain pool provides evidence in favour of 
balanced synthesis. However, the studies of Baumal & Scharff (1973), 
using both lymph node cells from hyperimmunised mice and a panel of 
myeloma tumours, are in contrast to the above investigations. These 
authors found balanced synthesis of H and L-chains in only a small 
number of cases. In all cases where unbalanced synthesis occurred, 
L-chain was the one synthesised in excess.
Besides glycosylation (see below), two post-translational processing 
events, 1) removal of H and L-chain precursor segments and 2) cyclis­
ation of N-terminal glutamine residues present in some V^ subgroups 
to PCA, are known to affect Ig polypeptide chains. It is generally 
assumed that the hydrophobic precursor segment is rapidly removed from 
the growing nascent chain once it enters the microsomal compartment, 
although this has been shown conclusively only for the L-chain 
(Milstein et al., 1972; Blobel & Dobberstein, 197 5b). PCA formation 
in a mouse IgG^^ myeloma protein (from Adj PC5 plasmacytoma line) has 
been investigated by Stott (1972). Cyclisation to PCA, which affects 
only H-chains in this tumour line, was barely detectable on nascent 
polypeptides precipitable with anti Fc antibody; and even after 1 or 
5 hours only 60-66% of the H-chains have N-terminal PCA. It was concluded 
from this investigation that cyclisation was, in fact, a post-trans-
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lational processing event, but not necessarily an early one in the 
Ig biosynthetic pathway. This finding is compatible with either rapid 
or delayed removal of the H-chain hydrophobic precursor segment.
The next stage in the intracellular life history of Ig is the assembly 
of H and L-chains into the characteristic Ig ^2^2 structure. It is 
evident that appreciable assembly of the chains does not occur until 
after they are released from the ribosomes. The early investigations 
of Williamson & Askonas (1967a) on Ig nascent chains in the mouse 
myeloma tumour line 5563 indicated that only insignificant amounts of 
L-chains could be detected by specific immunoprécipitation of H-chain 
nascent polypeptides. However, in subsequent investigations, these 
authors found that 131-I-labelled L-chains can associate in vitro 
with nascent H-chains (Askonas et al. , 1969) . The L-chain binding was 
spread across a broad range of polyribosome sizes, but was equivalent 
to only one L-chain per polyribosome complex (14-18 ribosomal units). 
Pulse-chase labelling of myeloma tumour cells and normal lymph node 
cells (Shapiro et al., 1966; Baumal et al. , 1971; Laskov et al., 1971) 
indicated that nascent H and L-chains were fully released 2 minutes 
after a 1-3 minute pulse. It was shown that during this time very 
little noncovalent or covalent assembly occurred. Moreover, 7 minutes 
after the chase, only 37% of the newly synthesised chains had been 
assembled into H^L^ structures. Lymph node cells were found to assemble 
H and L-chains more rapidly than the myeloma cells, although assembly 
in both cell types was not totally complete, with free L-chains and 
various intermediate forms also being secreted. Thus, while association 
of H and L-chains prior to release from the ribosomes can, and possibly 
does, occur to a very limited degree, this association is apparently
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not a very significant aspect of the whole assembly process.
The pathways of assembly of H and L-chains vary depending primarily on 
the structure (i.e. class) of the H-chain, and probably to a lesser 
extent on the species investigated. In Balb/c tumours, IgG^, IgG2^, 
and IgA assemble predominantly through H^ and then H^L intermediates, 
while IgG^j^ and IgM assemble primarily through the HL half molecule.
The intermediates formed in these pathways also reflect the order of 
noncovalent association of the polypeptide chains (Askonas et al.,
1969; Baumal et al., 1971; and reviewed by Scharff, 1974). The assembly, 
and possibly the surface deposition, of IgM as half molecules in 
human cells is also suggested by the findings of Kennel & Lerner (1972). 
These authors detected IgM half molecules on the surface of cells of the 
lymphoblastoid line Wil^-AB using lactoperoxidase iodination and SDS- 
PAGE analysis.
Are the pathways of Ig assembly mediated by cellular processes, or 
simply by the physical properties of the H and L-chains involved? The 
experiments of Petersen & Dorrington (1974) and Percy et al. (1975)
support the latter view. Thus, these authors found that the in vitro 
assembly kinetics and pattern of several mouse and human Igs is 
identical to the in vivo situation.
3.5. Glycosylation
Immnoglobulin molecules are glycoproteins. Carbohydrate is covalently 
attached to one or more specific sites in the constant region of each 
class of H-chain. Carbohydrate moieties are also found attached to H-chain 
and L-chain V-regions, although much less frequently. The composition.
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method of assembly and subcellular sites of assembly of Ig carbohydrate 
follows the general pattern observed for other glycoproteins.' These 
aspects are discussed below.
For both H and L-chains, the carbohydrate moiety consists of a 'core' 
region of linearly arranged N-acetylglucosamine and mannose subunits, 
attached to an asparagine residue via the N-acetylglucosamine. Recent 
evidence (Behrens et al., 1973; Hsu et al., 1974; Lennarz, 1975) has 
indicated that this 'core' region can be transferred in vitro, as a 
preassembled oligosaccharide, from a dolichol phosphate carrier. Eagon 
et al. (1975) have reported that such a transfer occurs in vitro to
nonglycosylated MOPC 46 L-chain obtained by 2-deoxyglucose inhibition.
The 'core' region linkage is specific for the tripeptide sequence 
asn-X-ser (or thr), and apparently also for certain undefined factors 
(i.e. protein conformation), since glycosylation does not occur at 
every asn-X-ser (or thr) tripeptide sequence (Shimizu et al., 1971).
Carbohydrate moieties on Ig molecules are of two general types: simple 
and complex. Simple carbohydrate moieties consist only of the 
(glcNAc)(mannose)^ 'core' region, which may be added as a preassembled 
oligosaccharide in a single step, as described above. Complex carbo­
hydrate moieties consist also of the 'core' region, to which are 
attached other 'side chain' sugars such as additional glcNAc, galactose, 
and terminal fucose or sialic acid (reviewed by Jentoft et al., 1976 
and Molnar, 1976). These additional sugars (and possibly some of the 
core sugars as well) are added by sequential transfer of individual 
sugars to the growing oligosaccharide side chains. These reactions 
are catalysed by a series of membrane-associated enzymes known collectively
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as the multiglycosyl-transferase system (MGT) (Schachter et al., 1970).
Each enyzme catalyses the transfer of a specific sugar from a sugar 
nucleotide to the oligosaccharide chain. Each enzyme requires the 
product of the proceeding enzyme as its substrate, and in turn generates 
the substrate for the next transferase. In addition to recognising the 
proceeding sugar as substrate, there is evidence that transferase enzymes 
(i.e. sialyltransferase) may also recognize the peptide sequence around 
the linkage amino acid, since the IgM y-chain oligosaccharides C2 and 
C3 are apparently identical, except that C2 contains two terminal sialic 
acid residues, whereas the C3 contains only one (Baenziger & Kornfeld, 
1974). The acceptor specificity exhibited by the glycosyl transferases 
in general appears quite stringent, and it is this stringency which is 
thought to determine the precise structure of a particular oligosaccharide 
(reviewed by Baenziger & Kornfeld, 1974) .
A number of groups have used a variety of ultrastructural and bio­
chemical methods to determine the subcellular biosynthetic sites and 
order of addition of carbohydrate residues to L-chains (Choi et al., 
1971ab),to IgG y-chains (Melchers & Knopf, 1967; Swenson & Kern, 1968; 
Melchers, 1970; Melchers, 1971a, 1971b), and to IgM y-chains (Schenkein & 
Uhr, 1970a, 1970b; Uhr, 1970; Uhr & Schenkein, 1970; Zagury et al., 1970; 
Parkhouse & Melchers, 1971).
The results of these studies, which are virtually identical to those 
obtained in investigations of the biosynthesis of non-Ig glycoproteins, 
are briefly outlined below. The glcNAc and mannose core sugars are 
incorporated either prior to polypeptide chain completion or shortly 
after release of completed polypeptides into the cisternae of the rough
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ER (Uhr, 1970). These sugars can also be incorporated at a slightly 
later stage in the sequential passage of the polypeptide chains through 
the various membrane compartments - i.e. at the level of the smooth ER 
or Golgi complex. Sugars which make up the side chains of complex 
oligosaccharides, such as galactose and/or additional glcNAc, are 
incorporated by membrane-bound transferases in the smooth ER and 
primarily in the Golgi complex. The terminal fucose and sialic acid 
residues appear to be added very close to the time of secretion 
(Parkhouse & Melchers, 1971; Melchers, 1972).
3.6. Secretion
The final stages of transport of Ig through the cisternal spaces of the 
endoplasmic reticulum (i.e. RER, SER, Golgi, and post-Golgi compartments) 
are poorly understood, as are the mechanisms which enable Ig, of all the 
intracisternal proteins, to be selectively secreted. An hypothesis has 
been proposed by Uhr (1970), which provides a basis for further under­
standing. According to the hypothesis, Ig molecules are transferred 
from the Golgi complex to the cell surface within vessicles formed from 
the endoplasmic reticulum. These vessicles are then thought to fuse 
with the plasma membrane, thereby releasing the Ig to the outside by 
reverse pinocytosis. For Ig to be selectively secreted according to 
the model, it would have to be free inside the vessicle, whereas non- 
secretory proteins would presumably be bound to the vessicular membrane. 
It has been proposed (Uhr & Vitetta, 1973) that Ig molecules are 
initially membrane-bound, and that at some point in their transport a 
'feignal' is read which results in their release into the vessicle.
There is no direct evidence to support this hypothesis, although Choi 
et al. (1971a, 1971b) have observed that sonication of microsomal
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fractions, which is thought to disrupt vessicles but leave the 
structure of the membrane basically intact, results in the selective 
release of Ig.
It has been argued that glycosylation of Ig is important for secretion, 
perhaps providing the 'signal' necessary for release of vesicular 
membrane-bound Ig (Uhr et al., 1974). However, nonglycosylated proteins 
such as L-chains or albumin can be secreted normally (Schachter, 1974) . 
Melchers (1973) used 2-deoxyglucose to selectively inhibit glycosylation 
of Ig in several myeloma tumours. Cell fractionation studies revealed 
that 2-deoxyglucose inhibited Ig transport from the polysomes to the 
RER, and from the RER to the SER, but Ig in the SER was quantitatively 
secreted. Thus it was concluded that addition of the terminal sugars 
fucose and sialic acid, and perhaps also galactose, was not required 
for secretion. Investigations of a variant cell line which synthesises 
a small (42,000 daltons) Y heavy chain, half the molecules of which are 
nonglycosylated (Weitzman & Scharff, 1976) , indicated that both the 
glycosylated and nonglycosylated y-chains were assembled and secreted 
with similar kinetics.
IgM and IgA molecules are further polymerised before secretion. In 
the case of IgM, the polymerised product consists of five IgMs subunits 
arranged radially and disulphide bonded to one another. In both Ig 
types, a third polypeptide chain, J-chain, has been found attached to 
the penultimate cysteine residue of the y-chain (Halpern & Koshland, 
1970; Mestecky et al., 1971). J-chain has a molecular weight of 
approximately 15,000, and is present in a ratio of one chain per 
polymer molecule (Mestecky et al., 1972; Halpern & Koshland, 1973).
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The function of J-chain is not clear, although it has been suggested 
that it may play a part in the assembly of the polymer (Della Corte & 
Parkhouse, 1973; Parkhouse & Della Corte, 1973; Chapuis & Koshland,
1974). However, Stott (1976) has shown that J-chain can be added to 
fully polymerised IgM in the myeloma tumour line Y5781, and is absent 
from intracellular IgMs in mitogen-stimulated spleen cells. These 
results therefore suggest that J-chain is not necessary for the 
polymerisation of IgM.
4. BIOSYNTHETIC PATHWAY OF CELL SURFACE IgM
4.1. Introductory Remarks
Experiments designed to investigate the synthesis and intracellular 
transport of cell surface IgM, as distinct from secretory IgM, have 
used either small murine splenic lymphocytes or human lymphoma cell 
lines as model systems. These experiments begin with the synthesis 
of Ig H and L-chains on membrane-bound polyribosomes, and follow 
the incorporation of 3H-sugars and the intracellular compartmentalisation 
of the Ig to the point of surface deposition. It has emerged that 
many of the basic steps of this process are the same for surface IgM as 
for secretory IgM. However, many questions concerning the control of 
the two pathways still remain to be answered. The details are 
reviewed below.
4.2. Synthesis and Early Intracellular Transport
The human lymphoma cell line Daudi (Klein et al., 1968) has been used 
for many of these investigations. Daudi cells have been shown to 
synthesize (Sherr & Uhr, 1971; Sherr et al., 1971) but not secrete
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(Klein et al., 1968; Nadkarni et al., 1969; Sherr & Uhr-, 1971; Sherr 
et al., 1971; Grundke-Iqbal. & Uhr, 1974) an IgMK molecule. Instead, 
cell surface IgMK is expressed, which is readily detectable by 
conventional techniques (Klein et al., 1967, 1968, 1970; Takahashi 
et al., 1969; Hammond, 1970). By electron microscopic examination 
(Hammond, 1970; Sherr & Uhr, 1971) Daudi cells have a paucity of 
membrane-bound polyribosomes and lack a well developed endoplasmic 
reticulum. Because of these characteristics Daudi cells have been 
considered a neoplastic counterpart and good experimental model for 
resting B-lymphocytes.
In the investigations of Sherr & Uhr (1971) and Sherr et al. (1971),
Daudi IgM was detected by 3H-leucine incorporation and antibody precip­
itation from various subcellular fractions. Although there was little 
membrane-bound protein synthesis in these cells, IgM was preferentially 
synthesized on membrane-bound polyribosomes. The newly synthesized 
IgM rapidly entered the microsomal compartment where it accumulated 
linearly for at least 90 minutes. The labelled microsomal IgM could 
not be chased into the cell sap during the 90 minute incubation with 
unlabelled leucine, indicating that any presumed degradation of IgM 
either acts on a very large intracellular pool; or alternatively, 
that degradation is the final step in an ordered intracellular transport 
of newly synthesized IgM which takes more than 90 minutes to complete.
4.3. Glycosylation and Transport to the Golgi Complex
As part of the same experiments described above (Sherr & Uhr, 1971;
Sherr et al., 1971), the incorporation of 3H-galactose was shown by 
autoradiography and electron microscopy to be localised in the Golgi
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complex. Galactose and fucose were also incorporated into IgM H and 
(putative) L-chains, which were isolated by immunoprécipitation from 
the microsomal fraction of the cells. These results were consistent 
with the addition of these sugars to Ig chains in the smooth ER or 
Golgi complex, similar to the situation observed with glycosylation 
of secreted Ig.
The pattern of glycosylation of cell surface IgM in mouse splenocytes 
has been more controversial, possibly due to the heterogeneity of the 
splenic lymphocyte population. Melchers & Andersson (1973) could not 
label slowly turning over (i.e. cell surface) IgM from mouse splenocytes 
with 3H-galactose. Consistent with this, Melcher & Uhr (1973) found 
splenocyte surface IgM p-chaina to be of variable and lower molecular 
weight than secreted IgM y-chains, from which they argued indirectly 
that glycosylation of sIgM may not be as complete as that of secreted 
IgM.
In contrast to their previous findings (Melcher & Uhr, 1973) and those 
of Melchers & Andersson (1973), Vitetta & Uhr (1974) reported that 
galactose and fucose were added to splenic cell surface IgM. These 
experiments involved the isolation of biosynthetically labelled 
(3H-amino acids and 3H-sugars) IgM from the surface of intact cells 
by immunoprécipitation. It was also shown by this method that labelled 
IgM appeared on the cell surface with a latent period of approximately
1-2 hours (Vitetta & Uhr, 1974; Uhr et al., 1974), Subsequent 
investigations on the size of splenic cell surface IgM (Melcher & Uhr,
1975) and Daudi lymphoma cell surface IgM (this thesis) provide additional 
indirect evidence that the glycosylation of sIgM is almost, if not
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entirely, equivalent to that of secreted IgM.
4.4. Post-Golgi Transport and Surface Deposition
As is the case for secretory Ig, the mechanism of post-Golgi transport 
and surface deposition of sIgM is not well understood. A model that 
has been put forward (Uhr, 1970; Uhr & Vitetta, 1973) proposes that 
the mechanism thought to'exist for secretory Ig —  that is, transport 
within post-Golgi vessicles, fusion of these vessicles with the inside 
of the plasma membrane, and reverse pinocytosis to release Ig into 
the extracellular environment —  is basically similar for cell surface 
IgM. The distinction is only that cell surface IgM remains attached 
to the membrane in the interior of the transport vessicle, rather than 
being free inside the vessicle. Thus, when reverse pinocytosis occurs, 
the sIgM molecules end up attached to the outer plasma membrane.
This model is consistent with the little available data, however it 
leaves many questions unanswered. The mode of attachment of sIgM to 
the microsomal membrane is not known, although ideas advanced to 
explain the mode of attachment of sIgM to the plasma membrane (section 2) 
presumably apply. A key feature of the Uhr (1970) model (also 
elaborated in Uhr & Vitetta, 1973; Vitetta & Uhr, 1975a)is that 
molecules destined both for surface deposition and secretion start off 
in the rough ER and progress to the Golgi complex bound, for a period 
during that migration, to intracellular membranes. This is presumed 
to be necessary for the addition of carbohydrate by membrane-bound 
glycosyl transferases.
During Golgi processing and post-Golgi transport, it is proposed that
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a 'signal' is read which results in release into the Golgi vessicle 
of the IgM destined for secretion, with the IgM destined for surface 
deposition being retained in the membrane. The nature of this 
hypothesised signal for the release of bound Ig in the Golgi complex 
has not been resolved. (The original idea of the models' authors, 
that the addition of terminal carbohydrate residues such as fucose 
to the secretory IgM molecule signaled its release (Uhr et al., 1974), 
is inconsistent with their own earlier data from Daudi cells, and 
subsequent data from splenocytes indicating fucose addition to sIgM 
as well.)
Do these synthetic pathways occur in the same or different subcellular 
compartments? The answer to this question is of course important in 
assessing the Uhr model. The kinetics of appearance of pulse labelled 
cell surface IgM (Uhr et al., 1974; Vitetta & Uhr, 1974) and secretory 
Ig (Scharff et al., 1967; Melchers, 1970; Uhr, 1970; Parkhouse, 1971) 
are relevant here. Experiments from the above laboratories have 
indicated that secretory Ig appears with a latent period of 20-30 minutes; 
whereas the previously cited investigation of Daudi cells indicated a 
latent period of 1-2 hours for the appearance of sIgM. A cursory 
comparison of these results appears to argue for different compartment­
alisation, and against the precise formulation of the Uhr model.
However, the interpretation is complicated because the kinetics were 
measured in very different cell types (i.e. mouse myeloma cells and 
Daudi human lymphoma cells). Moreover, the greater sensitivity 
generally required to detect sIgM by biosynthetic labelling may have 
resulted in an over-estimate of its latent period.
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5. Ig EXPRESSION DURING B-LYMPHOCYTE MATURATION
5.1. Introduction
The question of Ig expression during lymphocyte maturation has 
recently received considerable attention. This increased interest has 
derived principally from recent studies on the generation of Ig isotype 
diversity, both in vivo and in mitogen stimulated cultures (for recent 
reviews see Nossal et al., 1977? Parkhouse & Cooper, 1977? Kearney & 
Abney, 1978). These studies have re-emphasised other maturation- 
associated phenomena of Ig expression as well, such as the change 
from sig to secretory Ig and the amplification of Ig synthesis upon 
stimulation. The picture presented for Ig expression is one in 
which both pre-programmed control at the virgin B-lymphocyte level and 
antigen and/or accessory cell-dependent control appear to be operating. 
Forms of Ig expression which have been described, and which can occur 
in the progeny of a single precursor cell, include: 1) synthesis of 
cytoplasmic Ig (cig) without surface deposition, 2) surface deposition 
without appreciable cIg or secretory Ig synthesis, 3) surface deposition 
with cig and secretory Ig and 4) cig synthesis and secretion without 
appreciable surface deposition.
5.2. Isotypes and the Evidence for Isotype Diversity
The evidence that Ig H-chains (and L-chains) are composed of two 
functionally separate regions, termed V-region and C-region, is well 
established. In the H-chain, the region determines the antibody 
specificity (in combination with V^), while the region determines 
the Ig class (i.e. y , y, a, 6, and e) and subclass (y^, y^, y^ etc.) 
of the molecule. Thus, it was first recognized from amino terminal
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sequence analysis of Igs (Hood et al., 1966; Edelman & Gaily, 1967;
Pink et al., 1972) and from comparison of rabbit V-region (^ ) allotypes 
(Todd, 1963; Koshland, 1967 ; Todd & Inman, 1967) that Ig H-chains from 
most of the known classes share similar V-regions.
Further investigations revealed biclonal myeloma Igs which, although 
of different classes, share identical idiotypic determinants and 
apparently identical V-region sequences. Of such biclonal myelomas, 
those of the Ig classes IgM plus IgG^ (Wang et al., 1969 ; Wang et al., 
1970àb;Fudenberg et al., 1971), IgM plus IgG^ (Penn et al., 1970), IgM 
plus IgA (Seon et al., 1973 ; Yagi & Pressman, 1973), and IgA plus 
IgG (Sledge et al., 1976) have been described. In these cases of rare 
myelomas, it was generally agreed that transformation had occurred in 
a lymphocyte clone which, although precommitted to the synthesis of 
only one V^ region, was in the process of changing expression from 
one class to the other.
The predictions of clonal selection, together with the observation that 
normal immune responses 'mature' from IgM antibody to IgG (or IgA) 
antibody production, provided an early basis for the concept of H-chain 
constant region shifts within a clone of differentiating lymphocytes.
The term 'isotypes' is used for the Ig products of such clones, 
denoting the fact that these Igs possess identical V^ regions associated 
with different regions. (In contrast, both the V^ and regions 
of the L-chain are known to remain fixed during clonal differentiation.)
It is now firmly established that isotypes are generated during the 
life cycle of B-lymphocytes. The existence of biclonal myeloma proteins
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provided strong early support for this concept. In addition, 
various investigations have led to the conclusions that 1) the progeny 
of single antibody binding cells have identical idiotypes as the 
receptor Ig (Press & Klinman, 1973; Eichmann & Rajewsky, 1975; Gearhart 
et al., 1975; Trenkner & Riblet, 1975), 2) a small percentage of 
antibody forming cells secrete both IgM and IgG antibodies (Nossal 
et al., 1964; Ivanyi & Dresser, 1970; Nordin et al., 1970; Nossal et al., 
1971), 3) cells double staining for different classes of cellular Ig 
and surface Ig by immunofluorescence can be detected (Pernis et al.,
1971; Jones et al., 1973; Litwin & Cleve, 1973), and 4) sIgM and 
sIgD receptors (discussed below) on a single cell have the same idio- 
type (Salsano et al., 1974; Fu et al., 1975 ; Coding & Layton, 1976) 
and antigen specificity (Pernis et al., 1974).
5.3. Early Observations and Models of Ig Isotype Diversification 
Many investigations of the suppression of Ig production (Kincade et al., 
1970; Kincade et al., 1971; Herrod & Warner, 1972 ; Lawton et al., 1972 ; 
Kincade & Cooper, 1973 ; and reviewed by Lawton & Cooper, 1974) and the 
suppression of specific antibody production (Pierce et al., 1972a,
1972b, 1973) by heterologous anti Ig treatment of B-lymphocytes have 
established that Ig isotypes are sequentially expressed in vivo. Since 
IgM is the major detectable antigen receptor on B-lymphocytes, the 
concept emerged that IgG and IgA-producing cells arise in clones where 
the cells originally bore sIgM.
In a series of classical experiments, it was clearly demonstrated that 
anti y treatment of lymphocytes in embryonic chickens resulted , later 
in life, in a profound depression of serum IgM, as well as IgG (Kincade
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et al., 1970) and IgA (Kincade & Cooper, 1973) levels. Similar anti y 
treatment at hatch, however, depressed only serum IgM levels, but not 
serum IgG levels (Kincade et al., 1971). These studies were extended 
to neonatal germ-free mice, where it was shown that anti y treatment 
was only effective in eliminating IgG and IgA production if it was 
administered at a certain critical time during neonatal development 
(Lawton et al., 1972).
When heterologous anti Ig was used to suppress primary in vitro antibody 
responses, it was found that anti y suppressed responses of all Ig 
classes, whereas anti , anti and anti ot suppressed only IgG^,
IgG^, and IgA responses. In contrast, when primed cells were tested for 
a secondary in vitro response, it was found that anti y treatment had 
progressively less effect with time after priming (Pierce et al., 1972a, 
1972b). The authors concluded from these results that some slgM- 
bearing cells are precommitted to differentiate into cells secreting one 
of the other Ig isotypes.
The studies of Pierce et al. (1972a, 1972b) provided evidence for 
antigen-driven isotype diversification, or the so-called isotype 'switch' 
model (Nossal et al., 1964, 1971 ; Wang et al., 1970a; Warner, 1972; 
Pierce et al., 1973; Vitetta & Uhr, 1975a). The alternative model of 
isotype diversification, the 'minimal receptor' model (Makelâ, 1970; 
Makela & Cross, 1970) postulates that separate IgM, IgG and IgA 
precursors exist. The results cited previously, from Kincade, Lawton, 
Cooper and coworkers, provided support for this latter model, and 
further suggested that the generation of separate precursors occurred 
by sequential activation of receptor isotypes (IgM -> IgG ->IgA) during
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embryogenesis (Cooper et al., 1972a, 1972b). Both models therefore have 
in common the concept of isotype switch. They differ, however, in 
whether the switch is antigen driven (Model 1) or antigen-independent 
(Model 2).
Many of the observations of Ig isotype diversity appeared to be better 
explained by one or the other of the above models (Lawton & Cooper,
1974; Warner, 1974). Thus, the concept of sequential embryonic 
development of IgM -> IgG -> IgA-bearing cells, which then become the 
precursors of cells secreting the respective isotypes, was inconsistent 
or less consistent with the following observations, which have been 
reviewed above : 1) the presence of a small percentage of cells secret­
ing both IgM and IgG antibodies; 2) the phenomenon of biclonal myeloma 
proteins; 3) the stable persistence of sIgM in cells staining by 
fluorescence also for cytoplasmic IgG; and 4) various observations 
which link IgA and IgM expression, rather than IgA and IgG expression 
(such as the IgA plus IgM biclonal myeloma proteins, the cytoplasmic 
IgA, sIgM containing Payer's patch cells of the rabbit, and the 
effectiveness of anti y and not anti y iri suppressing IgA responses 
(Pierce et al., 1972b)).
5.4. Ig Expression in Ontogeny and in Mitogen-Stimulated Cells:
Current Concepts
Recent advances in the understanding of Ig isotype diversification 
have come mainly from immunofluorescence studies, which have identified 
Ig isotypes on lymphocytes both during ontogeny and in mitogen- 
stimulated cultures (Abney et al., 1975; Kearney & Lawton, 1975a, 1975b; 
Melchers et al., 1975a; Andersson et al., 1976; Kearney et al., 1976a,
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1976b; Raff et al., 1976; Askonas & North, 1977; Kearney et al., 1977a,
1977b; Parkhouse & Cooper, 1977; Pernis et al., 1977; Kearney &
Abney, 1978). It has become evident that sequential expression of 
receptor Ig isotypes is the rule for B-cell maturation, and that this 
receptor isotype diversification is independent of specific antigen 
or accessory cell influence. The ontogenetic and mitogen-stimulated 
expression of Ig isotype receptors has been incorporated, along with 
observations of the physical, functional and kinetic characteristics 
of subpopulations of antibody forming cells (Nossal et al., 1977), 
into an overall picture of B-lymphocyte differentiation. Such a 
picture includes other aspects of Ig expression aside from isotype 
diversification. The details are reviewed below.
5.4.1. Pre-B Cells: IgM-Synthesising, sIgM
Ontogenic studies in several laboratories have demonstrated the presence,
in 10-12 day fetal liver or adult bone marrow, of cells which stain
weakly for cytoplasmic IgM, but are negative for sIg (Melchers et al.,
1975a; Osmond et al., 1976; Phillips & Melchers, 1976; Raff et al.,
1976; Phillips et al., 1977; Rosenberg & Parish, 1977). These (pre-B)
cells preceed by 4-5 days the appearance of the first detectable 
+vesIgM B-cells (see below) . Morphologically, the pre-B cells are 
large cells. They may, as suggested by Nossal et al. (1977),
express very low amounts of rapidly turning over sIgM. In addition, 
the following observations are relevant to an understanding of the 
role of pre-B cells: 1) pre-B cells exhibit allelic exclusion 
(Lawton et al., 1977), 2) at the earliest detected appearance of a 
clonotype, it is represented by at least lo individual cells (Metcalf et al., 
1977), and 3) the bone marrow small lymphocytes show some cells which
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are also sig Based on the above, Osmond & Nossal (1974 a, 1974b)
have suggested that early (cycling) pre-B cells develop into more 
mature (nonr-cycling) cells by reduction division mitosis, accounting 
for observation (3). Cells at the pre-B stage are thought not to be 
generating clonotype diversity (based on the demonstration of allelic 
exclusion). Instead, the production of pre-B progeny cells by limited 
réduction-division would serve to amplify individual clones (Nossal 
et al., 1977), accounting for observation (2) above.
5.4.2. Early Primary B Cells: slgM^^^
Pre-B cells develop into primary B cells in the fetal liver or adult 
bone marrow through the acquisition of sIgM. That IgM is the first 
isotype expressed on developing B cells has been shown in several 
independent laboratories (Abney & Parkhouse, 1974; Melchers et al., 
1975a; Vitetta et al., 1975; Vossen & Hi]mans, 1975; Gathings et al., 
1976; Gupta et al., 1976; Raff et al., 1976), and is considered to be 
well established. These slgM^^^ cells: 1) respond to LPS and 2) can 
easily be tolerised by antigen in vitro, and are thus considered likely 
candidates for in vivo tolerance induction (Nossal & Pike, 1975;
Vitetta & Uhr, 1975a;Stocker & Nossal, 1976; Stocker, 1977), It has 
been further suggested that early primary B-cells (i.e. probably those 
positive for sIgM only) may, if they fail to acquire another receptor 
isotype, develop into non-switching clones, producing IgM antibody to 
relatively thymus independent antigens (Vitetta & Uhr, 1975a, 1977; 
Nossal et al., 1977).
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5,4,3. Maturation of Primary B Cells; Generation of Multiple 
Receptor Isotypes
The first indication of the existence of multiple isotypes on the
surface of B-lymphocytes was the identification of IgD as a major
receptor on human (van Boxel et al., 1972; Knapp et al., 1973; Rowe
et al., 1973; Kubo et al., 1974; Lobo et al., 1975) and on mouse
B-cells (Abney & Parkhouse, 1974; Melcher et al., 1974).
Ontogenic studies using carefully purified fluorescent anti Ig
antibodies have recently described the existence of murine B-lympho-
cytes also bearing IgG^, IgG^/ IgG^ and IgA isotypes (Parkhouse &
Cooper, 1977; Kearney & Abney, 1978). These studies demonstrated that
a small but significant percentage of cells in spleens from 3 day old
mice arise bearing the IgG^, IgG^, IgG^ or IgA isotypes. These isotypes
arise only on those cells previously slgM”^"^ ,^ thereby creating doubles
(i.e. sIgM , slgX^^^). Likewise, sIgD also arises on slgM^^^ cells
at this stage of development. This latter point was independently
established by anti p suppression, which was found to inhibit the
development of slgD^^® cells (Parkhouse & Cooper, 1977). Thus, it was
concluded that the early primary B-cell (slgM**'"^  ^only) is the pivotal
cell for the development of isotype diversity. An important further
conclusion from these studies was that only one of the additional
isotypes (IgG^, IgG^f igG^. and IgA) could arise on a single slgM^^^
+ve -fvecell (i.e. no IgG^ , IgG^ -type cells were found). This was
interpreted to indicate a precommittment to the synthesis of only one
of these additional isotypes within a clone (Kearney & Abney, 1978).
In contrast, the acquisition of sIgD was found to be an independent
+V0 *i"V0event, which occurs on a large percentage (20-30%) of sIgM , sIgX
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doubles, thereby creating trebles, and also on a large percentage
(approximately 50%) of sigM*"^^-only cells, thereby creating slgM^^^, 
+vesIgD doubles. That these events were antigen-independent was shown 
by Lawton & Cooper (1974) and Vitetta & Uhr (1975a), who demonstrated 
the identical sequence of isotype acquisition in germ-free mice.
5.4.4. LPS Stimulation to Ig Secreting Blast Cells
Recent improvements in LPS-stimulâtion techniques have enabled workers 
in several laboratories to obtain differentiation on IgG and IgA 
synthesising plasma cells (Kearney & Lawton, 1975a, 1975b; Melchers 
et al., 1975a; Askonas & North, 1977; Pernis et al., 1977). From these 
studies a general picture of antigen-driven isotype expression, based 
on the LPS model, has emerged. The major observations are reviewed 
below.
fveIt was shown that as soon as sIgM cells appear in the fetal liver
(day 16-17) they could be stimulated by LPS (Kearney & Lawton, 197 5b).
When surface Ig isotypes were examined, it was found that LPS rapidly
+veinduced the expression of other isotypes on a small percentage of sIgM 
cells, thereby creating doubles. This was completely analogous to the 
situation observed with ontogenetic expression. The expression of 
new receptor isotypes was independent of proliferation, but dependent 
on mRNA and protein synthesis, as determined from the use of the 
metabolic inhibitors cytosine arabinoside and hydroxyurea, actinomycin D, 
and cycloheximide respectively (Kearney & Abney, 1978).
+ve +ve
When sIgG2 , sIgM doubles were examined it was found that, coincident 
with the time of maximum cell proliferation (35 -96 hours), the sIgM
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was rapidly lost from the cells, leaving a population of slgGg^^^-only 
cells. Coincident with the transition of these cells to slgGg^^^-only, 
the appearance of cytoplasmic (and presumably secretory) IgG^ was 
detected (Kearney & Abney, 1978). It was also observed by several 
investigators (Askonas & North, 1977; Pernis et al., 1977; Kearney & 
Abney, 1978), that some of these cells could retain both cytoplasmic 
and sIgM during transition to IgG^ expression, and thus be double 
isotype producers (and presumably secretors). In a series of parallel 
experiments, Kearney et al. (1977b) demonstrated that the persistence
of cytoplasmic (and surface) IgM in cells differentiating to IgG2 
expression was enhanced by inhibition of cell proliferation. From 
these and similar studies (Askonas & North, 1977) it was concluded 
that cellular proliferation is required for the development of Ig class 
restriction in LPS responses, insofar as the loss of the primary 
receptor isotypes (sIgM and sIgD) and cytoplasmic IgM is concerned 
(Kearney & Abney, 1978). Cell proliferation also resulted in an 
increase in the absolute numbers of IgG-synthesising cells. Upon 
removal of sIgG2^^^ cells prior to culture with the fluorescence- 
activated cell sorter, Kearney & Abney (1978) reported a failure to 
deplete LPS-stimulated production of IgG2. The authors suggested from 
this result that there is a recruitment of single slgM^^^ cells as 
precursors for IgG^-synthesising cells.
The overall suggestion from the above results is that the apparent 
antigen-driven 'switch' phenomena, such as seen in LPS cultures and 
inferred from biclonal myelomas, can be explained fully in terms of the 
recruitment and stimulation of isotype-committed precursor cells. A key 
distinction here seems to be the concept that recruitment of slgM^^^
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cells to the synthesis and secretion of other isotypes (limited to only
one other isotype per clone) is different from antigen-driven switch
+ve
in that the cells first pass through an intermediate stage of sigM , 
slgX^^^. Since this intermediate stage has been shown to be an 
expression of the inherent differentiation capacity of B-lymphocytes, 
the actual isotype switch is reasoned not to be antigen-driven. It has 
been recognized, however, that B-lymphocyte differetiation is likely to 
be considerably more complicated than originally anticipated, and it 
would therefore be premature to attempt to fit all the observations 
into too rigid a conceptual framework (Nossal et al., 1977; Kearney & 
Abney, 1978).
MATERIALS
AND
METHODS
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1. GENERAL MATERIALS
1.1. Cell Culture Materials
RPMI 1640 Medium powder
Foetal Calf Serum
Penicillin, Streptomycin
Gibco Bio-Cult Ltd. 
Paisley, Scotland.
Flow Laboratories Ltd. 
Irvine, Scotland
Glaxo Pharmaceuticals Ltd. 
London, England
In addition, tissue culture flasks, petri dishes, tubes, and pipettes 
were supplied by Falcon Plastics Inc., Oxnard, California or by 
Corning Glass Works, Corning, New York.
1.2. Radiochemicals
The following radiochemicals were supplied by the Radiochemical Centre, 
Amershara, England
Amino Acids
L” {4,5- H} Leucine 
35L- { S} Methionine
3
L- {4- h } Phenylalanine
3
L- {3,4(n)- H} Proline 
L- {3-^h } Serine
L- {3,5- H} Tyrosine 
L— {3,4 (n}“ H} Valine 
Nucleotides 
{5,6-^H} Uridine
Other Radionuclides 
Iodine-125 
Iodine-131 
Phosphorous-32
Specific Activity 
55 - 60 Ci/mmole 
500 - 1200 
12 
40 
29 
43 
36
Specific Activity
40 - 60 Ci/mmole 
Specific Activity 
Carrier-free
II
30 - loo Ci/mmole
- q /_
35
In addition, L- { s} Cystine (20-60 Ci/mniole) was supplied by 
New England Nuclear Inc., Boston, Massachusetts.
1.3. Photographic and Liquid Scintillation Spectrometry Materials
X-Omat-R Film
DX-80 Developer
FX-40 X-Ray Liquid Fixer 
Lightproof Vinyl Film Bags
2,5 Diphenyloxazole (PPO)
Toluene, AR Grade 
Protosol
Triton X-lOO
Kodak Canada Ltd., Toronto, 
Ontario
Kodak UK Ltd,, London, 
England
H.A. West (X-ray) Ltd. 
Edinburgh, Scotland
Koch-Light Laboratories Ltd. 
Colnbrook, England
New England Nuclear Inc. 
Boston, Massachusetts
Rohm & Haas (UK) Ltd. 
Harrow, England
1.4. Enzymes
Creatine Kinase
Lactoperoxidase
Carboxypeptidase A
Boehringer Corporation (London) 
Ltd., Lewes, East Sussex
Sigma (UK) Ltd., London,
England
Worthington Biochemical Corpor­
ation, Freeport, New Jersey
1.5. Wheat Germ
Texan wheat germ, obtained from Mrs, H. Singer, was a gift 
from Dr. J. Tata, National Institute of Medical Research, London, 
Israeli wheat germ, obtained from Mrs. H. Singer, was a product 
of the Bar-Rav Mill, Tel Aviv, Israel.
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1.6 Fine Chemicals
The following fine chemicals were supplied by Sigma (UK) Ltd., London, 
England
Agarose
Creatine phosphate 
Cycloheximide 
Deoxycholic acid, Na salt 
Diethyl pyrocarbonate (DEP)
Dimethyl sulphoxide (DMSO)
D,L - Dithiothreitol (DTT)
N-2-Hydroxyethylpiperazine-N*-2-ethanesulphonic acid (HEPES)
lodoacetamide
lodoacetic acid, Na salt
Phenylmethylsulphonyl fluoride (PMSF)
Spermidine, free base
N,N,N',N'-Tetramethyl-ethylenediamine (TEMED)
Tris (hydroxymethyl) aminomethane (TRIZMA BASE)
The following fine chemicals were supplied as indicated
2-Mercaptoethanol Koch-Light Laboratories Ltd.,
Colnbrook, England
3-methyl-l-butanol "
(isoamyl alcohol)
Triton X-100, purified "
Adenosine 5'-triphosphate P-L Biochemicals Inc.
Milwaukee, Wisconsin
Guanosine 5'-triphosphate "
N,N' Methylene bisacrylamide Eastman Kodak Company
Rochester, New York
Nonidet P-40 Shell Chemicals UK Ltd.
London, England
Sucrose, ribonuclease free Schwartz/Mann
Orangeburg, New York
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Formaraide
N,N'-Diallyltartardiamide 
(DATD)
Absolute Alcohol, AR Grade 
Pepstatin-A
Fluka AG Chemische Fabrik 
Buchs, Switzerland
Serva Feinbiochemica 
Heidelberg, W. Germany
James Burrough Ltd,, London 
England
Protein Research Foundation 
Osaka, Japan
Heparin, mucous, freeze dried Evans Medical Ltd.,
Liverpool,England
Ampholine, carrier 
ampholytes
L-Amino Acids, A Grade
LKB Produkter AB, Bromma, 
Sweden
Calbiochem Ltd,, 
Bishops-Stortford, England
All other chemicals were, whenever possible, "AnalaR" grade reagents, 
supplied by BDH Chemicals Ltd,, Poole, Dorset, England.
1,7, Chromatography and Other Materials
Oligo dT Cellulose
Sepharose 4b
Sephadex G-25 coarse 
Sephadex G-200 medium 
DEAE Sephadex 
QAE Sephadex 
Nitrocellulose filters
Collaborative Research Inc., 
Waltham, Massachusetts
Pharmacia (Great Britain) Ltd. 
London, England
Millipore Corporation 
Bedford, Massachusetts
In addition, materials for ultrafiltration were supplied by Amicon 
Corporation, Lexington, Massachusetts, or by Schleicher & Schuell 
GMBH, Dassel, W. Germany.
2. STANDARD SOLUTIONS
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table 1
COMPOSITION OF RPMI 1640 MEDIUM
Amino Acids mg/litre
L-Arginine (free base)
L-Asparagine 
L-Aspartic Acid 
L-Cystine (2 HCl)
L-Glutamic Acid 
Glycine
L-Histidine (free base) 
L-Hydroxyproline 
L-Isoleucine (Alio free)
L-Leucine (Methionine free) 
L-Lysine HCl 
L-Methionine 
L-Phenylalanine
L-Proline (Hydroxy-L-Proline free) 
L-Serine
L-Threonine (Alio free)
L-Tryptophane
L-Tyrosine
L-Valine
200.0
65.0
20.0
65.0
20.0 
10.0
15.0
20.0
50.0
50.0
40.0
15.0
15.0
20.0
30.0
20.0 
5.0
28.94
20.0
Inorganic Salts
Ca(NO^)2.4H2O
mg/litre
100.0
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Table 1 continued
Inorganic Salts
KCl
MgSO^
NaCl
Na^HPO^ (anhyd.)
Vitamins
Biotin
D-Ca pantothenate 
Choline Cl 
Folic Acid 
i-Inositol 
Nicotinamide 
Para-aminobenzoic acid 
Pyrodoxine HCl 
Riboflavin 
Thiamine HCl 
Vitamin B^2
Other Components 
Glucose
Glutathione (reduced)
Phenol red
*NaHC0u
mg/litre
400.0 
48.84
6000.0
800.0
mg/litre
0.2
0.25
3.0
1.0 
35.0
1.0
1.0
1.0
0.2
1.0
0.005
mg/litre 
2000.0 
1.0 
5.0 
2000.O
*added separately to dissolved medium
The pH was adjusted with concentrated HCl to 7.0. The media
was sterilised by filtration and stored at 4 C,
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2.1. Cell Culture Medium
The composition of RPMI 1540 powdered medium is shown in Table 1.
The complete tissue culture medium was prepared immediately before 
use and consisted of;-
80% (by volume) RPMI 1640 medium
20% " Foetal calf serum
10^ units/1 Penicillin
loo  mg/1 Streptomycin
2.0 mM Glutamine
The foetal calf serum was heat inactivated by incubation at 560C for 
1 hr and stored at -20^C.
The penicillin/streptomycin and glutamine were stored as separate 
lOOx solutions at -20^C.
I am grateful to the tissue culture staff, and in particular to 
Mrs. Irene Gall and Mrs. Jacqui Grieves, for the routine preparation 
of the above cell culture medium and stock solutions.
2.2. Phosphate Buffered Saline
Phosphate buffered saline, solution A, consisted of:-
PBS-A
170 mM NaCl
3.4 mM KCl 
10 mM Na^HPO^
1.8 mM KH^PO^ pH 7.2
2.3. Scintillation Spectrometry Solutions
Toluene-PPO 
4 9 /I PPO in toluene
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Triton-Toluene-PPO 
57% (by volume)
33%
4 g/1
Toluene 
Triton X-lOO 
PPO
3. HAEMATOPOIETIC CELL LINES
The human lymphoma cell lines under investigation in this thesis, and 
some of their general characteristics are shown in Table 2.
The lymphoblastoid and lymphoma cell lines were obtained as indicated 
below:-
Bec-11, Bri-8 , Mich 
RPMI-1788
Tay-3
U698M
BJAB, Daudi, Namalwa, 
Raj i-ATG
A generous gift from Searle 
Research Laboratories, Ltd.,
High Wycombe, England
A generous gift from Dr. C.M. 
Steel, MRC Clinical and 
Population Cytogenetics Unit, 
Western General Hospital, 
Edinburgh, Scotland
A generous gift from Dr. C. 
Sundstrom, Karolinska Institute, 
Stockholm, Sweden
A generous gift from Dr. G. 
Clements, Department of Path­
ology, Western Infirmary, 
Glasgow, Scotland
4. SEROLOGICAL REAGENTS
4.1. Immunoglobulins
The immunoglobulin reagents used in this thesis, their designations, 
classes and methods of preparation are summarized in Table 3.
Immunoelectrophoretic analyses for purity and light chain class of 
the various reagents are shown in Fig. 1 and Fig. 2 respectively.
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TABLE 2
CHARACTERISTICS OF LYMPHOMA CELL LINES
Designation Origin Surface Markers References
BJAB Burkitt's sIgM, (F ), (C3)
Lymphoma
Klein et al., 1974 
Menèzes et al., 1975
Daudi sIgM, F^, C3 Klein et al., 1968
Namalwa sIgM, F^, C3 Reedman & Klein, 1973
Raii-ATG (sIgM), (F^), C3 Pulvertaft, 1965 
Epstein et al., 1966 
Nyormoi et al., 1973
U698M Lymphosarcoma sIgM, (sIgD) 
(tonsil)
Nilsson & Sundstrom, 1974
Abbreviations: F^, F^ receptors; C3, complement (C3) receptors
( ) = weakly positive
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t a b l e 3
SUMMARY OF IMMUNOGLOBULIN PREPARATIONS
Designation, Source
Human Immunoglobulins 
GM, Wald. Macro.
7A, myeloma serum 
3F, myeloma serum 
2L, myeloma serum 
Rh IgMs, rheumatoid sera
GA, myeloma serum 
3F, myeloma serum 
2K, myeloma serum 
3H, myeloma serum 
8L, myeloma serum 
2P, myeloma serum
Ford, myeloma serum
Class
IgMK
IgMK
IgM\
IgMÀ
IgMKÀ
IgAic
IgAK
IgAic
IgAA
igAtc
IgAA
igGA
Method of 
Preparation
BA, G-200 
BA, G-200 
BA, G-200 
BA, G-200 
BA, G-200
AS, DEAE
AS, DEAE
AS, DEAE
AS, DEAE
AS, DEAE, G-200
AS, DEAE, G-200
AS, QAE
Budapest, myeloma serum 
AI, myeloma serum
IgDA
IgDA
AS
AcA 34, DEAE*
Rabbit Immunoglobulins
NoRIgG, normal rabbit serum NA AS, G-200
RbIgG, Nordic Immunological NA
Laboratories Ltd., Maidenhead,
Berks, England
*R. Jefferis, Journal Immunol. Methods 9_, 231-234 (1976)
(BA) boric acid precipitation; (AS) ammonium sulphate precipitation; 
(G-200) G200 Sephadex Chromatography; (DEAE) DEAE Sephadex 
Chromatography; (QAE) QAE Sephadex Chromatography; NA, not applicable
Fig. 1
Immunoelectrophoretic Analysis for Purity 
of Immunoglobulin Reagents
Immunoelectrophoresis was carried out essentially as described 
by Scheidegger (1955). A solution of 50 mM Veronal buffer, 
pH 8.6, containing 1% w/v agarose was pipetted onto microscope 
slides at 60°C and allowed to cool. Wells and troughs were cut 
in the agarose gel using a cutting template. The wells were 
filled with the Ig sample to be tested (approximately 1 yl) and 
the gels electrophoresed at 6 V/cm for 1-2 hr. After electro­
phoresis the troughs were filled with antisera as indicated 
(50-100 yl) and the gels incubated in a humid chamber (overnight 
at 20°C) to develop the precipitin arcs. The gels were then 
washed at 4°C in three changes of PBS-A and finally stained in a 
solution of 0.1% w/v Coomassie Blue dye in methanol:water :acetic 
acid (45 :45:10).
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GM IgM
WHS
GA IgA
7A IgM
WHS
7A IgM 
2L IgM
WHS 
3F IgM 
WHS
Rh IgMs 
WHS
-RC2590%lgM
r
2K IgA 
WHS
8L IgA, 
 ^WHS RC77CXIgA
8L IgA
2P IgA
^ 3H IgA 
♦ * MilmOCIgA
3F IgA
A I IgD 
WHS 
Bud IgD 
WHS
Ford IgG 
WHS
Ford IgG
FR30.lgG
Fig. 2
Immunoelectrophoretic Analysis to Determine the Light Chain 
Class of Various Immunoglobulin Reagents
Immunoelectrophoresis was carried out as described in the legend 
to Fig, 1. The results are summarised in Table 3.
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7A IgM
.a-K
1M IgM
rite.2L IgM .a-K
3F IgM
GM IgM I
a-K
2R IgM ;
3F IgA
lA IgA
2K IgA 
*7M IgA
3H IgA
8L IgA
2P IgA
OT IgA
a-L
Ot-L
a-L
a-L
WHS ]
WHS
L a-lgD
w:-----
—  Ford IgG
a-K
a -L
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Ford myeloma serum was obtained from Dr, B. Thomas, NIMR, Mill Hill, 
London, England.
Budapest myeloma serum was a kind gift from Dr. J. Gergeley, Budapest, 
Hungary.
The AT IgD myeloma protein, in highly purified form, was a kind gift 
from Dr. R. Jefferis, University of Birmingham Medical School, 
Birmingham, England.
All other serum samples were obtained from Dr. Eva Kirkwood, Depart­
ment of Immunology, Western Infirmary, Glasgow, Scotland.
4.2. Antisera and Antibody Preparations
The following antisera against human immunoglobulins were obtained as 
indicated:-
Rabbit anti-IgA ( a -specific) Miles Laboratories Research
Products, Ltd., Stoke Poges, 
Slough, England
Rabbit anti-IgM ( y  -specific) "
Rabbit anti-IgD ( 6 -specific) "
Rabbit anti-K (Bence-Jones) "
Rabbit anti-X (Bence-Jones) "
Rabbit anti-IgD (R.33, unabsorbed) A kind gift from Dr. J. Gergeley
Budapest, Hungary
Rabbit anti-IgD (R.164, 6-specific) "
Rabbit anti-IgD (R.410, F^6 - A kind gift from Dr. R,
specific) Jefferis, University of
Birmingham Medical School, 
Birmingham, England
In addition, several antisera were raised to the immunoglobulin 
reagents described in the previous section (4.1), and from these
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t ab le 4
DERIVATION AND PREPARATION OF PURIFIED ANTIBODIES
Antibody From Antiserum Against Ag Selected on Immunoadsorbent
RAHIgM
prep. 1 RC 79 (AS) IgMK (GM, 7A) IgMA (3F, 2L)
prep. 2 RC 259 (G-200) IgMK (7A) IgMKA (Rh)
prep. 3 RC 259 (W) IgMK (7A) IgMKA (Rh)
RAHIgG
prep. 1 FR 1 (DEAE, G-200) IgGA (Ford) IgGA (Ford)
prep. 2 FR 1 (DEAE, G-200) IgGA (Ford) IgGA (Ford)
RAHIgA
prep. 1 RC 77 (AS) IgAK (GA, 8L) IgAA (2P, 3H)
prep. 2 RC 479 (W) IgAK (3F, 8L)
GARIgG
prep. 1 G 320 (AS) Rb IgG (Nordic) NoRIgG (NRS)
prep. 2 G 315 (G-200) Rb IgG (Nordic) NoRIgG (NRS)
prep. 3 G 315 (AS) Rb IgG (Nordic) NoRIgG (NRS)
(AS) ammonium sulphate globulin fraction; (G-200), G-200 Sephadex 
IgG fraction; (DEAE) DEAE Sephadex IgG fraction; (W) whole 
antiserum.
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antisera purified antibody preparations were made. The relevant 
information is summarized in Table 4.
Immunoelectrophoretic analyses of the specificity of each antisera 
or antibody preparation used are shown in Fig. 3.
5. CELL CULTURE METHODS
5.1. Maintenance Culture Method
Cell lines were grown in continuous suspension culture in complete 
RPMI 1640 medium (section 2.1) in 250 mi plastic flasks in a 5% 
002-95% air atmosphere. Subculturing was done every third or fourth
day by replacing 80-90% of the cell culture with fresh medium.
5.2. Bulk Culture Method
Cells were grown in continuous suspension culture in sealed 2.5 1 
glass burlers (400 ral/burler).
5.3. Cell Viability Determination
A 0.2% w/v solution of trypan blue was added to an equal volume of 
culture fluid, and cell numbers determined by counting in a Neubauer 
type haemocytometer.
Trypan Blue Dye Solution
4 parts 1% w/v NaCl
1 part 1% w/v Trypan blue dye
5.4. Contamination Checks
5.4.1. Bacterial
Fig. 3
Immunoelectrophoretic Analysis of Antiserum 
and Antibody Specificities
Immunoelectrophoretic analysis was carried out as described in 
the legend to Fig. 1, The sources of the various antisera 
analysed, and their designations are summarised in Table 4.
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Blood-agar plates were prepared to the following formulation :- 
For 10 Plates
50 ml 4% w/v Blood-agar, "Difco Bacto"
5 ml Horse blood
Concentrated cell suspensions were spread on blood-agar plates and 
incubated at 37°C in a humid chamber. If positive, colonies 
developed in 2-5 days.
5.4.2. PPLO
PPLO-agar plates were prepared to the following formulation :- 
For 10 Plates
25 ml 3.5% w/v PPLO-agar, "Difco Bacto"
7.5 ml Horse serum
3.7 5 ml 0.5% w/v Yeast extract
3.75 ml Tryptose phosphate broth, 29.5 g/1
0.4 ml 1.25% w/v Thallous acetate
0.15 ml Penicillin, 2.5 x lO^ units/ml
Agar plates were pierced several times with a pasteur pipette 
containing concentrated cell suspensions and the plates placed in a 
sealed jar in a 5% C02-95% atmosphere. If positive, colonies
developed in 3-7 days.
5.5. Frozen Storage of Cell Lines
Cell freezing medium was prepared to the following formulation ;-
Freezing Medium
40% (by volume) 2 x RPMI 1640 (minus NaHCO^)
10% " DMSO
20% " Foetal calf serum (heat inactivated)
30% " Distilled water
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Cells were centrifuged (500 x g for 5 min) and resuspended at 
approximately 5 x 10^ cells/ml in cold Freezing Medium, The 
temperature of the culture was then reduced slowly (1°C per min) , 
and the frozen cells stored in liquid nitrogen.
To thaw, the frozen cells were quickly brought to 37^C by immersion 
in a water bath and diluted into 10 volumes of complete RPMI 1640 
medium. The cells were centrifuged (500 x 5 for 5 min) and resus­
pended in fresh medium for initiation of normal growth.
I am grateful to the tissue culture staff, and in particular to 
Mrs. Irene Gall for carrying out contamination checks and for the 
frozen storage and recovery of cell lines,
6. PREPARATION OF SEROLOGICAL REAGENTS
6.1. General Preparation Methods
6.1.1. Ammonium Sulphate Fractionation
All steps were done at room temperature. The serum sample was 
centrifuged (10,000 x g for 15 min) to remove insoluble material, and 
then diluted with an equal volume of PBS-A. Saturated ammonium 
sulphate (53.6% w/v at 20^C) was added dropwise, with mixing, until 
40% saturation was obtained. After standing a minimum of 2 hr, the 
precipitate was collected by centrifugation, washed once with 40% 
saturated ammonium sulphate, dissolved in PBS-A and dialysed.
6.1.2. Boric Acid Precipitation of Euglobulins
All steps were done at room temperature. The serum sample was 
centrifuged to remove insoluble material, and then added dropwise
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with mixing into a solution of 2% w/v boric acid (20:1 v/v). After 
standing for a minimum of 2 hr, the precipitate was collected by 
centrifugation, dissolved in PBS-A and dialysed.
6,1,3. DEAE Sephadex Chromatography
The sample was dialysed extensively against Column Buffer, centri­
fuged to remove insoluble material, and applied as a narrow band to 
the top of a column (1.25 cm i.d. x 25 cm,bed volume 40 ml) of 
DEAE Sephadex equilibrated in Column Buffer. A linear gradient of 
increasing buffer concentration (usually 0.01 M - 0.40 M potassium 
phosphate, pH 6.5) was applied to the column using an LKB Ultro- 
grad gradient maker at the rate of 20 ml/hr for a total of 16 hr. 
Fractions were collected and the appropriate peak fractions pooled 
on the basis of absorbancy measurements.
DEAE Column Buffer
0.01 M Potassium phosphate, pH 6.5 1 ■ *9^ ')
6.1.4. QAE Sephadex Chromatography
The sample was dialysed extensively against Column Buffer, centri­
fuged to remove insoluble material, and applied as a narrow band to 
the top of a column (1.25 cm i.d. x 25 cm, bed volume 40 ml) of 
QAE Sephadex equilibrated in Column Buffer. Buffer was applied to 
the top of the column, and fractions collected and monitored by 
their absorbency at 280 nm. IgG was the only significant
protein eluted under these conditions.
QAE Column Buffer
0.1 M Tris-HCl, pH 6.5
I am grateful to Mrs. Jacki Bennett for the QAE Sephadex purification 
of Ford IgG.
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5.1.5. Sephadex G-200 Chromatography
A column (2,5 cm i.d. x 100 cm,bed volume 500 ml) was packed with 
Sephadex G200 equilibrated in Column Buffer and de-gassed.
G20Q Column Buffer
0.1 M Tris-HCl, pH 8.0
0.2 M NaCl
The sample was dialysed extensively against Column Buffer, centri­
fuged to remove insoluble material, and applied to the top of the gel 
bed under the buffer solution. The column was connected by an 
airtight system to a buffer reservoir, and a flow rate of 10-15 ml/hr 
achieved by adjustment of the hydrostatic pressure head. Fractions 
were collected and the appropriate peak fractions pooled on the basis 
of absorbance measurements.
6.2. Raising of Antiserum
6.2.1. Primary Immunisations
Immunoglobulin preparations for injection (0.5-1 ml) were mixed 
with an equal volume of complete Freund's adjuvant and the mixture 
emulsified by sonication. Rabbits were given two primary injec­
tions intramuscularly at times separated by one week. From 0.2 
to 1.0 rag of protein antigen was used per injection,
6.2.2. Booster Immunisation
Booster injections were given every four weeks, beginning four weeks 
after the last primary injection. Approximately 0.2 mg of antigen 
was used and the injections given at multiple sites subcutaneously,
6.2.3. Collection of Antiserum
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Rabbits were bled from the ear vein, beginning six weeks after the 
last primary injection, and thereafter at 1-2 week intervals. 
Twenty to 50 ml of blood was taken at each bleeding, and allowed 
to clot at 37°C for 30 min and overnight at 4°C, The serum was 
sterilised by filtration and stored at -20°C.
I am grateful to Mrs. Liz Blakely for preparation of much of the 
antisera used in this thesis.
6.3. Sepharose Immunoadsorbents (Axen et al., 1967)
Sepharose 4B was washed thoroughly with distilled water and reacted 
with cyanogen bromide (100 mg CNBr/ml packed Sepharose) in aqueous 
solution of approximately 25% v/v Sepharose. The reaction was 
carried out inside a fume cupboard at room temperature with gentle 
mixing. The pH was monitored and adjusted continually to 11.0 -
11.5 by addition of 5 ^  NaOH and the reaction stopped when the pH 
stabilised. The activated Sepharose was washed with an ice cold 
solution of 0.1 M NaHCO^ and immediately resuspended in approximately 
5 volumes of the same buffer. The immunoglobulin sample to be 
coupled (l-lO mg Ig/ml activated Sepharose)was then added and the 
reaction allowed to proceed at 4°C with gentle mixing for 16 hr.
The Sepharose was then washed with 0.1 M NaHCO^, the absorbance 
(A^b o  ^ of the eluates measured and used to determine the total 
uncoupled Ig. The amount of coupled Ig was then calculated according 
to the following formula:-
Coupled Ig = (Total Ig) - (Uncoupled Ig)
The Sepharose was then reacted at 4°C for 16 hr with a molar equiva­
lent (relative to the CNBr) of glycine to 'quench' any remaining
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active sites. The Sepharose was then washed with PBS-A,suspended 
in PBS-A containing 0,05% sodium azide as preservative and stored 
at 4°C.
6.4. Preparation of Purified Antibody
Antiserum was passed slowly through a small column of Sepharose 
immunoadsorbent at room temperature. After thorough washing of 
the column with PBS-A, the bound antibody was eluted with one of the 
following buffers:-
Elution Buffers
(i) 0,2 M Glycine-HCl, pH 2,5
(ii) 0.1 M Acetic acid
(iii) 1.0 M Propionic acid
The elution was monitored by absorbance measurements at 280 nm, and 
the fractions containing the antibody were pooled and immediately 
neutralised with Trizma Base. The antibody was then dialysed against 
PBS-A, concentrated and stored as aliquots at -20°C. Sepharose 
immunoadsorbents were regenerated by washing with PBS-A and stored 
at 4°C in PBS-A containing 0.05% sodium azide as preservative. They 
could be used repeatedly with only moderate progressive loss of 
absorption capacity.
6.5, Radioiodination of Immunoglobulins
Immunoglobulins were radioiodinated by tbe chloramine-T method of 
Hunter and Greenwood (1962), The reaction mixture was held on ice 
inside a fume cupboard. All reactants (except the radioiodine) 
were prepared in PBS-I.
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PBS-I
50 mM Sodium phosphate, pH 7.2 i -
150 mM NaCl
Generally, 500 yg of Ig (5 mg/ml) was placed in an Eppendorf poly­
propylene tube (1.6 ml capacity) to which the following was added, 
in order :~
1 mCi Iodine-125, or Iodine-131 (5-10 yl)
20 yl Chloramine-T, freshly prepared, 1 mg/ml
and, after 3 min of vigorous mixing:-
20 yl Sodium metabisulphite, freshly prepared,
1 mg/ml
10 yl lOO mM KI
The iodinated Ig sample was then dialysed extensively against PBS-A 
and stored in aliquots at -20°C.
7. SEROLOGICAL PRECIPITATION METHODS
Several methods were employed to analyse the parameters of indirect 
immunoprécipitation, as they apply to the isolation of cellular immuno­
globulin. In this section these methods are described and illustrated.
7.1. Equivalence Titrations Against GARIgG
Equivalence titrations against Goat anti-Rabbit IgG were done for 
each rabbit antiserum in order to establish the most efficient pre­
cipitation conditions for each system. GARIgG antibody (lOO yg) 
was mixed with increasing amounts of a rabbit anti-human Ig antiserum 
in a constant volume (0.2-0.5 ml) of PBS-A. After incubation for 1 hr
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at 37°C and overnight at 4^C, the precipitates were collected by 
centrifugation (8,000 x g for 2 rain) and washed three times with ice 
cold PBS-A, The washed precipitates were dissolved in 0.2 ]N 
NaOH and the absorbance (^280^ determined. The amount of precipitate 
was plotted against the amount of rabbit antiserum reacted, yielding 
a titration curve similar to that shown in Figure 4A. The point 
of maximum precipitation is the equivalence point for the system. The 
equivalence points for many of the serological precipitation systems 
used in this these are shown in Table 5.
7.2. Indirect Immunoprécipitation Using GARIgG
7.2.1. Effect on Antigen Binding of Non-Equivalence Precipitations 
Since it was not always practical to use exact equivalence of 
rabbit antiserum and GARIgG, the efficiency of primary antigen 
(human Ig) precipitation under non-equivalence conditions was 
investigated. A trace amount of 1-125 labelled human IgM (0,2 yg;
33,000 cpm) was introduced into an equivalence titration with GARIgG 
antibody (100 yg) and rabbit anti-human IgM antiserum. Precipitation 
of the human IgM was monitored by gamma counting of the washed immuno- 
precipitates, and plotted on a normalised scale against the amount of 
rabbit antibody reacted. The results are illustrated in Fig. 4A, and 
show precipitation of primary antigen (human IgM) to be essentially 
complete in a broad region from antibody (GARIgG) excess to antigen 
(Rb anti-IgM) excess,
7.2.2. Binding Capacity of the System of Equivalence 
Increasing amounts of human IgM were aliquoted into a series of 
small test tubes and a constant amount of 1-125 labelled human IgM 
(0.2 yg; 33,000 cpm) added. Indirect immunoprécipitations were
then carried out using anti-human IgM and GARIg antibody and the
Fig. 4
Titration Curves for Indirect Immunoprécipitation
(A) Precipitation of IgM as a Function of Anti- 
IgM: GARIgG Equivalence
A trace amount of 1-125 labelled human IgM (0,2 yg; 33,000 cpm) 
was added to a series of tubes containing increasing amounts of 
Rb anti-human IgM antiserum (Miles Laboratories) in a constant volume 
of 0.2 ml PBS-A. Goat anti-Rb IgG (GARIgG) antibody (100 yg in 
10 yl PBS-A) was then added and incubation for 1 hr at 37°C and 
overnight at 4°C allowed. The iramunoprecipitates were collected 
by centrifugation (8000 x g for 2 min) and washed three times with 
ice cold PBS-A. The washed precipitates were dissolved in 1 ml of 
0.2 ^  NaOH and the absorbency ^^280^ determined. The radioactivity 
in the dissolved immunoprecipitates was then determined by gamma 
counting. The amount of immunoprecipitate (1.4 mg/ml Ig = 1 A^q^ 
unit) and the percentage of labelled IgM precipitated are plotted 
versus the amount of Rb antiserum used.
(B) Capacity of Anti-IgM and GARIgG at Equivalence to 
Precipitate IgM
Increasing amounts of IgM were aliquoted into two identical sets of 
tubes and label introduced by addition of a constant trace amount 
(0.2 yg; 33,000 cpm) of 1-125 labelled IgM. Indirect immunopré­
cipitations were then carried out by addition of either 1 yl anti-IgM 
(1 hr at 37°C) followed by 40 yg GARIgG (overnight at 4°C) to one set 
of tubes, or 3 yl anti-IgM followed by 120 yg GARIgG to the other set 
of tubes. The immunoprecipitates were collected and washed as des­
cribed above, and the radioactivity determined by gamma counting. The 
percentage of labelled IgM precipitated is plotted versus the amount of 
unlabelled IgM present in the reaction mixture.
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TABLE 5
EQUIVALENCE AMOUNTS OF VARIOUS ANTISERA AND 
ANTIBODY PREPARATIONS WITH GARIgG
Antiseraf Antibody Designation
RAHIgM Antibody
RAHIgG Antibody
RAHIgA Antibody
Miles Anti-Human IgM
Miles Anti-Human IgA
Miles Anti-Human IgD
Miles Anti-Human Bence Jones k
Miles Anti-Human Bence Jones A
R. 33 Anti-Human IgD
R, 164 Anti-Human IgD
R. 410 Anti-Human IgD (AI)
Normal Rabbit IgG
Equivalence for 100 pg 
GARIgG Antibody
20-25 yg 
20-25 yg 
20-25 yg
2.5 yl
3.5 yl 
Not used
2.0 yl
2.0 yl 
Not used 
Not Used
2.0 yl 
20-25 yg
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precipitation of IgM monitored by gamma counting of the washed 
immunoprecipitates. The percent of IgM precipitated was plotted 
against the amount of IgM present in the reaction mixture. The 
results are illustrated in Fig. 4B, and show greater than 75% 
binding of up to 30 yg of IgM (equivalent to 6 yg of IgG) using 
3 yl of antiserum.
7.3. Indirect Immunoprécipitation Using 5. Aureus ImiQunoadsorbent 
(Kessler, 1975)
A 10% v/v solution of formalin-fixed S. aureus CCowan I strain) was 
added in place of GARIg antibody in immunoprécipitations using rabbit 
antiserum (or antibody) to human immunoglobulins in the first stage. 
Fifty microliters of S. aureus solution was used per lO yg of rabbit 
antibody, or per 1 yl of antiserum.
8. LABELLING AND ANALYSIS OF CELLULAR PROTEINS
8.1. Biosynthetic Labelling
Aliquots (1-5 X 10^ cells) of log phase cultures were centrifuged and 
the cells washed once with, and resuspended in, labelling medium 
containing the radioactive amino acid to be used (lyophilised).
Labelling Medium
RPMI-1640 medium, without serum and minus 
the labelling amino acid
8.1.1. Pulse Labelling
Incubation in the labelling medium was allowed to proceed at 37°C for 
5-90 min.
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8.1.2. Pulse-Chase Labelling
Following the incubation as above, complete RPMI-1640 medium (with 
serum) was added, and the incubation continued for a further 4-18 hrs, 
depending on the individual experimental protocol.
For details of labelling conditions for individual experiments, see 
figure legends.
8.2. Radioiodination of Cell Surface Proteins
The lactoperoxidase method of Marchalonis et al. (1971) was used, with
7
minor modifications. An aliquot of healthy log phase cells (1 x 10 
cells, greater than 95% viable) was taken. The cells were centrifuged 
(500 X g for 5 min), washed twice with ice cold serum-free medium, 
twice with ice cold PBS-I (section 6.5) and then resuspended in 50 yl 
of PBS-I in an Eppendorf polypropylene tube (1.6 ml capacity). The 
following reagents, all prepared in PBS-I (except the radioiodine), 
were added in order :-
50 yl Lactoperoxidase, 1 mg/ml
1-2 mCi Iodine-125 or Iodine-131 (5-10 yl)
10 yl H^O^, freshly prepared as a 1:1000
dilution
The reaction mixture was incubated at 30°c for 3 min, and the reaction 
stopped by addition of 1 ml ice cold PBS-I containing 5 m^ potassium 
iodide. The cells were centrifuged and washed twice with 1 ml aliquots 
of PBS-I, and once with 1 ml of TKM buffer.
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TKM Buffer
lo o  mM Tris-HCl, pH 8.2
lOO raM KCl
5 mM MgCl^
8.3. Cell Lysis
The labelled cells were centrifuged (500 x g for 5 min) and resuspended 
in 20 yl TKM buffer. A small volume (0.2-1 ml) of ice cold lysis 
buffer was then added and the mixture held on ice for lO min. Lysis 
buffers were made to the following formulations:-
NP-40 Lysis Buffer 
25 mM Tris-HCl, pH 8.2
150 mM N a d
1% v/v NP-40
(0.1% v/v) PMSF, IM in dimethyl formamide 
(100 roM) lodoacetate,sodium salt.
The NP-40 lysis buffer was used in early experiments, either with or 
without the protease inhibitors PMSF and iodoacetate.
. T.Mosmann, personal communication)
1 part 5% w/v SDS
1 part lO% w/v Deoxycholate, sodium salt
1 part 10% v/v Triton X-lOO
1 part 10 X TKM buffer
6 parts Distilled water
(0.1% v/v) PMSF, IM in dimethyl formamide
(0.1% v/v) Pepstatin-A, 0.7 mg/ml in 50% ethanol
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The 3-D TKM lysis buffer was used in later experiments, either with or 
without the protease inhibitors PMSF and pepstatin-A. When used, the 
PMSF and pepstatin-A were added to the lysis buffers immediately before 
use. The cell lysates were centrifuged twice - first to pellet the 
nuclei (2000 x g for 10 min) and then to pellet any cellular debris 
(30,000 X g for 1 hr). The final supernatants were used for all sub­
sequent extractions of cellular proteins. Post-nuclear and/or final 
supernatants were sometimes stored at -70°C but were then given an 
additional high speed centrifugation (30,000 x g for 1 hr) upon thawing.
The lysis conditions used in some experiments differed from the standard 
method outlined above. For details of individual experiments, see 
figure legends.
8.4. Analysis of Cellular Proteins
8.4.1. Acetone Precipitation
Aliquots of cell lysate were precipitated by addition of acetone 
(5:1 v/v) at room temperature. The precipitate was collected by 
centrifugation (8,000 x g for 2 rain) and air dried.
8.4.2. TCA Precipitation
An aliquot of cell lysate (10-50 yl) was mixed thoroughly with 50 yg 
of carrier protein (NoRIgG) and precipitated by the addition of 1 ml 
ice cold 10% w/v TCA. The precipitate was allowed to form for a 
minimum of 2 hr on ice and then collected by centrifugation (8,000 x g 
for 2 min).
8.4i3. Indirect Immunoprécipitation
Rabbit anti- human Ig antiserum (or purified antibody) was added to the 
cell lysate, and a 5-15 min incubation at room temperature allowed. An
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equivalence of GARIgG antibody (see Table 5) or S.aureus immunoadsorbent 
(Section 7.4) was added, and the immunoprecipitate allowed to form for 
30 min at 37°C and overnight at 4°C. The immunoprecipitate was collected 
by centrifugation (8,000 x g for 2 min) and washed three times with 1 ml 
aliquots of lysis buffer.
The details of immunoprécipitations are given for individual experiments 
in the figure legends.
9. LABELLING AND ANALYSIS OF CELLULAR RNA
9.1. 32P Labelling
Approximately 50 ml of a log phase culture was taken 16 hr before 
harvesting and the cells centrifuged (500 x g for 5 min). The cells 
were resuspended in an equal volume of Phosphate-Free Medium con­
taining 5 mCi of 32P and incubated at 37°C until harvesting for 
polysome preparation.
Phosphate-Free Medium
80% (by volume) RPMI-1640 medium minus Na^HPO^
20% " Foetal calf serum (dialysed vs. normal saline)
plus Penicillin/streptomycin and Glutamine 
(section 2.1.)
9.2. 3H-Uridine Labelling
Approximately 16 hr before harvesting, 10 raCi of ^H-Uridine was 
added to one bur1er (400 ml) of log phase cells. Incubation 
was continued until harvesting.
9.3. Preparation of Polysomes
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Cells were harvested in mid log phase at a viability of greater than 
95%. Just prior to harvesting, the cell culture was made to 0.1 mg/ml 
cycloheximide and swirled gently for 2 min at 37°C. All steps from 
this point were done at 4°C. The cells were centrifuged (500 x g for 
10 min), the medium thoroughly removed, and the cells washed twice 
with 200 ml aliquots of ice cold PBS-A containing 0.1 mg/ml cyclohex­
imide ,
9.3,1. Method of Fitzmaurice, Bennett, and Williamson (in press) 
Polysome extraction solutions were prepared immediately before harvest­
ing of cells, to the following formulations;-
Lysis Buffer A
0.88 M Sucrose
1 mg/ml Heparin
0.1 mg/ml Cycloheximide
0.08% v/v Triton X-lOO
Made to volume with 
Solution C
Lysis Buffer B
0,88 M Sucrose
1 mg/ml Heparin
0.1 mg/ml Cycloheximide
0.08% v/v Triton X-100
0.2 M KCl
0.05% w/v Deoxycholate, 
sodium salt
Made to volume with 
Solution C
Solution C 
50 mM 
25 mI4 
5 raM 
7 mM
Tris-HCl, pH 7.4 
NaCl
Magnesium acetate 
2-Mercaptoethanol
The washed cell pellet was homogenised in a Dounce homogeniser in
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5 volumes of Lysis Buffer A, with two strokes of a loose-fitting pestle. 
The lysate was centrifuged (10,000 x g for 20 min) and the super­
natant (Fraction I) removed and held on ice. The resulting nuclear 
pellet was homogenised as above in 5 volumes of Lysis Buffer B, The 
second lysate was centrifuged (50,000 x g for 20 min) and the super­
natant (Fraction II) removed. Fractions I and II were combined, 
centrifuged (10,000 x g for 10 min) to remove debris and then layered 
onto 10 ml cushions of 1.5 M sucrose (prepared in Solution C, con­
taining 0.1 mg/ml cycloheximide, 1 mg/ml heparin), in screw cap poly­
carbonate tubes to fit the Spinco 60 Ti rotor. The polysomes were 
pelleted through the sucrose cushion by centrifugation in a Beckman 
L5-65 Ultracentrifuge (45,000 rpm for 3 hr).
9.3.2. Modified Method (T. Mosmann, unpublished communication)
Polysomes were extracted using Lysis Buffer A*, prepared to the 
following formulation:-
Lysis Buffer A '
0.88 M Sucrose
0.1 mg/ml Heparin
0.1 mg/ml Cycloheximide
2% v/v Triton X-lOO
Made to volume with Solution C
The washed cell pellet was homogenised in 5 volumes of Lysis Buffer A' 
by vigorous whirhmixing and the lysate centrifuged (10,000 x g for 3 min) 
The supernatant was removed, made to 1 mg/ml heparin, layered onto 10 ml 
sucrose cushions and centrifuged (45,000 rpm for 3 hr) to pellet the 
polysomes. For both methods, the final polysome pellet was
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washed by gentle swirling in 0.25 M sucrose, and dissolved in a small 
volume (1-2 ml) of the same solution. The polysome concentration was 
determined by dissolving a 10 yl aliquot in 1 ml of 1% w/v SDS 
(1:100 dilution) and measuring the absorbancy at 260 nm and 280 nm. 
Polysomes were stored at -70°C.
9.3.3. Sucrose Density Gradient Centrifugation of Polysomes 
Linear sucrose gradients of 0.5 to 1.25 M sucrose in Solution C were 
poured into 12 ml polyallomer tubes to fit a Spinco SW41 rotor.
Gradients were overlayed with 5-10 units of polysomes (50-100 yl),
and centrifuged at 4°C in a Beckman L5-65 Ultracentrifuge (40,000 rpm 
for 90 min). ^260 were obtained by pumping the sucrose
gradient through a spectrophotometer flow cell of 1 mm path length.
9.4. Phenol Extraction of Polysomal RNA
The method of Mendecki et al. (1972) was used. Polysomes were 
dissolved in phenol extraction buffer at a concentration of approximately 
10 ^260 units/ml, and shaken vigorously at room temperature with an 
equal volume of buffer-saturated phenol (redistilled): chloroform: 
isoamyl alcohol (50:50:1). The phases were separated by centrifu­
gation (10y000 X g for 5 min), the aqueous phase removed, and the phenol 
phase again extracted with an equal volume of buffer. The two aqueous 
phases were combined and extracted with an equal volume of fresh phenol: 
chloroform:isoamyl alcohol. The final aqueous phase was removed 
carefully, 1/lOth volume of 4 M NaCl added, and the RNA precipitated 
overnight at -20°C with 2 volumes of ethanol.
Phenol Extraction Buffer
0.1 M Tris-HCl, pH 9.0
0.1 M NaCl
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1 raM EDTA
2% w/v SDS
9.5. Oligo dT Cellulose Chromatography
The method of T. Hunt (unpublished communication) was used. Poly­
somal RNA which had been twice ethanol precipitated, was centrifuged 
(10,000 X g for 15 min) and the pellet dried under a stream of 
nitrogen. The polysomal RNA was dissolved in a small volume (1-5 ml) 
of Loading Buffer and applied to a column of oligo dT cellulose 
(bed volume 0.5-1 ml) which was equilibrated in the same buffer. The 
column was washed thoroughly, the absorbance (^260^ the eluant 
monitored, and the washing stopped when the absorbance was less than 
0.04. The column was next washed with Intermediate Buffer and the 
washing stopped when the absorbance (Ag^^) was essentially nil. The 
poly(A) RNA was then eluted in a small volume of Elution Buffer. One 
tenth volume of 4 IM NaCl was added to the eluate, and the RNA pre­
cipitated overnight at -20°C with 2 volumes of ethanol. Ethanol pre­
cipitation was repeated and the poly(A) RNA was finally dissolved in 
distilled water at 100 yg/ml (A = 2.2) and stored at -70°C.
Loading Buffer Intermediate Buffer
lO mM Tris-HCl, pH 7.5 10 mM Tris-HCl, pH 7.5
1 mM EDTA 1 mM EDTA
0.1% w/v SDS 0.1% w/v SDS
0.5 M LiCl 0.1 M LiCl
Elution Buffer
10 mM Tris-HCl, pH 7.5
1 mM EDTA
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10. WHEAT GERM CELL-FREE TRANSLATION SYSTEM
10.1. Preparation of Wheat Germ Extract
The wheat germ extract was prepared according to the method of Marcu 
& Dudock (1974). All glassware was baked at 200°C to destroy ribo- 
nuclease, and all steps were done quickly at 4°C. Untoasted wheat 
germ (2 g) was ground in a mortar for 60 sec with an equal weight of 
powdered glass. Extraction Buffer (4 ml) was then added, to make 
a paste which was then removed and centrifuged (30,000 x g for lO min) , 
The supernatant (approximately 1 ml) was applied to a column (1.4 cm
i.d. X 25 cm) of coarse Sephadex G25 (treated overnight in 0.1% v/v 
DEP to destroy ribonuclease) and washed thoroughly with Column Buffer.
Extraction Buffer Column Buffer
20 mM HEPES buffer 20 mM HEPES buffer
1 mM Magnesium acetate 5 raM Magnesium acetate
100 raM KCl 120 mM KCl
2 mM CaCl^ 6 mM 2-Mercaptoethanol
6 m^ 2-Mercaptoethanol Adjusted to pH 7,6 with KOH,
Adjusted to pH 7,6 with KOH yielding final potassium con­
centration of 132 mM
The wheat germ supernatant was eluted with Column Buffer, and the 
turbid fractions collected, pooled and centrifuged (30,000 x g for 
20 min). The supernatant was immediately frozen in small aliquots 
and stored in liquid nitrogen.
The following formulation and assay conditions were developed by 
Mrs, H. Singer (Singer and Williamson, in preparation). I am also 
grateful to Mrs. H. Singer for making available to me wheat germ 
extracts and supplementary solutions and for running many of my assays,
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10.2, Supplementary Solutions
The following supplementary solutions were prepared and stored in 
small aliquots at -20°C (except the creatine kinase).
ATP Mixture
Sixty mg of ATP was dissolved in 2 ml distilled water and 
neutralised with KOH, To this was added 0.2 g of creatine 
phosphate and 1 mg GTP, The volume was adjusted to 5 ml.
DTT Mixture
A solution of 0.12 M DTT was prepared, and deaerated by 
bubbling through it for 30 min.
Creatine Kinase Solution
A solution of 0.5 mg/ml creatine kinase was prepared just 
prior to preparation of the assay mixture.
Spermidine Solution
A solution of 4 mM spermidine was prepared.
Salt Solution
0.7 M HEPES buffer, pH 7.8 (adjusted with KOH)
1.6 M KCl
10.3 Preparation of Assay Mixture
An Energy Mixture was prepared immediately before the assay, accord­
ing to the following formulation
Energy Mixture
25 yl ATP mixture
10 yl DTT mixture
5 yl Creatine kinase solution
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10 y1 Salt solution
50 yl Distilled water
100 yl Total volume
The Assay Mixture was then prepared to the following formulations;
Assay Mixture
15 y1 Wheat germ extract
10 yl Energy mixture
5 yl Spermidine solution
5 yl Poly (A), RNA, 100 yg/ml
  Radiolabelled amino acid(s), lyophilised
15 yl Distilled water
50 y1 Total volume
The assays were incubated at 25°C for 90 min in sealed Eppendorf 
polypropylene tubes (1.6 ml capacity).
10.4. Analysis of Cell-Free Translation Products 
After the incubation period, assays were diluted with 4 volumes of 
3-D TKM Buffer (section 8.3), and debris pelleted by centrifugation 
(8,000 X g for 2 min). Aliquots were then removed'for TCA, acetone, 
or serological precipitation.
10.4.1. Acetone Precipitation
Acetone precipitations were done as described in section 8.4.1.
“ 04“
10.4.2, TCA Precipitation
To determine the amount of incorporation of radiolabelled amino 
acid(s), a 25 yl aliquot (10%) of each diluted assay was removed, 
and an equal volume of 0.2 NaOH added. Incubation was allowed 
to proceed for 15 min at 37°C to hydrolyse charged tRNA molecules. 
Twenty yg of carrier protein (NoRIgG) was added, and the proteins 
precipitated at 4°C by addition of 50 yl of 25% w/v TCA followed 
immediately by 1 ml of 10% w/v TCA. The precipitates were allowed 
to form on ice for 1 hr, collected by centrifugation (8,000 x g for 
2 min), and washed three times with 10% w/v TCA.
10.4.3. Indirect Immunoprécipitation
Indirect immunoprécipitation was done as described in section 8.4.3,
11. DISCONTINUOUS SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS
Discontinuous SDS-PAGE using a Tris-glycine buffer system was done 
according to the method of Laemmli (1970) . Slab gels (20 x 25 x 
0.15 cm) were prepared•from stock solutions as follows;-
11.1. Stock Solutions 
Solution A
30% w/v Acrylamide
0.8% w/v N/N’ Methylene bisacrylamide
Deionised, filtered and stored at 4°C
Solution B
1.5 M Tris-HCl, pH 8.8
0.13% v/v TEMED
Filtered and stored at 4°C
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Solution C
0.65 M Tris-HCl, pH 6.8
Filtered and stored at 4°C
11,2. Separating Gel Preparation
The following table was used to prepare 100 ml of separating gel 
solution of the required percentage acrylamide
Percentage Acrylamide
5% 7.5% io% 12.5% 151
Solution A (ml) 16.7 25 33.3 41.7 50
Solution B (ml) 25 25 25 25 25
10% w/v SDS (ml) 1 1 1 1 1
Distilled water to lOO ml
The gel solution was degassed and ammonium persulphate added to 1 mg/ml.
The gel was poured immediately and left to polymerise at room temperature
for 1 hr.
11.3. Stacking Gel Preparation
Gel solution for 5% polyacrylamide stacking gel was prepared as follows 
4 ml Solution A
2.4 ml Solution C
0.24 ml 10% w/v SDS
24 yl TEMED
Distilled water to 24 ml
The gel solution was degassed and ammonium persulphate added to 1 rag/ml.
The gel was immediately poured on top of the separating gel and left
to polymerise around a 26-place PTFE (teflon) 'well' template.
■se­
ll .4 Sample Preparation and Electrophoresis
Protein samples to be electrophoresed were dissolved in 50 yl of
o
Sample Buffer, and heated at lOO C for 2 min.
Sample Buffer 
1 part Solution C
1 part Glycerol
2 parts 10% w/v SDS
(100 mM) DTT
6 parts . Distilled water, containing 0.01 mg/ml 
bromophenol blue
The samples were loaded into the sample wells, under the Reservoir 
Buffer, and electrophoresed overnight at 4°C at 15-20 mA/gel constant 
current.
Reservoir Buffer, pH 8.8 
0.025 M Trizraa base
0.192 M Glycine
0.1% w/v SDS
12. CONTINUOUS SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS
Continuous SDS-PAGE using a phosphate buffer system was done according 
to the method of Summers et al. (1965). Either slab gels (20 x 25 x 
0.15 cm) or cylindrical gels (0.55 cm i.d. x 6 cm) were prepared from 
stock solutions as follows:-
-87-
12.1. Stock Solutions 
Solution A, A *
30% w/v Acrylamide
0.8% w/v(A) N,N' Methylene bisacrylamide
1,2% w/v (A') N,N' Diallyltartardiamide (DATD)
6 ^  Urea
Deionised, filtered and stored at 4°C
Solution B
0.4 M Sodium phosphate, pH 7,2
6 M Urea, deionised
Filtered and stored at 4°C
12.2. Gel Preparation
The following table was used to prepare gel solutions of the required 
percentage acrylamide
*3% 5% 6% 10%
Solution A or A" (ml) 10 16.7 20 33.3
Solution B (ml) 25 25 25 25
10% w/v SDS (ml) 1 1 1 1
6 M Urea, deionised, to 100 ml
*agarose to a final concentration of o,5 % w/v was 
incorporated into the gel solution by heating to 
80°C in the 6 M Urea.
The gel solution was degassed and ammonium persulphate added to 1 mg/ml. 
Gels were poured immediately. Cylindrical gels were overlayed with 
water and left to polymerise at room temperature. Slab gels were poly­
merised around a 26-place PTFE (teflon) 'well’ template.
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12.3. Sample Preparation and Electrophoresis
Protein samples to be electrophoresed were first dissolved in a 
small volume (10- lOO yl) of Sample Buffer by heating at 100°C for 
2 min.
Sample Buffer
0.25 part Solution B
2 parts 10% w/v SDS
1 part Glycerol
6.75 parts 9M Urea, deionised
Bromophenol blue to 0.01 mg/ml final concentration
Samples to be reduced and alkylated were treated by addition of 
l/20thuvolume of IM DTT (30 min at 37°C) followed by 1/lOth volume 
1.25^ iodoacetamide (30 min at 20°C)-
The samples were loaded on top of cylindrical gels, or into the sample
wells of slab gels, under the Reservoir Buffer, and electrophoresed 
at 4°C at 10 mA/cylindrical gel, or 50 mA/slab gel.
Reservoir Buffer
0.1 M Sodium phosphate, pH 7.2
0.1% w/v SDS
13. POLYACRYLAMIDE GEL ELECTROPHORESIS OF RNA
Polyacrylamide gel electrophoresis of RNA in 99% formamide was done 
according to the method of Duesberg and Vogt (1973).
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13.1. Gel Preparation 
The gel solution was made as follows 
10 mM Na^HPO^
10 mM NaHgPO^ {pH 7.0)
Made to volume with formamide, dissolved with stirring overnight at 
4°C with light excluded.
3% w/v Acrylamide (recrystallised)
0.5% w/v N,N' Methylene bisacrylamide (recrystallised)
The gel solution was degassed and ammonium persulphate added to 1 rag/ral, 
Cylindrical gels (0.6 cm i.d. x 8 cm) were poured immediately and left 
to polymerise at room temperature.
13.2. Sample Preparation and Electrophoresis 
The RNA samples to be electrophoresed were dissolved in 20 yl 
buffered formamide containing O.Ol mg/ml bromophenol blue, and 5 yl 
glycerol added with vigorous mixing. The samples were applied to 
the tops of the gels, under a 2 cm layer of buffered formamide, and 
electrophoresed at lOO V constant voltage for 6 hr.
Reservoir Buffer
0.04 M Sodium phosphate, pH 7.0
14. ISOELECTRIC FOCUSING (lEF)
14.1. Stock Solutions 
Solution A
30% w/v Acrylamide
0.8% w/v N,N' Methylene bisacrylamide
■yu“
10 M Urea, deionised, to volume,filtered and stored 
at 4°C.
Solution B
10 M Urea, deionised, filtered and stored at 4°C
14.2. Gel Preparation (Awdeh et al, 1968)
The following table was used to prepare gel solutions of the required 
percentage acrylamide
5%______6%____7.5%______10%
Solution A (ml) 1 1.2 1.5 2
40% w/v Ampholine carrier
ampholytes (ml) 0.3 0.3 0.3 0.3
Solution B To 6 ml
TEMED to O.1% v/v and ammonium persulphate to 1 mg/ml were added and
the gel solution introduced as a 1 mm thick layer between a siliconized
2glass plate and a chromic acid washed glass plate (7.5 cm ) so as to 
adhere to the latter plate.
14.3. Sample Preparation and Focusing
Gels were placed face down onto carbon electrodes in a humidified 
chamber and prefocused for 1 hr at 50 V constant voltage. The 
electrodes were first coated lightly with the following solutions :-
Anode : 2% v/v Phosphoric acid
Cathode; 5% v/v TEMED
Samples were dissolved in 9 M urea (deionised) and applied to the pre­
focused gel as small volumes (10-20 yl) soaked into 0.5 cm x 1 cm 
filter papers. The samples were focused at 50 V for 1 hr, and then
•9 I
150 V overnight at room temperature,
15. RECOVERY OF PROTEINS FROM POLYACRYLAMIDE GELS
15.1. Localisation of the Protein Bands
Dried slab gels were overlayed with their respective autoradiographs, 
and the two carefully aligned using the fine edge markings of the gel 
which could be seen on the autoradiograph. The positions of the bands 
were marked on the gel by puncturing through with a drawing pin. The 
protein bands were then sliced out with a scalpel, and the paper 
backing scraped off.
15.2. Elution of Proteins
Proteins were eluted by overnight incubation of gel slices at 60°C 
in 0.2-lml of Elution Buffer.
Elution Buffer
250 Tris-HCl, pH 8.2
2% w/v SDS
(20 mM) DTT
The progress of the elution was monitored (with iodinated proteins) by 
gamma counting of both eluate and gel slice. When not directly measured, 
the elution efficiency was inferred from the above results. After 
sufficient protein was eluted (usually 50-80%), the gel slices were 
removed and carrier protein (50-250 yg/ml) added to the eluates. A 
further incubation at 37°C for 30 min was allowed and alkylation was 
then carried out as described in section 12.3, For charge-shift 
titration the specific conditions of alkylation are shown in the 
legend to Fig. 3.7.
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15.3. Preparation of Proteins for Microsequencing and Carboxy- 
peptidase Digestion
After alkylation, the eluted proteins were precipitated with acetone 
(5:1 v/v) at room temperature, and washed once with acetone;water 
(5:1) .
The dried protein pellet was redissolved in 0.1 ml of 30% v/v glacial 
acetic acid and then diluted to 1.0 ml. Aliquots were removed for 
determination of radioactivity and the samples lyophilised.
15.4. Preparation of Proteins for lEF - Removal of SDS
After alkylation, the eluted proteins were precipitated with acetone 
(5:1 v/v) at room temperature. The precipitates were redissolved in 
200 yl of 9 22 urea containing 10 mM Tris-HCl (pH 8.2) and again pre­
cipitated with acetone. This cycle of dissolution and acetone pre­
cipitation was repeated twice more. The samples were then dissolved 
in 9 M urea for lEF.
16. CARBOXYPEPTIDASE DIGESTIONS (Winstead & Wold, 1964)
16.1. Sample Preparation
Lyophilised samples containing 0.5 mg BSA and the radiolabelled
(3H-tyrosine) polypeptides to be analysed were dissolved in 0.9 ml
Digestion Buffer by heating at 100°C for 2 min. Insoluble material
was removed by centrifugation (8,000 x g for 2 min) and the pH adjusted
to 8.0-8.2 with 0.5 N HCl (5-10 yl).
Digestion Buffer
0.05 M NaHCO„—  3
0.2 M': LiCl
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16.2. Enzyme Preparation
Crystals of carboxypeptidase A were washed with two successive 1 ml 
aliquots of distilled water and just before use dissolved in 10% w/v 
LiCl and the concentration adjusted to 0.2 mg/ml using its absorbency
at 280 nm iA^Q^/2,3 —  mg/ml) , The enzyme solution was kept on ice
until use.
16.3. Digestions
An aliquot of sample (75 yl) was taken for determination of total 
radioactivity, brought to 0.2 ml by addition of Digestion Buffer and 
counted in 20 ml of Triton-Toluene-PPO scintillation liquid. A 
second aliquot (150 yl). was taken for determination of TCA soluble 
radioactivity before addition of enzyme (Time O), added to 50 yl 
of 40% w/v TCA and kept on ice.
Digestion at an enzyme-substrate ratio of 1:100 was initiated by 
addition of 10 yl enzyme solution (2 yg carboxypeptidase, mol.wt. 
34/7400) to remaining sample at room temperature. Aliquots (150 yl) 
were removed at specified times of incubation (0.2, 1, 2, 5 min)/ 
added to 50 yl of 40% TCA and kept on ice for a total of 30 min.
The resulting TCA precipitates were centrifuged (8,000 x g for 2 min)
and the supernatants (200 yl) carefully removed and counted in 20 ml 
of Triton-Toluene-PPO scintillation liquid.
17. DETECTION OF RADIOACTIVITY
17.1. Scintillation Counting of Aqueous Samples
Aqueous samples for liquid scintillation counting were from the
following sources:-
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(i) Acetone precipitated cellular or wheat germ proteins, 
dissolved in 2% w/v SDS, 9 M urea, or SDS-PAGE sample 
buffer.
(ii) TCA precipitated cellular or wheat germ proteins, 
dissolved in 0.2 N NaOH and neutralised with 1 M 
acetic acid.
(iii) Serological precipitates dissolved in 2% SDS, 9 M urea, 
or SDS-PAGE sample buffer.
Aqueous samples were counted in a Beckman LS 333 Scintillation Counter 
as either 1% or 10% v/v solutions in Triton-Toluene-PPO scintillation 
liquid. Comparisons were made only between samples counted in an 
identical manner.
17.2. Scintillation Counting of Polyacrylamide Gel Slices
Gel slices of polyacrylamide crosslinked with N,N' raethylenebis- 
acrylamide were solubilised by incubation at 60°C for 2 hr with 0.5 ml 
Protosol in tightly capped scintillation vials. Toluene-PPO 
scintillation liquid <5 ml) was then added with vigorous mixing.
Gel slices of polyacrylamide crosslinked with DATD were solubilised 
by room temperature incubation for 2 hr with 0.5 ml 2% periodic 
acid. Triton-Toluene-PPO scintillation liquid (5 ml) was then 
added. Samples were counted in a Beckman LS 333 Scintillation Counter,
17.3. Autoradiography of Slab Gels
Slab gels were washed with three changes (500 ml each) of 20% v/v 
ethanol and dried on to Whatman 3MM paper under vacuum. The dried gels
were held in contact with Kodak X-Oraat-R film between two glass
plates, and stored for the required exposure time in light-proof
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bags at room temperature.
17.4. Fluorography of Slab Gels (Bonner & Laskey, 1974)
Slab gels were washed in three successive 250 ml volumes of dimethyl 
sulphoxide (DMSO) for 30 min each and then impregnated with PPO by 
gentle agitation in a solution of 20% w/v PPO in DMSO (40 g PPO +
160 g DMSO) for 45 min. Excess PPO-DMSO solution was decanted off, 
and the gels flushed continuously with water for 1 hr. Gels were 
dried on to Whatman 3MM paper under vacuum and the dried gels held in 
contact with Kodak X-Omat-R film between two glass plates, and stored 
for the required exposure time in light-proof bags at -70°C.
RESULTS
AND
DISCUSSION
CHAPTER I
SYNTHESIS, SURFACE DEPOSITION, AND SECRETION OF IMMUNOGLOBULIN 
IN SELECTED HUMAN LYMPHOID CELL LINES
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1.1 EARLY STUDIES OF LYMPHOMA CELL SURFACE IgM
1.1.1. Purpose of Investigations
The use of lactoperoxidase catalysed radioiodination as a specific 
means of labelling cell surface proteins for biochemical analysis 
has been described by Marchalonis et al. (1971). One of the early 
aims of this project was to assess the efficacy of this method, 
combined with SDS-PAGE analysis of specific immunoprecipitates, for 
the identification of surface Ig (sig) on lymphoid cells.
1.1.2. Surface IgM Detection on Cell Lines Daudi and Raji
Two lymphoma“derived cell lines, Daudi and Raji, which were available 
to me in the beginning of my investigations were analysed for the 
presence of sIg. Previous workers had shown by immunofluorescence 
that Daudi cells expressed high levels, and Raji cells extremely low 
levels of sIgM (see Materials and Methods, Table 2). In addition, 
Sherr et al. (1972) and Kennel (1974) had identified Daudi sIgM by
SDS-PAGE analysis.
In the present investigation, the cells were surface radioiodinated 
and the labelled sIgM analysed by immunoprécipitation and SDS-PAGE on 
phosphate-buffered 6% polyacrylamide tube gels. Figure 1.1 shows 
the profiles obtained from the reduced immunoprecipitates. The Daudi 
sIgM (Pig. 1.1 (A)) was readily identified by the presence of a large 
peak of radioactivity comigrating with the p marker protein. In 
addition, a small light chain peak (K type) and a large peak of 
slightly slower mobility were resolved. This latter peak is discussed 
in Chapter 3. The SDS-PAGE profile shown in Fig. 1.1 (A) was in
Fig. 1.1
SDS-PAGE Profiles of Daudi and Raji Cell Surface IgM
7Cell surface proteins from 1 x 10 cells were labelled by lacto­
peroxidase iodination (1-125, 0.25 mCi) as described in Methods, 
section 8.2, and the cells lysed in 1 ml NP-40 lysis buffer con­
taining PMSF and iodoacetate (Methods, 8.3). Immunoprécipitations 
from the lysates were carried out by addition of 2 yl anti-IgM 
(15 min at 4°C) followed by lOO yg GARIgG (15 min at 4°C). Washed 
immunoprecipitates were dissolved in 75 yl SDS-PAGE sample buffer 
and half removed for reduction and alkylation (Methods 12.4). 
Electrophoresis was in phosphate-buffered tube gels of 6% poly­
acrylamide (Methods, 12), The radioactivity in individual gel 
slices was determined by gamma counting. Molecular weight marker 
y , Y, and light chains were electrophoresed in a separate tube gel.
(A) Daudi sIgM (Reduced)
(B) Raji sIgM (Reduced)
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good agreement with those obtained by Sherr et al. (1972) and 
Kennel (1974).
The Raji SDS-PAGE profile (Fig. 1,1 (B)) proved more difficult to 
interpret. While a peak of y mobility was resolved, the radioactivity 
in this peak was only slightly above background levels. Moreover, 
the background radioactivity in the Raji profile itself resolved into 
non-specific peaks which contained in some cases more label than the 
putative y peak.
1.1.3, Conclusions: Limitations of Methodology
These preliminary results indicated that sIgM could be readily 
detected by SDS-PAGE when it was expressed at high levels. However, 
the limitations of the methodology for the biochemical analysis of 
extremely low levels of sIgM (as with Raji cells) were also clearly 
illustrated. These limitations had also been reported by workers 
applying this methodology to similar problems such as the detection 
of putative T-lymphocyte sig (Haustein et al., 1975) . Modifications 
in the methodology which significantly improved the sensitivity of 
SDS-PAGE analysis of sig are discussed below.
1.2. METHODOLOGICAL CONSIDERATIONS FOR THE SDS-PAGE ANALYSIS 
OF IMMUNOGLOBULIN EXPRESSION
1.2.1. Background Radioactivity in SDS-PAGE Profiles of Immuno­
precipitates
The peaks of background radioactivity seen in the Raji SDS-PAGE profile 
(Fig. 1.1 (B) ) are typical of results from many other laboratories 
performing similar analyses. Much of this background radioactivity
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is generally accepted to be the result of non-specific binding of 
cellular proteins to immunoprecipitates (see Melchers & Andersson,
1973, for detailed analysis). However, some debate exists as to 
whether all of the peaks are truly non-specific. The SDS-PAGE pro­
files of the B-lymphocyte receptor (Basten et al., 1972; Cline
et al./ 1972), for example, have striking features in common with the 
non-specific background profiles, notably the broad peaks of radio­
activity migrating with proteins of approximately 40-50,000 molecular 
weight. It has also been suggested in work leading up to this 
thesis investigation (Premkumar et al., 1975a, 1975b) that certain of 
these peaks may represent proteins specifically associated with sIgM 
in the outer cell membrane, perhaps as sIgM anchor proteins.
1.2.2. Characterisation of Background Radioactivity by High Resolution 
SDS-PAGE
Using high resolution SDS-PAGE on slab gels (Laemmli, 1970), experi­
ments were undertaken to better resolve and identify the background 
radioactivity in immunoprecipitates. In one such experiment, surface 
radioiodinated and biosynthetically labelled samples were prepared 
from several IgM-producing cell lines. Samples of labelled IgM were 
isolated by immunoprécipitation and electrophoresed adjacent to 
samples of total cell lysate from the corresponding cells in a 12.5% 
polyacrylamide slab gel (Fig. 1.2), After fluorographic exposure 
the tracks containing the immunoprecipitates (even numbered) clearly 
showed the expected background radioactivity, as well as the specific­
ally precipitated y and (in some cases) light chains.
The SDS-PAGE profiles shown in Fig. 1,2 revealed several features of 
the background radioactivity as well. Thus, the background profiles 
consisted of bands representing most of the labelled proteins in the
Fig. 1.2
SDS-PAGE Analysis of Background Radioactivity 
in Immunoprecipitates
7
Cells surface proteins from 1 x 10 cells were labelled by lacto­
peroxidase iodination (1-131, 2 mCi) as described in Methods, 
section 8.2, and the cells lysed in 0.5 ml NP-40 lysis buffer con­
taining PMSF (Methods, 8.3). Aliquots of lysate were removed for 
acetone precipitation (Methods, 8.4,1). Immunoprécipitations were 
then carried out by addition of 25 yg RAHIgM plus 25 yg NoRIgG 
(15 rain at 20°C) followed by 200 yg GARIgG (1 hr at 20°C, overnight 
at 4°C).
For biosynthetic labelling, 1 x 10^ cells from log phase 
cultures were incubated for 1 hr in 0.2 ml labelling medium con­
taining 100 yCi 35S-methionine. Complete medium (0.8 ml) was then 
added and a further 6 hr incubation allowed (Methods 8.1). The 
cells were separated from the culture medium and lysed in 0,25 ml 
NP-40 lysis buffer as described above. Aliquots of lysate were 
removed for acetone precipitation. Immunoprécipitations were carried 
out by addition of 5 yg RAHIgM plus 45 yg NoRIgG (15 min at 20°C) 
followed by 200 yg GARIgG (1 hr at 20°C, overnight at 4°C). Washed 
acetone and immune precipitates were dissolved in lOO yl 2% SDS,
Five microlitre to 10 yl aliquots of immunoprecipitates (10% of sample) 
and acetone precipitates (2% of iodinated and 5% of biosynthetic 
samples) were added to 50 yl reducing sample buffer for discontinuous 
SDS-PAGE in a 12.5% polyacrylamide slab gel (Methods, 11). The gel 
was processed for fluorography (Methods, 17.4) and the fluorogram 
developed after an exposure of 24 hr. The y and light chains from 
the cells investigated were used as mobility markers.
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cell lysates. Most bands were labelled in the background profiles 
approximately proportional to their labelling intensity in the cell 
lysate, as expected in the absence of any specific binding. More­
over, the prominent peaks of radioactivity with mobilities between 
those of Y and light chain (see Raji profile. Fig. 1,1 (B)) could be 
seen in Fig, 1,2 to correspond to the highly labelled cellular pro­
teins actin and myosin (indicated by arrows).
1.2.3. Identification of Specific Immunoglobulin Bands Against 
a Constant Background
With the SDS-PAGE analysis shown in Fig. 1.2, it was possible to 
detect extremely low levels of IgM synthesis and surface deposition 
against a high background of radioactivity. Thus, the radioiodinated 
(track 2) and biosynthetically labelled (track 20) Raji y bands 
could be readily distinguished. In contrast, a non-producer mutant 
of cell line Namalwa showed only a background profile in both the 
radioiodinated (track 4) and biosynthetically labelled (track 18) 
samples. Although in this experiment the background radioactivity 
was quite high, the principle of identifying specifically enriched 
immunoprecipitated bands was clearly illustrated. With immuno­
precipitates having lower background radioactivity, this type of 
analysis gives a considerably greater sensitivity than previously 
possible,
1.2.4, Conclusions Concerning Non-Specific Binding to Immuno­
precipitates
The above results were therefore inconsistent with there being any 
specific binding to immunoprecipitates, other than that of the anti­
genic y and light chains to which the antiserum was directed. The 
single unique exception to this conclusion was found to be the p33
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protein associated with Daudi sIgM (track 8). Further investigation 
of this phenomenon is discussed in detail in Chapter 3.
1.2.5. Methods for Improved Sensitivity and Specificity of Immuno­
précipitation and SDS-PAGE; A Summary
In the previous section, results were cited which suggested the
cause of background radioactivity to be non-specific binding to the
precipitating immune complexes.. Over the course of many experiments
subsequent to this finding, steps were taken to reduce this unwanted
background radioactivity. Following is a summary of the modifications
in the methodology which were found to be useful.
1.2.5.1. Reduction in Amount of Immunoprecipitate
As background radioactivity was found to be approximately proportional 
to the amount of immunoprecipitate, steps were taken to minimise the 
amount of antiserum or antibody used. Complete immunoprécipitation
7
of cellular and/or secreted Ig produced by 1 x 10 cells under normal 
conditions of labelling was found to require 10-50 yg of specific anti­
body. In order to deliver this quantity with the minimum of rabbit 
Ig, affinity purified antibody was used. Immunoprecipitates formed by 
the subsequent addition of GARIgG were as much as tenfold smaller 
(i.e. 40-200 yg) than if whole rabbit antiserum was used.
1.2.5.2. Reduction in Cell Lysate and Labelling Medium Volumes 
This step was necessary for efficient immune complex formation with
7
the lesser quantities of antibody employed. Accordingly, 1 x 10 
cells (as for radioiodination) were generally lysed in 0.5 ml lysis 
buffer. For biosynthesis, 1 x 10^ cells were labelled in 0,2 ml 
medium, and lysed in 0,25 ml lysis buffer. In the case of biosynthetic­
ally labelled cells, proportionately less antibody was required, and
-103-
therefore used.
1.2.5.3. Use of Three-Detergent Lysis Buffer
Immunoprécipitations from cell lysates and wheat germ extracts in 
3D-TKM lysis buffer (Materials and Methods, section 8.3) were found 
generally to have somewhat less non-specific binding. It was 
further found that washing of immunoprecipitates with 3D-TKM buffer 
reduced background binding.
1.2.5.4. Use of Fixed S.Aureus Immunoadsorbent
A very useful reduction in amount of immunoprecipitate was achieved 
in later experiments using minimal amounts of purified antibody in 
a sandwich precipitation with fixed S,aureus immunoadsorbent(Kessler, 
1975) instead of GARIgG. Because of the inherently low non-specific 
binding of the S.aureus immunoadsorbent, this method significantly 
reduced the background radioactivity. This approach also had other 
important advantages. First, because it does not rely on formation 
of precipitable immune complexes, the reaction is both fast and 
relatively independent of reactant (i.e. antigen, antibody) con­
centrations. Secondly, because of the reduced protein recovered 
from immunoprecipitates, larger proportions of each precipitate could 
be loaded onto polyacrylamide slab gels. This decreased the exposure 
time required to see specific bands, and therefore increased the 
sensitivity of the methodology.
1.2.5.5. Use of High Energy, High Specific Activity Isotopes 
High specific activity biosynthetic labelling was achieved using 
less cells (1 x 10^) than commonly reported in the literature, in a 
small volume (0.2 ml) of labelling medium. Relatively large amounts 
of isotope were added to the labelling medium by prior lyophilisation, 
The use of the high energy g-emitters 131-1 and 35S-methionine gave
-104-
a considerable increase in sensitivity when combined with fluoro­
graphic development of slab gels.
1.2.5.6. Minimal Loading of Polyacrylamide Slab Gels 
Slab gel wells with cross-sectional dimensions of 0.15 x 0.5 cm were 
loaded with a maximum of 10-15 yg of immunoprecipitate. Larger 
loadings were found to cause distortion of the bands and high back­
ground radioactivity at a mobility equivalent to that of the antibody 
y-chains.
1.3. HIGH RESOLUTION SDS-PAGE OF LYMPHOMA CELL SURFACE IgM
1.3.1. Introductory Remarks
The identification of sIgM on lymphoid cells was greatly improved 
in later studies by adoption of the system of high resolution SDS-PAGE 
(Laemmli, 1970) on polyacrylamide slab gels. The lymphoma cell lines 
described below, which were initially screened for sIgM expression, 
represent an enlarged selection used for many of the subsequent 
investigations to be described in this thesis. The cell lines BJAB, 
Daudi, Namalwa and Raji were all derived from patients with Burkitt's 
lymphoma. The cell line U698M was derived from a patient with 
lymphosarcoma of the tonsils (see Materials and Methods Table 2 for 
details).
1.3.2. Detection of y-Chain Bands
Figure 1.3 (A) shows the SDS-PAGE profiles obtained in a 12.5% 
polyacrylamide slab gel from the reduced anti-IgM immunoprecipitates 
of the above cell lines. These cell lines had all been previously 
reported to have surface immunoglobulin of the IgM class and the results
Fig. 1.3
SDS-PAGE Screening of Several Lymphoid Cell 
Lines for Cell Surface IgM and IgD Expression
7
Cell surface proteins from 2 x 10 cells were labelled by lacto- 
perioxidase iodination (1-131, 1 mCi) as described in Methods, section
8.2, and the cells lysed in 0.5 ml NP-40 lysis buffer containing 
PMSF (Methods, 8.3), Immunoprécipitations were carried out by 
addition of 10 yg RAHIgM to 40% of each lysate and 0.5 yl R.410 
anti-IgD to 20% of each lysate (15 min at 20°C) followed by either 
50 yg or 25 yg respectively of GARIgG (1 hr at 20°C, overnight at 
4°C). Washed immunoprecipitates were dissolved in 9M urea (RAHIgM 
precipitates) or 2% SDS (anti-IgD precipitates), and aliquots (25%) 
precipitated with acetone and redissolved in reducing sample buffer 
for discontinuous SDS-PAGE in a 12.5% polyacrylamide slab gel 
(Methods, 11). The gel was processed for fluorography (Methods 
17,4) and the fluorogram developed after an exposure of 4 days. The 
y and light chains from the cells investigated, and the 6-chains 
from radioiodinated A^ IgD were used as mobility markers.
(A) Anti-IgM Precipitates
(B) Anti-IgD Precipitates
—105—
(A)
(-)
CO
<
X
V
I
I li
(B)
ill
i
<
Z Ï I
Q.
E
%
«
Ü
c
c
.2
EO)
■
(+)
-106-
obtained were consistent with those reports. Thus bands of radio­
activity corresponding to the mobility of y-chain were clearly 
resolved (indicated by arrow). As expected, all the y-chain bands 
comigrated (except Daudi y , discussed below).
1.3.3. Relative Labelling of y-Chains by Surface Iodination 
Because the conditions of labelling and analysis of the cell surface 
IgMs were identical, the observed intensities of the y bands in 
Fig. 1.3 (A) accurately reflects the relative amounts and/or 
susceptibility to radioiodination of the sIgMs. Thus, the sIgM from 
BJAB, Daudi, Namalwa, and U698M was always found to be very highly 
labelled, whereas the Raji sIgM was only weakly labelled. These 
results were consistent with the observations of other workers, (see 
Materials and Methods, Table 2) using mainly immunofluorescence to 
visualise the sIgM of these lymphoma cells, and seems to indicate a 
similar susceptibility of the sIgM to labelling by both techniques,
1.3.4. Higher Apparent Molecular Weight of Daudi Surface y-Chains 
High resolution SDS-PAGE revealed that the y-chain of Daudi sIgM 
migrated with a markedly higher molecular weight than other radio­
iodinated y-chains (Fig. 1,3 (A)). This finding had been reported 
previously by Kennel (1974), although not as well documented with 
respect to a panel of other surface radioiodinated y-chains. As shown 
in Fig. 1.3 (A) and confirmed in other studies, Daudi surface y-chains 
were unique in their higher apparent molecular weight. An estimate
of the molecular size of Daudi surface y-chains could be made by 
extrapolation from the semi-log plot of molecular weight versus 
SDS-PAGE mobility shown in the inset to Fig. 3.2 (Chapter 3) and the 
data shown in Fig. 2.1 (Chapter 2). Thus, Daudi surface y-chain was 
determined to have an apparent molecular wiehgt of 88-90,000. This
-107-
value is 3-5000 daltons larger than the other surface y-chains 
(see Chapter 2).
In addition, the Daudi sIgM profile shows the presence of a novel 
polypeptide of approximately 33,000 molecular weight (see Chapter 3) 
and an unusually large K-chain (discussed below).
1.3.5. Variable Mobilities of Light Chains on Discontinuous SDS-PAGE 
As can be seen from Fig. 1.3. (A), individual light chains (indicated 
by brackets) showed a range of mobilities in this SDS-PAGE system.
This phenomenon has been noticed by other workers (T. Mosmann, 
personal communication). In my investigations the mobility of each 
individual light chain was found to be characteristic and reproducible. 
The relative mobilities of the light chains investigated during the 
course of this thesis work are shown in Table 1.1. In general 
X-chains were found to migrate more slowly than K-chains (X-chains, 
5.4-5.9 cm; K-chains, 5.9-6.2 cm). It seems likely that amino
acid differences in the constant regions of the X and K-chains 
are responsible for the class specific mobility differences 
observed. Variations among individual light chains of the same class 
may arise from either amino acid or carbohydrate differences in the 
variable regions.
1.3.6. Higher Apparent Molecular Weight of Daudi K-Chains
As shown in Table 1.1, Daudi K-chains migrated significantly slower 
than the other K-chains (5.7 cm as compared with 5.9 - 6.2 cm for 
the other K-chains). It has been suggested by the work of Kennel 
(1974) that Daudi K-chains contain carbohydrate, although these 
authors may instead have been detecting the carbohydrate associated 
with the Daudi p33 protein. However, further investigations of
-10b-
'TABLE 1.1 Relative Mobilities of Ig Light Chains by
1
Discontinuous SDS-PAGE
Cell Line Light Chain Type
Com)
Namalwa A 5.4
Bec-11 A 5.7
Daudi K 5.7
1788 A 5.8
Raji K 5.9
Mich K 6,0
Tay-3 K 6,0
U698M K 6.0
Bri-8 K 6.1
BJAB K 6.2
1. Mobilities represent approximate relative values obtained by 
SDS-PAGE in a 12.5% polyacrylamide slab gel.
2. This faster mobility was often obtained with biosynthetically 
labelled Daudi k •
3. Thife faster mobility was obtained with one preparation of 
1788 A (see Fig. 2.3).
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Daudi K-chain and its cell-free translated precursor (see Chapter 2, 
section 2 .4 6)'are indeed consistent with the presence of carbohydrate 
moieties on the cellular K-chains which would confer on them a higher 
molecular weight. It has not been possible, however, to determine 
whether ordinary, or perhaps excessive levels of glycosylation are 
involved.
1.4. HIGH RESOLUTION SDS-PAGE OF LYMPHOMA CELL SURFACE IgD
1.4.1. Introductory Remarks
Much evidence has accumulated in recent years to firmly establish cell 
surface IgD as an important receptor on B-lymphocytes (for review see 
Immunological Reviews, 37, 1977). According to most schema of B-cell 
differentiation, cell surface IgD first appears on early B-lymphocytes 
which are already expressing cell surface IgM, A large proportion of 
these B-cells then continue to express both sIgM and sIgD on their cell 
surfaces, as determined by immunofluorescence studies.
Morphologically as well as by the criteria of sIgM expression, the 
Burkitt's lyraphoma-dervied cell lines are ideal human cells to investigate 
by SDS-PAGE for the presence of sIgD, In addition, the cell line U698M 
had been previously demonstrated by immunofluorescence to have sIgD 
CSundstrüm, 1977).
1.4.2. Detection of 6-Chain Band from U698M Cells
Several of the Burkitt's lymphoma-derived cell lines were surface radio­
iodinated and the cell lysates immunoprecipitated with a rabbit anti­
human IgD antiserum. Figure 1.3 (B) shows the SDS-PAGE profiles of 
the reduced immunoprecipitates. Of the cell lines investigated
- 1 1 0 -
(BJAB, Daudi, Namalwa, Raji, and U698M) the U698M cells alone showed 
a readily detectable band of radioactivity (indicated by arrow in 
Fig. 1.3 (B)) which approximately comigrated with the 6 marker protein. 
This result agreed with the finding of sIgD on U698M cells by Sudstrom 
(1977). However, due to suspected cross-reactivity in the anti-IgD 
antiserum, and the ambiguity of 6-chain SDS-PAGE mobility (see section 
1.4.4.2), the result shown in Fig. 1.3 (B) was not sufficient to prove 
the SDS-PAGE detection of sIgD 6-chain.
1.4.3. Confirmation of sIgD and sigM on U698M Cells
To determine whether the band in the U698M profile (Fig. 1.3 (B) ) was 
indeed 6-chain, another aliquot of U698M cells was labelled by lacto­
peroxidase iodination and the resulting cell lysate immunoprecipitated 
with either anti-IgM or anti-IgD in the presence or absence of competing 
unlabelled myeloma proteins. Figure 1.4 shows the SDS-PAGE profiles 
obtained from the reduced immunoprecipitates. The anti-IgM profile 
(track 1) shows the presence of the U698M sIgM ]i and K-chains, as 
expected. The anti-IgD profile with competing IgA, IgG and IgM but 
without competing IgD (track 2) was identical to the anti-IgD profile 
shown in Fig. 1.3 (B), except that the longer exposure in Fig. 1.4 also 
revealed an apparent degradation product of the 6-chain, as well as the 
U698M K-chain. In contrast, the inclusion of IgD in the mixture of 
competing Ig eliminated all the radioactive bands from the profile 
(track 3).
The above result confirmed the finding by radioiodination and SDS- 
PAGE of both sIgD and sIgM on the U698M cell line. Spiegelberg (1977) 
has recently reported a similar finding on a human lymphoblastoid 
cell line (Wil-2WT)K but has not presented any data.
Fig. 1.4
SDS-PAGE Analysis of U698M Cell Surface IgM and IgD
7Cell surface proteins from 1 x lO cells were labelled by lacto­
peroxidase iodination (1-131, 0.8 mCi) as described in Methods, 
section 8.2, and the cells lysed in 0.5 ml NP-40 lysis buffer con­
taining PMSF (Methods, 8,3). The lysate was divided into three 
aliquots and immunoprécipitations carried out in the presence of 
ccmpeting unlabelled antigen by addition of either; (1) 10 yg 
each IgAk and IgGA, followed by 4 yg RAHIgM;(2)30 yg each IgAk,
IgGA, and IgMA, followed by 0.4 yl R.410 anti-IgD; or (3) 10 yg 
each IgAk, IgGA, IgMA, and IgDA, followed by 0.4 yl R.410 anti-IgD. 
Incubation for 15 min at 20°C was followed by addition of 20 yg 
GARIgG (overnight at 4°C). Washed immunoprecipitates were dissolved 
in reducing sample buffer for discontinuous SDS-PAGE in a 12.5% 
polyacrylamide slab gel (Methods, 11). The gel was processed for 
fluorography (Methods, 17.4) and the fluorogram developed after an 
exposure of 2 days. The U598M y , 6, and K-chains; as well as the 
putative cleavage product of U698M surface 6 are indicated by the arrows
Track
(1) Anti-IgM Precipitate
(2) Anti-IgD Precipitate
(3) IgD-Competed Anti-IgD Precipitate
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1.4.4. SDS-PAGE Mobility of U698M Surface 6-Chains
1.4.4.1. Comparison to Surface y-Chain
The SDS-PAGE profiles shown in Fig. 1..4 demonstrated U698M cell 
surface 6-chains to migrate markedly faster than the surface y-chains. 
This finding is in agreement with those of Ferrarini et al. (1976)
and Spiegelberg (1977) who also used surface radioiodination on 
chronic lymphatic leukemia (CLL) and tonsil cells, or on CLL and 
normal peripheral blood lymphocytes, respectively. In addition, 
Spiegelberg (1977) also reported the same finding upon investigation 
of a human lymphoblastoid cell line (Wil-2WT) . Finkelman et al.
(1976), however, have reported that surface y and 6-chains of 
normal adult peripheral blood and cord blood lymphocytes migrate 
identically.
1.4.4.2. Comparison to Serum 6-Chains
Indirect evidence, derived from the fact that 90% of IgD myeloma 
proteins are A (Jancelewicz et al. , 1975) while the majority of surface 
IgD is K (Rowe et al., 1973), has been interpreted to suggest that 
6-chains from these sources may be of different subclasses. Possible 
support for this idea comes from the work reported by Spiegelberg (1977) 
where surface 6-chains were shown to be of higher apparent molecular 
weight than their serum counterparts by SDS-PAGE, although these workers 
also point out that this difference may instead be related to the 
attachment of surface IgD to the cell membrane.
From the results of the present investigation, it was possible to 
compare the SDS-PAGE mobilities of surface and serum 6-chains.
Figure 1.3 (B) shows that the myeloma IgD 6-chain used as a molecular 
weight marker migrated as two bands (indicated by arrows) . This was
in agreement with the observation of Goyert et al. (1977), who 
showed this to be the result of spontaneous degradation of the serum 
6-chain at the carboxy-terminal end. According to the reported 
findings of Kennel et al. (see Spiegelberg (1977)), the U698M 
surface 6 would be expected to migrate more slowly (by a reported 
2500 dalton difference) than undegraded serum 6. Goyert et al. (1977)
reported an apparent molecular weight difference of 3000 daltons 
for the two serum 6 species, and so a similar mobility difference 
would be expected for serum versus surface 6. As can be seen in 
Fig. 1.3 (B), this difference in mobility was not observed.
One likely explanation for the above finding would be that the U698M 
surface 6-chains were partially degraded during their isolation. In 
this regard the previously mentioned authors used the protease 
inhibitors EACA, benzamidine, and PMSF during cell lysis and immuno­
précipitation. In the present investigation, however, only PMSF was 
used. Moreover, direct evidence for some spontaneous degradation 
( in the form of a second, faster-migrating 6-band) can be seen in 
the profile shown in Fig. 1.4 (track 2j,
1.5. BIOSYNTHESIS AND FATE OF IgM IN NONSECRETORY AND 
SECRETORY LYMPHOID CELLS
1.5.1. Introductory Remarks
Over the course of many experiments, the rate of synthesis and 
secretion of IgM in several lymphoid cell lines representing different 
stages of differentiation was investigated. Although synthesis and 
secretion naturally varied somewhat from experiment to experiment, it
was possible to distinguish patterns of IgM expression, based on
(i) the percentage synthesized relative to total cellular proteins,
(il) the distribution (cellular or extracellular) after pulse-chase 
labelling, and (iii) the molecular form (8S or 19S) of the extra­
cellular IgM. In addition, the pattern of IgM expression (secretion 
or surface deposition) was reflected in the molecular size of the 
biosynthetic y-chains (discussed in detail in Chapter 2).
The results to be described are from a single biosynthetic labelling 
experiment, which illustrated well the general pattern of IgM 
synthesis and secretion observed from a composite of experimental 
results. Cells were allowed to incorporate 35S-methionine for 
1 hr in methionine-free medium, and then for a further 4 hr in complete 
RPMI 1640 medium. After incubation, the cell lysates and culture 
media were analysed for labelled IgM by immunoprécipitation and SDS- 
PAGE of the reduced immunoprecipitates (Fig. 1.5).
1.5.2. Biosynthesis of IgM in the Nonsecretory Lymphoma Cell Lines 
Daudi and Raji
Daudi and Raji cells were consistently found to be nonsecretory, as 
illustrated by the complete lack of extracellular IgM in the culture 
medium Fig. 1.5,(tracks 6 and 10, respectively). The lack of 
secretion from Daudi cells was consistent with the findings of Sherr 
& Uhr (1971) and Grundke-Iqbal & Uhr (1974), who also used incor­
poration of labelled amino acids and immunoprécipitation to detect 
intracellular IgM,
The SDS-PAGE profiles of intracellular IgM from Daudi and Raji 
(tracks 5 and 9, respectively) show distinct bands of y mobility.
Fig. 1.5
SDS-PAGE Analysis of Biosynthetically Labelled Intracellular and 
Secreted IgM from Several Lymphoid Cell Lines
For biosynthetic labelling, 1 x 10^ cells from log phase cultures were 
incubated for 1 hr in 0.2 ml labelling medium containing 100 yCi 35S- 
methionine. Complete medium (0.8 ml) was then added and a further 
4 hr incubation allowed (Methods, 8.1). The cells were separated 
from the culture medium and lysed in 0.25 ml NP-40 lysis buffer con­
taining PMSF (Methods, 8.3). The medium was centrifuged to remove 
residual cells (500 x g for 10 min) and debris (30,000 x g for 30 min). 
Immunoprécipitations were carried out by addition of 4 yg RAHIgM 
to the lysates and 8 yg to the medium (15'min at 20°C), followed by 
either 20 yg or 40 yg respectively of GARIgG (6 hr at 4°C). In the 
case of U598M, 0.2 yl R.410 anti-IgD was also added to the lysate and 
0.4 yl to the medium, followed by addition of extra GARIgG (10 yg 
and 20 yg extra respectively).
Washed immunoprecipitates were dissolved in sample buffer for dis­
continuous SDS-PAGE in a 12.5% polyacrylamide slab gel (Methods, 11). 
The gel was processed for autoradiography (Methods, 17.3) and the 
autoradiogram developed after an exposure of 8 hr. The mobilities of 
the y and light chains from the various cell lines are indicated by the 
arrows and brackets.
Odd Numbered Tracks: Intracellular IgM
Even Numbered Tracks: Secreted IgM
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as expected. The labelled intracellular IgM in these cells was 
consistently 0,2 to 1% of the total labelled cellular proteins - 
consistently the lowest value found among the cell lines investigated 
(see Table 1.2).
1.5.3. Biosynthesis and Secretion of IgM in the Lymphoma Cell 
Lines BJAB, Namalwa, and U698M
The three lymphoma cell lines - BJAB, Namalwa, and U698M - which
express high levels of surface IgM (and sIgD in the case of U698M),
were also found to synthesize and secrete moderate amounts of IgM
(see Table 1,2). Figure 1.5 shows the SDS-PAGE profiles of IgM
immunoprecipitated from the culture medium of these cell lines. Of
the three, BJAB (track 2) shows the lowest level of secretion (just
visible in the figure) . This observation is reflected upon
quantitative analysis as well. Thus, in several experiments, after
a 4-6 hr incubation in complete medium (following a 1 hr pulse
labelling) only lo to 25% of the labelled IgM from BJAB cells was
secreted. In contrast, both Namalwa and U698M cells were generally
found to secrete 25 to 50% of their labelled IgM under the same
conditions,
The intracellular anti-IgM precipitates from these cell lines often 
revealed two bands of y mobility on SDS-PAGE -■a phenomenon apparently 
related to the large quantities of surface IgM expressed.• Thus, 
track 1 clearly shows two bands of y mobility in the BJAB cell lysate, 
the slower band migrating with the surface y-chains of Daudi and Raji 
cells and the faster band migrating with the intracellular y-chains 
from the lymphoblastoid cells, i.e. Bri-8 (see Chapter 2 for detailed 
discussion). An equivalent, weakly labelled y band of slower mobility
-117-
TABLE 1.2 Summary of Secretion and Surface Deposition of
IgM by Lymphoma and Lymphoblastoid Cells
Cell Line
IgM Synthesis 
(% of Total Protein)
Surface** 
Secretion# Deposition
Lymphoma Cells
Daudi
Raji
BJAB
Namalwa
U698M
0.25
0.25
0.5
2
2
1%
1%
2%
3%
3%
++
++
+++
+-
+++
+
+
Lymphoblastoid Cells
Bri-8
Tay-3
1788
-  10% 
- 10% 
- 10%
+++
+++
+++
+ -
+—
+—
**Surface Deposition
(+++) 3-5% of Total Surface Proteins
(+) 1% of Total Surface Proteins
(+“) 0.1-1% of Total Surface Proteins
*Secretion
(+) 19S IgM in medium, 10-25% secreted after 5 hr chase 
C++) 19S IgM in medium, 25-50% secreted after 5 hr chase 
(+++) 19s IgM in medium, 50-90% secreted after 5 hr chase
-XJLO-
can also be seen, although barely, in the Namalwa (track 7) and U698M 
(track 13) profiles. In addition a weak band corresponding in 
mobility to 6-chain can just be detected in the profile from U698M 
cell lysate (track 13), which was also immunoprecipitated with anti- 
IgD.
1.5.4. Biosynthesis and Secretion of IgM in the Lymphoblastoid 
Cell Lines Bri-8, Tay-3, and 1788
The three lymphoblastoid cell lines - Bri-8, Tay-3, and 1788 - which
were found to express extremely low levels of surface IgM, were
generally the most active in the synthesis and secretion of IgM. This
is illustrated by the relatively intense y bands in the SDS-PAGE
profiles (Bri-8, ttcacks 3 & 4; Tay-3, tracks 11 & 12; 1788, tracks
15 & 16) of immunoprecipitates from both cell lysates and culture media,
Quantitatively, 50 to 90% of the labelled IgM in these cells was 
generally secreted during 4-6 hr labelling periods (see Table 1.2).
In some cases, however, (for example see tracks 11 & 12) the secretion 
was found to be anomalously low, which may reflect the growth phase 
or general health of the cell cultures at the time of labelling.
1.5.5, Conclusions
In general, the investigations of IgM biosynthesis and secretion 
indicated that the lymphoid cell lines studied could be divided with 
respect to IgM expression into either (i) nonsecretors or (ii), 
secretors. This distinction between nonsecretors and secretors was 
found to be strict, whereas the secretory cell lines varied con­
tinuously from low to high rate IgM synthesis and secretion. The 
lymphoma-derived cell lines, all of which express high levels of
surface IgM, except Raji (Fig. 1.3), were either nonsecretors or low 
rate secretors. The lymphoblastoid cell lines, all of which were 
found to have very low levels of surface IgM (data not shown) , were 
only secretors (generally high rate). Moreover the overall level 
of IgM synthesis, expressed as a percentage of total labelled cellular 
proteins increased steadily with the progression from nonsecretors to 
high level secretors. The relevant information is summarized in 
Table 1.2.
1.5.6. Molecular Size of Secretory IgM Investigated 
To establish whether the IgM isolated from the culture medium was of 
the normal 19S secretory form, SDS-PAGE analysis of the unreduced 
molecules was performed. Figure 1.6 shows the results from three of 
the lymphoblastoid cell lines (Bri-8; Tay-3; 1788) and one of the 
lymphoma-derived cell lines (BJAB). The major peak of radioactivity 
in each case migrated with the 19S IgM marker protein (indicated by 
arrow). In addition, small peaks of approximately 8S were resolved, 
consistent with the findings of Kennel & berner (1973), and probably 
indicative of either turnover of surface IgM (in the case of BJAB) , or 
leakage of unpolymerised IgM from ruptured cells. This latter 
explanation would appear the most likely in the case of the lymphoblastoid 
cells, because of their negligible levels of sIgM. It was not possible, 
however, to distinguish between these possibilities on the basis of the 
available data.
1.6. SYNTHESIS, SURFACE DEPOSITION, AND SECRETION OF IgG BY 
BEC-11 LYMPHOBLASTOID CELLS
1.6.1, Early SDS-PAGE Analysis
In a screening experiment designed to determine the surface and
Fig. 1.6
SDS-PAGE Analysis Showing Secreted IgM to be 19S
The anti-IgM immunoprecipitates from the labelling media of several 
cell lines were obtained as described in the legend to Fig. 1.5. 
Aliquots (10%) of each immunoprecipitate were added to non-reducing 
SDS-PAGE sample buffer and electrophoresed in phosphate-buffered 
tube gels of 3% polyacrylamide-0.5% agarose. The radioactivity in 
individual gel slices was determined by scintillation counting of 
the Protosol-solubilised slices (Methods, 17.2). Marker 19S IgM 
and 7S IgG (radioiodinated as described in Methods, 6.5) were electro­
phoresed in a separate tube gel.
-120-
19 S
i
(Al BJAB
1-
l
85
i
^O O OOO OOOO
To 20 30
(B) B R I - 8
10 -
co
85O
X
CL
O L __
10 20 30
z: 19 5
l—H
O
z>
ÜJ
ICI T A Y - 3
85
X
ro
OOoOOoGt){X)OoOl 
---------------- r -----------------
10 20 3019 s
i
ID)  1 7 8 8
10-
p bc.ooo^ o<yC- 
10
DOOOOO-OO-OoOo 
20 30
M i g r a t i o n  [mm]
secretory Ig expression of several cell lines, Bec-11 cells were 
either surface radioiodinated or biosynthetically labelled for 6 hrs 
with 3H-leucine. Labelled Ig was isolated from the cell lysate and 
culture medium (biosynthetic labelling) or from the cell lysate alone 
(surface radioiodination) by immunoprécipitation using a mixture of 
anti-IgG and anti-IgM antiserum. The SDS-PAGE profiles of the reduced 
immunoprecipitates are shown in Fig. 1.7.
Bec-11 cells had been previously characterised, as IgG-secreting 
(F. Cramer, personal communication) and the biosynthesis results shown 
in Pig. 1.7(A) and (B) confirmed this. Thus, the SDS-PAGE profile of 
Bec-11 secreted Ig (Fig. 1.7(B)) shows a broad, symmetrical peak 
comigrating with the y marker protein (indicated by arrow), as well 
as a light chain peak. Intracellularly (Fig. 1.7(A)) the y and light 
chain peaks are also clearly seen, although the y peak has a distinct 
shoulder, suggesting the presence of another peak of slower mobility.
The profile obtained from the Bec-11 surface radioiodinated Ig 
(Fig. 1.7(C)) had a predominant peak of radioactivity migrating 
approximately midway between the y and y markers. This SDS-PAGE 
mobility has been reported by several laboratories (Ferrarini et al., 
1976; Spiegelberg, 1977) to be characteristic of 6-chain from 
human cell surface IgD. Thus, the detection of sIgD on Bec-11 cells 
by antiserum cross-reactivity was an attractive hypothesis to explain 
the foregoing result.
1.6.2. Identification of Surface IgG on Bec-11 Cells 
As shown in Fig. 1.7(C), cell surface Ig heavy and light chains were 
detected on Bec-11 cells by immunoprécipitation with anti-IgG plus 
anti-IgM antiserum. The major heavy chain species detected had a
Fig. 1.7
SDS-PAGE Profiles of Intracellular, Secreted, and Cell Surface
Ig of Bec-11 Cells
For biosynthetic labelling, 5 x 10^ cells from log phase cultures were
incubated for 6 hr in 1 ml labelling medium containing 62.5 yCi
3H-leucihe (Methods 8.1) . The cells were separated from the culture
medium and lysed in 1 ml NP-40 lysis buffer containing PMSF and
iodoacetate (Methods 8.3). Immunoprécipitations from both lysate
and medium were carried out by addition of 2 yl each anti-IgG and anti-
IgM (15 min at 4*^ C) followed by 200 yg GARIgG (15 min at 4°C) .
7Cell surface proteins from 1 x 10 cells were labelled by lacto- 
peroxidase iodination (1-125, 0.25 mCi). Cell lysis and immuno­
précipitation were carried out as described above.
Washed immunoprecipitates were dissolved in 75 yl SDS-PAGE sample 
buffer and half removed for reduction and alkylation (Methods 12.4). 
Electrophoresis was in phosphate buffered tube gels of either 10% 
polyacrylamide (DATD crosslinked) for the biosynthetic samples, or 
6% polyacrylamide for the radioiodinated sample (Methods 12). Radio­
activity in individual gel slices was determined for biosynthetic 
samples by scintillation counting of periodic acid-solubilised slices 
(Methods 17.2), or for radioiodinated samples by gamma counting. 
Molecular weight marker y, y, and light chains were electrophoresed 
in separate 6% or 10% polyacrylamide tube gels.
(A) Intracellular Ig (biosynthetic)
(B) Secreted Ig (biosynthetic)
(C) Cell Surface Ig (radioiodinated)'
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mobility approximately equal to that reported for human 6-chains, 
and in further experiments was also shown to be precipitable by anti- 
IgD antiserum (data not shown).
To determine the heavy chain class of the Bec-11 sig, the following 
experiment was performed. Bec-11 cells were surface radioiodinated 
and the NP-40 lysate divided into aliquots for immunoprécipitation 
with polyvalent anti-Ig (including anti-IgD) . Before addition of 
antisera, however, separate aliquots were treated by addition of 
excess unlabelled IgA, IgM and IgD (1) ; IgD alone (2) ; IgA, IgM and 
IgG (3) or IgG alone C4) .The SDS-PAGE profiles of the resulting 
reduced immunoprecipitates are shown in Fig. 1.8, tracks 1-4. Excess 
unlabelled IgD alone (track 2) , or in combination with IgA and IgM,
(track 1) did not compete successfully with the Bec-11 labelled sIg;
whereas IgG alone (track 4) or in combination with IgA and IgM, (track 3)
did compete successfully, and therefore it was concluded that the 
surface Ig detected on Bec-11 cells was IgG,
1.6,3. Comparison of SDS-PAGE Mobilities of Bec-11 Surface and 
Secretory IgG y-chains
As indicated in Table 1.2, when Bec-11 cells were labelled bio­
synthetically generally 2-5% of the total.labelled cellular proteins 
were IgG. Moreover, after 4-6 hr labelling periods, 50-90% of this 
IgG was generally found secreted into the culture medium. High 
resolution SDS-PAGE analysis of Bec-11 secretory IgG (Fig. 1.8, track 5)
showed it to consist of two molecular forms of y-chain, as well as
X-light chain. That both of the observed heavy chain bands were 
indeed y-chain was confirmed by antigen competition experiments 
similar to those described in the previous section. Thus excess
Fig. 1.8
SDS-PAGE Analysis Identifying Bec-11 Cell Surface IgG, and Comparing 
its Mobility to that of Secreted IgG
The cell lysate obtained as described in the legend to Fig. 1.3 was 
used for the isolation of iodinated cell surface Ig. The remaining 
lysate (40%) was divided into four aliquots (50 yl each) and immuno­
précipitation carried out in the presence of competing unlabelled 
antigen by addition of either (1) 10 yg each IgAk, IgMA and IgDA ;
(2) 10 yg IgDA; (3) 10 yg each IgAk, IgMA and IgCA ; or (4) 10 yg
IgGA - followed in each case by 1 yl of conbined anti-IgM, IgG, IgA, 
IgD. Incubation for 15 min at 20*^ C was followed by addition of
50 yg GARIgG (overnight at 4°C).
For the isolation of biosynthetically labelled secreted Ig, 1 x 10^ 
cells were incubated for 1.5 hr in 0.2 ml labelling medium containing 
200 yCi 35S-methionine. Complete medium (1 ml) was then added and 
a further 18 hr incubation allowed (Methods, 8.1). The cells were 
separated from the culture medium, and the medium centrifuged to 
remove residual cells (500 x g for 10 min) and debris (30,000 x g for 
30 min). Immunoprécipitation was carried out on aliquots (25%) of 
medium by addition of either (5) 5 yg RAHIgG or (6) 100 yg IgGA 
followed by 5 yg RAHIgG. Incubation for 15 min at 20°C was followed 
by addition of 25 yg GARIgG (overnight at 4°C).
Washed immunoprecipitates were dissolved in sample buffer for dis­
continuous SDS-PAGE in a 12.5% polyacrylamide slab gel (Methods, 11). 
The gel was processed for fluorography (Methods, 17.4), and the 
fluorogram developed after an exposure of 24 hr. The mobilities of 
6-chain from radioiodinated AI IgD, normal cell surface y-chains 
(bands not shown), and Bec-11 light chain are indicated by the arrows,
Surface Iodinated Tracks
Samples (1) Anti-Ig(Polyvalent), Competed by IgA,IgM,IgD
(2) " " " " IgD
(3) " " " " IgA,IgM,IgG
(4) " " " " IgG
Biosyntheti c Tracks
Samples (5) RAHIgG Precipitate, Uncompeted
(6) RAHIgG Precipitate, Competed by IgG
Markers Track
(7) AI serum IgD
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unlabelled IgG added to the cell lysate before immunoprécipitation 
with anti-IgG selectively eliminated both heavy chain bands and the 
A band from the SDS-PAGE profile (Fig. 1.8, track 6). In this 
regard, neither IgD, IgM, or IgA myeloma proteins were able to 
compete with the Bec-11 secretory immunoglobulin in immunoprécipitations 
using anti-IgG (data not shown). The nature of the two forms of 
Bec-11 y-chain is currently under further investigation.
Despite the unusual banding pattern of Bec-11 secretory IgG y-chains, 
a comparison of the SDS-PAGE profiles in Fig. 1.8 clearly shows the 
surface y-chain to be of higher apparent molecular weight than 
either of the secretory forms. Moreover, when biosynthetically labelled 
intracellular IgG from Bec-11 cells was analysed (data not shown), a 
y band corresponding to the surface form, as well as those corresponding 
to the two secretory forms could be demonstrated.
1.7. CONCLUDING REMARKS
Considerable interest is attached to the biochemical events which underly 
B-cell maturation. Among these events are: 1) the mode of integration 
of H-chain V and C region genes, and their expression during isotype 
diversification; 2) the mode of surface binding and signal transmission 
of the several receptor isotypes;3) the pathways which regulate the 
expression of cell surface bound and secreted Ig; and 4) the mechanisms 
involved in amplification of Ig synthesis. Many of these events take 
place at the level of the B-lymphocyte, and efforts are being made to 
investigate them in homogeneous B-lymphocyte model systems.
Spontaneously derived murine B-lymphomas (Shevach et al., 1972;
Ramasamy & Munro, 1974; Kim et al., 1978), or B-lymphomas induced by 
Abelson virus transformation (Premkumar et al., 1975b) have been 
identified and partially characterised. In contrast to the situation 
with fresh splenic or peripheral blood lymphocytes, these lymphoma 
cell lines are not readily stimulated to maturation by antigen or 
mitogen. This makes biochemical analysis of maturation-associated 
events difficult. Recently, two new approaches have been described:
1) the use of mitogen plus T-cells to induce in vitro maturation 
of human lymphoma and lymphoblastoid cell lines (Kishimoto et al., 1978), 
and 2) hybridisation of murine lymphoma and myeloma cells in order to 
stimulate the maturation of lymphoma cell-associated processes, such 
as IgM expression (Laskov et al., 1978).
A third approach is the use of differentiation-arrested lymphoma cell 
lines. Because of their inherently stable phenotypic expression, such 
continuous culture cell lines are ideally suited for biochemical 
investigations —  particularly those concerned in the first instance 
with molecular structure. The work described in this section was 
undertaken to characterise several human lymphoma cell lines with 
respect to Ig synthesis. It was hoped that the cell lines available 
would be representative of a series of early stages in B-lymphocyte 
differentiation analogous to the situation described for murine myeloma 
tumours (Andersson et al., 1974). The characteristics of the individual 
cell lines were found to mirror those described for B-lymphocytes in 
ontogeny and during mitogen stimulation (see Introduction, section 5).
A general pattern in the relative synthesis of cell surface and secretory 
IgM emerged from a comparison of the human cell lines. Among the 
lymphoma cell lines, several strong producers of surface IgM were
- 1 2 7 -
identified (i.e. Daudi, BJAB, Namalwa and U698M). Daudi was found to 
combine strong IgM expression with no detectable secretion, confirming 
the findings of others.- This result emphasised the usefulness of 
Daudi cells for the investigation of sIgM-associated questions. The 
other lymphoma cell lines (excluding Raji) exhibited strong sIgM 
expression with moderate secretion of 19S IgM. Cells such as these are 
analogous to those which would be-produced in the very early stages of 
mitogen-induced maturation, at the onset of active secretion. Thus, 
using these cell lines it may be possible to study the events which 
accompany the onset of polymerisation and active secretion, as well as 
the factors which affect the relative amounts of Ig expressed in the 
two pathways. In such studies, the lymphoblastoid cell lines (such 
as Bri-8, Tay-3, RPMI 1788) would represent a further differentiated 
cell type, since their expression of secretory IgM with little or no 
sIgM is characteristic of the stage of differentiation seen in later 
mitogen stimulated cultures.
As a corollary to the investigation of sIgM-secretory IgM coordination, 
further study of Raji cells may prove useful. These cells synthesise 
significant amounts of cytoplasmic IgM, yet they secrete no detectable 
IgM and appear to deposit only very little in the surface membrane. 
According to present concepts of secretion, one might postulate that 
Raji cells are deficient in membrane fusion and reverse pinocytosis of 
post-Golgi vessicles. In their Ig expression, Raji cells are similar 
to the 'pre-B* cells which have been described. It is fascinating 
to speculate that the pre-B cell to primary B cell differentiation 
step may be marked principally by acquisition of the mechanisms for 
secretion.
“ IZD-
Although even a moderate level of secretion was found to mask the 
biochemical characterisation of slgM-associated phenomena (such as the 
resolution of a higher molecular weight surface y-chain), one particular 
cell line, BJAB, exhibited a more balanced expression, which would 
allow analysis of both these pathways in a single cell. Such an 
investigation could focus on the intracellular transport of surface versus 
secretory IgM where the two are distinguishable (i.e. by the size of 
the y-chain). One important question would be whether sIgM and 
secretory IgM are compartmentalised independently or together during 
transport to the cell surface.
Unfortunately, no double-secreting cell lines could be reliably identified
in these studies. However, the biochemical identification of an 
+ve +ve
sIgM , sIgD lymphoma cell line (U698M) presents equally exciting
+V0 *f“V 0prospects for biochemical analysis. Since sIgM , sIgD B-lympho- 
cytes are common in vivo, it may be expected that B-lymphoma cell 
lines possessing this characteristic will be reported frequently in 
the future. Such reports have already been made for a human cell 
line (Spiegelberg et ail., 1977) and a mouse lymphoma cell line (Laskov 
et al., 1978). The characteristics of sIgD acquisition during 
ontogeny, as well as its susceptibility to proteolysis,indicate a 
special role for this receptor isotype. Such a role may well be 
determined in some way by the mode of binding of sIgD to the lympho­
cyte membrane, and in this regard it would be valuable to compare the 
binding of sIgD and sIgM in a single cell line (i.e. are both or 
either integral membrane proteins).
The characterisation of a lymphoblastoid cell line (Bec-11) which 
appears to both secrete and deposit in the surface membrane IgG,
underlines another possibility which derives from the use of continuous 
culture cell lines. The simultaneous expression of receptor and 
secretory IgG has been characterised both in ontogeny and in mitogen 
stimulated cultures (see Introduction, section 5), but it is a 
relatively rare event. As such, the biochemistry of the cells 
involved would be extremely refractory to analysis. The availability 
of a cell line apparently arrested in this stage of differentiation, 
however, allows this problem to be circumvented. Similar to the 
situation with IgM synthesising cells, questions concerning the 
membrane binding of sIgG and coordination of secretory IgG and sIgG 
synthesis can be asked using Bec-11 cells. The finding described 
in this section that Bec-11 surface y-chains are of higher apparent 
molecular weight than secretory y-chains is consistent with the idea 
that surface IgG is an integral membrane protein with a C-terminal 
hydrophobic extra sequence inserted into the membrane.
CHAPTER II
STRUCTURAL CHARACTERISTICS AND BIOSYNTHESIS OF
CELL SURFACE IgM
2.1. MOLECULAR SIZES OF CELL SURFACE AMD SECRETORY y-CHAINS
2.1.1, General Observations
During the course of investigations of the synthesis, secretion, 
and surface deposition of IgM by cultured human lymphoid cells, two 
particular features of the SDS-PAGE profiles on polyacrylamide slab 
gels were observed. Firstly, the small molecular weight difference
between intracellular and secreted y-chains, presumably caused by
addition of the terminal carbohydrate residues of fucose and sialic 
acid to the latter (Swenson & Kern, 1968; Schenkein & Uhr, 1970; 
Zagury et al., 1970; Parkhouse & Melchers, 1971), could be con­
sistently resolved. Secondly, the surface y-chains labelled by
lactoperoxidase radioiodination had consistently slower SDS-PAGE 
mobilities than either the intracellular or secreted y-chains from 
secretory cells. These observations led me to perform a more 
detailed investigation of the SDS-PAGE mobilities of y-chains from 
several nonsecretory and secretory cell lines.
2.1.2 Biosynthetic IgM samples from secretory and nonsecretory cells 
Surface, intracellular and secreted IgMs of several secretory and 
nonsecretory lymphoid cells were biosynthetically radiolabelled. 
Incorporation of 35S-methionine was allowed to proceed for 1 hour 
in labelling medium, followed by a further 5 hours in complete medium. 
After the labelling period, IgM was isolated from both cell lysates 
and culture media by immunoprécipitation. A pattern of biosynthetic 
labelling emerged which was consistent with the identification of 
the labelled IgM as either surface, intracellular, or secretory.
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Table 2.1 shows that the two nonsecretory cell lines, Raji and 
Daudi, synthesized less than 0.5% of their total cellular proteins as 
IgM (nonspecific background radioactivity corrected for). Moreover, 
after the 5 hour chase, almost all of the synthesized IgM was 
retained within the cell. This is consistent in the case of Daudi 
cells, with reports from other laboratories (Klein et al.,1968;
Sherr & Uhr, 1971), and presumably reflects the stable association 
of IgM with the outer cell membrane and the lack of an active 
secretion mechanism in Daudi and Raji cells. The two secretory 
cell lines investigated, Tay-3 and 1788, synthesized considerably 
more of their total cellular proteins as IgM (2.5% and 5.2% 
respectively). Much of this IgM is secreted into the culture 
medium during 5 hr chase. SDS-PAGE analysis of the unreduced 
extracellular IgM confirmed it to be the 19S secretory form (see■
Fig. 1.6).
2,1.3. Comparison of the SDS-PAGE mobilities of surface, intra­
cellular (IC) and secretory (EC) IgM y-chains 
To more accurately compare the apparent molecular weights of y-chains 
obtained from both secretory and nonsecretory lymphoid cells, 
surface radioiodinated and biosynthetically labelled samples of IgM 
isolated by immunoprécipitation were reduced and analysed by SDS- 
PAGE on adjacent tracks of a 12.5% polyacrylamide slab gel.
As a control, to show that the radioiodination itself did not affect 
the mobility of the y-chains, biosynthetically labelled Daudi cells 
were subjected to a lactoperoxidase catalysed surface iodination 
using unlabelled iodine. When the biosynthetically labelled sIgMs 
from the iodinated and untreated Daudi cells were analysed on
-132-
TABLE 2.1 Biosynthesis and Turnover of Ig from Nonsecretory and 
Secretory Lymphoid Cells after Pulse-Chase Labelling
Level of Distribution of Ig
Cell Synthesis (a) after 5 hr chase {%)
Line Class (%) Intracellular Extracellular
BJAB IgM 1.1 77 23
Daudi IgM 0.4 93 7
Raji IgM 0.3 99 1
Tay-3 IgM 2.5 49 51
1788 IgM 5.2 13 87
Bec-11 IgG 2.1 26 74
(a) 35S'-methionine counts/min relative to total labelled cellular
proteins after 1 hour pulse labelling.
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adjacent tracks of a polyacrylamide slab gel, the profiles obtained 
were indistinguishable (see Fig. 1.5, track(s) 5).
Figure 2.1 shows a comparison by SDS-PAGE of u-chains from secretory 
and nonsecretory cells. Three forms of y-chains are seen. Intra­
cellular and secreted y-chains from secretory cells and surface 
y-chains from nonsecretory cells each migrate with distinctive 
apparent molecular weights (except Daudi). Surface y-chains always 
appear larger than secreted y-chains, which in turn appear larger 
than intracellular y-chains (i.e. those from secretory cells).
Molecular size estimations of the above forms of y-chain were made 
based on a semi-log plot of molecular weight versus migration. As 
standards, the a and a chains of RNA polymerase ( Coggins et al., 
1977), immunoglobulin y-chain, and actin were used. The apparent 
molecular weights were determined to be: surface y , 85,000;
secretory y , 83,000; and intracellular y, 81,000. Because of 
the uncertainty of molecular weight determinations of glycoproteins 
using SDS-PAGE mobilities (Melcher & Uhr, 1976) I consider these 
values to be useful for comparative purposes only. Thus, the 
surface y-chains studied were approximately 2000 daltons larger than 
secretory y-chains. This difference is in good agreement with that 
reported for murine splenic cell surface y-chain versus murine 
secreted y-chain (Melcher & Uhr, 1976).
2.1.4. Correlation of Biosynthesis and Surface Labelling Results 
The detection of the various forms of y-chain by SDS-PAGE, revealed 
a pattern characteristic of either nonsecretory or secretory cells.
Fig. 2.1
Comparison of the SDS-PAGE Mobilities of Cell Surface, Intra­
cellular, and Secretory igM y-Chains
7Cell surface proteins from 1 x 10 cells were labelled by lacto- 
peroxidase iodination (1-131, 2 mCi) as described in Methods, 
section 8.2, and the cells lysed in 0.5 ml NP-40 lysis buffer 
containing PMSF (Methods, 8.3) ,
For biosynthetic labelling, 2 x lO^ cells from log phase cultures 
were incubated for 1 hr in 0.4 ml labelling medium containing 
100 yCi 35S-methionine. Half of the cells were removed and kept 
at 0°C. Complete medium (0.8 ml) was then added to the remaining 
cells and a further 5 hr incubation allowed (Methods, 8.1). The 
cells were separated from the pulse and chase media and lysed in 
0.25 ml NP-40 lysis buffer as described above. The chase media was 
centrifuged to remove residual cells (500 x g for 10 min) and debris 
(30,000 X g for 30 min). Aliquots of pulse labelled cell lysate were 
removed for TCA precipitation.
Immunoprécipitations were carried out by addition of 20 yg RAHIgM to 
the radioiodinated lysates and biosynthetic chase media, and 5 yg 
RAHIgM to the biosynthetic pulse and chase lysates (15 min at 20°C), 
followed by lOO yg or 25 yg respectively of GARIgG (1 hr at 37°C, 
overnight at 4°C). Washed immunoprecipitates were dissolved in 200 yl 
2% SDS and aliquots removed for determination of radioactivity (see 
Table 2.1). Aliquots of iramunoprecipitate were applied in reducing 
sample buffer to a 12,5% polyacrylamide slab gel for discontinuous 
SDS-PAGE (Methods, 11). Biosynthetic IC and EC samples were derived 
from the 5 hr chase experiment. The gel was processed for fluorography 
and the fluorograms developed after a 2 hr exposure to film (a), and 
three months later after a 24 hr exposure to film (b). The 1788 tracks 
are not shown in panel (a).
(S) Surface lodinated 
(IC) Biosynthetic, Intracellular 
(EC) Biosynthetic, Extracellular
(a) Exposed for 1-131 
and S -3 5
(b) Exposed for S -3 5  
after d ecay of 1-131
Raji Daudi BJAB
S IC^'s ic"s IC EC
• i
Origin
■ Surface ^ , 
-Extracell.p- 
'Intracell.p'
Raji Daudi BJAB 1788
1 r~~i r 1 v ~ ~ \
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In nonsecretory cells, a band corresponding in mobility to the surface 
labelled p-chain is detected by biosynthetic labelling. However, 
no band of the intcitcellular y-chain size could be detected in those 
cells. In contrast, rapidly secreting cell lines such as 1788 
show only y-chain of the intracellular size which persisted even 
after a 5 hour chase. These cells did not show a band of the 
surface y-chain size under the labelling conditions described. In 
agreement with this observation is the extremely low level of sIgM 
detected by lactoperoxidase radioiodination on rapidly secreting 
lymphoblastoid cells. Several lymphoblastoid cell lines under 
investigation in our laboratory conform to this pattern of IgM 
expression, among them Bri-8, Smi-1, Tay-3 and 1788. Thus, it 
appears that secretory cells retain only a small amount of their 
immunoglobulin product as the distinct surface immunoglobulin.
The anomalously slower mobility of Daudi sIgM has been mentioned 
above. Figure 2.1. shows that the biosynthetically labelled bands 
also reflect this anomaly, in that after the 5 hour chase period a 
faint band corresponding to the large surface iodinated form can 
be seen (see also Fig, 1.5). However, the major biosynthetically 
labelled band of Daudi y comigrates with the normal surface forms 
from the other cell lines investigated. When a short pulse label­
ling is used, this latter band is the only y-chain detected in the 
Daudi sIgM profile (see Figs. 2.3 and 2.4). Based on this obser­
vation I favour the hypothesis that the modification of Daudi surface 
y-chains which confers an abnormally high apparent molecular weight 
on them is a secondary phenomenon, such as the addition of terminal 
sugar moieties additional to that added in the normal pathway for 
the expression of cell surface IgM, This phenomenon may be related to
136-
the glycosylation of Daudi K(see section 2.3,9) and to the presence 
of the novel p33 polypeptide associated with the sIgM of Daudi cells 
(see chapter 3).
2.1.5, Surface deposition and secretion of IgM by BJAB cells 
The lymphoma cell line BJAB showed an unusual pattern of IgM 
synthesis, which proved useful to the present investigation.
Table 2.1 shows that the synthesis of IgM in BJAB cells was inter­
mediate in amount to that of the secretory and nonsecretory cells.
In addition, a significant amount (23%) of the IgM synthesised was 
detected in the culture medium. This extracellular IgM was also 
found to be of the 19S secretory form (see Fig. 1.6). Since BJAB 
cells also have readily detectable surface IgM, they provide a 
useful model system for the biochemical analysis of surface depos­
ition and secretion of IgM in a single cell line.
In BJAB cells the three forms of y-chain distinguished as surface, 
intracellular and secretory, can be identified by their migration on 
SDS-PAGE with characteristic mobilities similar to their counter­
parts in other cell lines (Fig. 2.1). A pattern of IgM expression 
similar to that seen in BJAB is also found in two other lymphoma 
cell lines, Namalwa and U698M (see Figs. 1.3 and 1.5). The most 
striking difference observed between these lymphoma cells and the 
IgM-secreting lymphoblastoid cells such as Tay-3 and 1788 was the 
high level of sIgM expressed on the former cells contrasting with 
the barely detectable sIgM on the lymphoblastoid cells.
The lower portion of Fig. 2.1 shows the migration of BJAB K-chain 
co-precipitated with the various forms of y-chain. The K-chains 
associated with intracellular secretory and surface (lactoperoxidase
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radioiodinated) y-chains were indistinguishable. This is in 
contrast to the situation with the y-chains, and is evidence against 
structural differences of light chains regulating surface deposition 
or secretion of associated immunoglobulins.
2,2. CARBOXY-TERMINAL ANALYSIS OF CELL SURFACE AND 
SECRETORY y-CHAINS
2.2.1 Rationale for Investigation
The previous findings that cell surface y-chains (section 1.6.3) 
and y-chains (section 2.1) are of higher apparent molecular weight 
than their secreted counterparts is consistent with current con­
cepts of receptor Ig binding to the cell surface. Thus, it has 
been postulated (Singer, 1974; Vitetta & Uhr, 1975) that the 
basically hydrophilic Ig heavy chains may possess an extra hydrophobic 
sequence when they are sequestered in the membrane. The findings 
that murine surface y-chains are of higher molecular weight than 
secreted y-chains (Lisowska-Bernstein & Vassalli, 1975; Melcher &
Uhr, 1976) supports this idea. In addition, the same relationship 
has been shown between cell surface IgD and myeloma IgD 6-chains 
(Spiegelberg, 1977) . It has been further shown that murine sIgM 
y-chains are less soluble in aqueous medium (Melcher et al., 1976) 
and bind more detergent (Melcher & Uhr, 1977) than y-chains from 
serum IgM, consistent with an extra hydrophobic sequence in the 
surface form.
A widely favoured model of receptor Ig membrane binding places the 
extra hydrophobic sequence at the carboxy terminus of the surface
138-
y-chain, in order to orientate the receptor Ig with its antigen 
binding sites clearly exposed. Direct evidence for this model 
has been sought by carboxy-terminal analysis of surface y-chains.
The method used exploits the known presence of a C-terminal tyrosine 
residue on secretory y-chains (Putnam et al., 1973), and the ability 
of the enzyme Carboxypeptidase-A to rapidly and completely remove 
C-terminal tyrosine (reviewed by Ambler, 1967). It is reasoned 
that surface y-chains, if they possess an extra hydrophobic sequence 
at their C-terminal end, would not have a terminal tyrosine residue.
Mcllhinney et al., (1977) have used the above approach to investigate 
the carboxy terminus of 3H-tyrosine labelled surface y-chains from 
human (Bri-8 cell line) lymphoid cells and mouse (McPC 1748) myeloma 
cells. They reported significant release of tyrosine, and therefore 
argued against a C-terminal extra sequence. However, work already 
presented in this thesis on the Ig expression of Bri-8 cells (section 
1,5,4) raises serious objections to these findings. Specifically, 
these authors have not convincingly demonstrated the y-chains they 
investigated to be the surface form. In addition, their data does not 
provide kinetic evidence that the released tyrosines were indeed C- 
terminal (and not, for instance, preceded by one or more rapidly 
released amino acid). .
In view of the criticisms of the above investigation, I felt it 
useful to perform a similar investigation of the surface y-chains 
of Daudi and Raji lymphoma cells, and to compare the results obtained 
with those from the secretory y-chains of 1788 and Bri-8 cells. One 
advantage of this system is that Daudi and Raji cells not only 
express surface IgM, but are also strictly non-secretory. Moreover,
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the y-chains from these cells can be distinguished from secretory 
y-chains by their slower mobility on SDS-PAGE, thus providing 
additional evidence that they are indeed the surface form of y-chain.
2.2,2. Source of Samples for Digestion
To obtain appropriately labelled y-chains (and light chains) for 
C-terminal analysis, Daudi, Raji, 1788, and Bri-8 cells from log 
phase cultures were labelled by incorporation of 3H-tyrosine for 
1 hr. The cells were separated from the labelling medium and lysed 
in NP-40 lysis buffer containing protease inhibitors. Labelled IgM 
was isolated from the cell lysates by immunoprécipitation, and the 
washed immunoprecipitates subjected to SDS-PAGE under reducing con­
ditions in a 10% polyacrylamide slab gel. The gel was processed 
for fluorography and exposed to film, giving profiles similar to 
those shown in Fig. 2.3, tracks 8-10 (Bri-8, not shown, was identical 
to 1788). The fluorograph was then placed over the dried gel and 
the area of gel underlying each y or light chain band carefully 
sliced out and the radiolabelled chains eluted (Methods, 15) . 
Approximately 15-20,000 counts/min was recovered for each chain to 
be analysed, except 1788 y , which yielded 60,000 counts/min and was 
therefore used in preliminary experiments to determine the kinetics 
of digestion.
2.2.3 Kinetics of Release of Carboxy-Terminal Tyrosine by 
Carboxypeptidase A
The secretory y-chain from 1788 cells was expected to have a C-
terminal tyrosine (Putuam et al., 1973) and so was used to establish
the kinetics of release characteristic for tyrosine at the C-terminal
position. A previous investigation of aldolase (Winstead & Wold,1964)
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was particularly useful in this regard. This investigation clearly 
showed that a rapid time course and nearly 100% release of C- 
termj.nal tyrosine could be expected, even with comparatively mild 
digestion conditions.
A preliminary digestion was performed on labelled 1788 y-chain, 
with the parameters used in the investigation of aldolase (Winstead & 
Wold, 1964) as a guideline. Incubation was at 25°C, using an 
enzyme to substrate (carrier BSA) ratio of 1:100. The digestion was 
rapidly stopped at times of 0.2, 2, and 30 min by dilution of the 
reaction mixture into ice cold trichloroacetic acid, and the acid 
soluble counts/min determined. The results indicated detectable 
release of tyrosine after 0.2 min and maximum release after 2 or 30 
rain incubation, A second digestion was then performed with several 
additional time points. The counts/min released were consistent with 
those from the first digestion, and are plotted as a function of 
digestion time in Fig, 2.2 A. The figure shows that a plateau value 
was reached by 2 min, and that the release of C-terminal tyrosine 
approached 100%, based on a tyrosine content of 18 residues per 
1788 y-chain. This is a reasonable estimate of y-chain tyrosine 
content since the y constant region is known to contain 9 tyrosine 
residues (Putnam et al,, 1973) and, based on a sampling of 18 complete 
human V-region sequences from subgroups I, II and III (Rabat et al., 
1977) y-chains would be expected to vary in tyrosine content from 
12 to 17 residues. On the other hand, taking all the known 
positions from partial and complete V-region sequences where tyrosine 
has been found (Rabat et al., 1977) a maximum figure of 23 tyrosine 
residues per y-chain would be obtained.
Fig. 2.2
Release of Carboxy Terminal Tyrosine from Cell Surface and 
Secretory IgM y-Chains by Carbodypeptidase Digestion
For biosynthetic labelling, 1 x 10^ (1788, Bri-8) or 5 x lO^ (Daudi, 
Raji) cells from log phase cultures were incubated for 1 hr in 0.2 ml 
or 1.0 ml of labelling medium containing 500 yci/ml 3H-tyrosine. The 
cells were separated from the culture medium and lysed in 0.2 ml (1788, 
Bri-8) or 0.5 ml (Daudi, Raji) NP-40 lysis buffer containing PMSF and 
pepstatin-A (Methods, 8.3). Immunoprecipitates were carried out by 
addition of 10 yg (1788, Bri-8) or 25 yg(Daudi, Raji) RAHIgM (15 min 
at 20°C) , followed by 40 yl or 100 yl respectively of S.aureus immuno- 
adsorbent (overnight at 4°C). Washed immunoprecipitates were dis­
solved in reducing sample buffer for discontinuous SDS-PAGE in a 10% 
polyacrylamide slab gel (Methods, 11). The gel was processed for 
fluorography (Methods, 17.4) and exposed to film for 8 hrs, giving 
profiles similar to those shown in Fig. 2.3, tracks 8-10 (Bri^8 not 
shown).
The area of gel containing each y and light chain band was sliced out 
and the radiolabelled chains were eluted, amidomethy1ated, and lyo- 
philised as described in Methods, section 15. The lyophilised samples 
were then dissolved in Digestion Buffer (0,05 M NaHCO^, 0.2 M LiCl), 
pH 8.0 - 8.2, and carboxypeptidase-A Digestion carried out at 20°C at 
an enzyme to substrate ratio of 1:100 (Methods, 16.3), Aliquots of 
the digestion mixture were removed at specified times and added to 1/3 
volume of 40% ice cold TCA. After approximately 1 hr at 0°C, the TCA 
insoluble material was pelleted by centrifugation (8000 x g for 2 min) . 
Released tyrosine was measured as TCA soluble radioactivity, and plot­
ted versus digestion time. The hypothetical 100% release values 
represent l/20th the total radioactivity per aliquot (except for 1788, 
where the released tyrosine approached l/18th the total radioactivity).
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From the above experiment^ the digestion conditions used were found 
to be satisfactory for following the kinetics of C-terminal tyrosine 
release from human p-chains; the kinetics observed being consistent 
with those for aldolase (Winstead & Wold, 1964). It therefore seems 
appropriate to point out the possibility of misinterpreting digestion 
data which is not based on kinetic analysis. Thus, the previous 
investigation of aldolase clearly showed that substantial release 
of aromatic amino acids Ci.e, tyrosine) several residues from the 
carboxy terminus occurs when the intervening amino acids are also 
rapidly released species Ci.e, aromatic or hydrophobic),
2.2,4 Carboxypeptidase - A Digestion of Surface and Secretory yi-Chains 
Having established the kinetics of release of c-terminal tyrosine from 
1788 secretory y-chains, Carboxypeptidase-A digestions were performed 
on Bri-8 secretory y-chain and Raji and Daudi surface y-chains. The 
results are shown in Fig, 2,2, B,C, and D,
Tyrosine was released from Bri-8 y with kinetics and yield (100% 
release, based on 20 residues/chain) nearly identical to those 
observed with 1788 y , consistent with the identification of both 
these y-chains as secretory.
Digestion of Daudi and Raji surface y-chains was expected to show 
either tyrosine release similar to that from 1788 and Bri-8 y-chains, 
arguing against an extra C-terminal sequence; or alternatively, a 
lack of tyrosine release, arguing in favour of such an extra sequence. 
The results obtained were not completely consistent with either of 
these expectations. Tyrosine was released from the surface y-chains 
with kinetics indicating a C-terminal location, but with a yield in
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both cases significantly lower than expected. Figure 2.2 C and D shows 
the yields to be approximately 35% for Daudi and 70% for Raji p-chains, 
based on the arbitrary but convenient figure of 20 tyrosine residues/ 
chain. As evident from the preceding discussion, however, 20 
tyrosine residues/chain is likely to be an overestimate. Therefore 
the yields determined above are, if anything, likely also to be over­
estimates.
2.2,5 Discussion of Surface p-Chain Digestion Results 
The digestion results described above and shown in Fig. 2.2 for 
both C-terminal tyrosine positive {1788 and Bri-8 y-chains) and 
negative (k and X light chains) polypeptide's provide strong evidence 
for the sensitivity and reproducibility of this experimental approach.
In particular, the data argue strongly against nonuniform release of 
tyrosine, both with respect to kinetics and yield. Therefore, in 
considering interpretations of the results, I have assumed that the 
partial release of C-terminal tyrosine from the surface y-chains is 
significant and must be explained,
2.2.5.1 Interpretations Against a.ModifiedC-terminus
Several trivial explanations are possible for the low yields of 
released tyrosine from Daudi and Raji y-chains, which would argue 
against a modified carboxy terminus. If the total radioactivity in 
these y-chains was overestimated due to the presence of contaminating 
proteins, the data might be consistent with complete release of 
C-terminal tyrosine. However, the SDS-PAGE profiles (Fig. 2.3, 
tracks 8-10) showed no evidence of such contamination, especially in 
the case of Daudi y-chain, which was better resolved and also contained 
more radioactivity relative to the background than Raji y-chain, and
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yet had a lower yield of released tyrosine. Another possible 
explanation for the apparent partial release of carboxy terminal 
tyrosine would be if the tyrosine content of the y-chains was greatly 
underestimated. However, to conclude that there was 100% release 
on this basis would require 28 tyrosine residues in Raji and 57 in Daudi 
y-chains - clearly inconsistent with the reported figures indicating a 
likely 12-17 residues/chain.
2.2.5.2 Interpretations Favouring a Modified C-terminus 
In view of the above discussion, the digestion results from Daudi and 
Raji y-chains appear to be most consistent with the existence of two- 
forms of y-chain. According to this interpretation, a form possessing 
a C-terminal tyrosine residue (putative secretory type y-chain) would 
account for approximately 35% of Daudi and 70% of Raji y-chains, while 
a form negative for C-terminal tyrosine (putative surface y-chain) 
would account for the remainder in each case.
The presence of two forms of y-chain in the Daudi and Raji cells would 
not be unexpected. Molecules with C-terminal tyrosine may reasonably 
be thought to arise in either the synthetic or dégradative pathways of 
surface IgM expression by cleavage of a putative C-terminal extra 
sequence. Cleavage immediately following synthesis could divert newly 
synthesised y-chains from surface expression, thereby regulating the amount 
of surface IgM on the cell. Such cleavage may in fact yield a y-chain 
of similar structure to the secretory form; however, since Daudi and 
Raji cells do not secrete IgM, cleavage could not alone be sufficient 
for secretion.
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Alternatively, cleavage of the putative extra sequence could be 
a signal for the degradation of the surface IgM molecule. However, 
the rapid labelling of C-terminal tyrosine’ containing jj-chains argues 
against this explanation.
2.2.5.3 Conclusion: Detection of a Modified C-terminus on a
Portion of Daudi and Raji y-Chains
According to the discussion outlined above, I believe these experiments
provide strong evidence in favour of a modified C-terminus on a portion
of Daudi and Raji y-chains. This conclusion is in basic agreement with
the recently reported findings from another laboratory using similar
methods (Williams & Grey, 1978). These workers reported no C-terminal
tyrosine but good yields of C-terminal valine upon carboxypeptidase
digestion of Daudi y-chains. With regard to the contradictory results
of Mcllhinney et al. (1977) , I believe their experiments lacked the
sensitivity to detect a modified C-terminus on putative surface y-chains,
especially if their preparations were contaminated with secretory type
y-chains.
Assuming that the above evidence for two forms of y-chain in Daudi and 
Raji cells is correct, it remains problematic whether the forms detected 
are those of functional secretory y-chains and surface y-chains (i.e. 
those containing an extra hydrophobic C-terminal sequence). Two 
observations provide indirect evidence that this is indeed the case. 
First, only with the sIgM-expressing Daudi and Raji cells, and not with 
any of the IgM secreting cells investigated, can the clear presence of 
modified y-chains be demonstrated. Second, the higher proportion of 
modified y-chains from Daudi cells (70%, compared to 35% for Raji) is 
consistent with the greater ease of sIgM detection on Daudi cells, A 
more convincing demonstration that the forms detected are indeed the
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putative surface and secretory U-chains would ideally show their resol­
ution by SDS-PAGE and, importantly, show that the form not contributing 
the C-terminal tyrosine is the higher molecular weight form. In this 
regard, a difference of about 20 amino acid residues would be expected? 
this being the approximate length of several hydrophobic membrane- 
associated sequences recently discovered, including Ig light chain 
precursor piece (Milstein et al., 1972; Mach et al., 1973; Burstein 
& Schechter, 1976), Ig heavy chain precursor piece (H. Singer & Williamson, 
in preparation), and the glycophorin membrane-associated region (Segrest 
et al., 1972) . It has been demonstrated by comparative SDS-PAGE of 
nonglycosylated mouse 5563 y 2^ heavy chain and its cell-free synthesised 
precursor (H. Singer & Williamson, in preparation) that a difference of 
19 amino acid residues, out of approximately 450, can be resolved.
Figure 2.3 (tracks 8-10) shows that the normal cellular U-chains 
isolated from Daudi and Raji cells do not resolve into two bands. This 
observation is apparently contradictory to the evidence from the car­
boxypeptidase digestion, but can however be reconciled with the latter 
evidence in one of several ways. First, the molecular weight difference 
between the two forms of U-chain may be too small to be resolved; 
but not necessarily too small to be consistent with a functional hydro- 
phobic sequence on the surface U-chains, Alternatively, variable 
glycosylation of the two forms of U-chain may mask the molecular weight 
difference contributed by an extra hydrophobic sequence, SDS-PAGE 
analysis of nonglycosylated Daudi and Raji U-chains synthesised in vivo 
in the presence of tunicamycin (see section 2.3.7) lends strong support 
to this latter explanation.
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2.3 ANALYSIS OF NONGLYCOSYLATED CELL SURFACE AND SECRETORY 
]i-CHAINS
2.3.1 Rationale for Investigation
Carbohydrate constitutes approximately 15% of the molecular weight 
of human IgM, and is known to occur as either linear or branched 
structures attached at five sites on each u-chain (Spragg & Clamp,
1969 Shimizu et al., 1971) . The attachment of carbohydrate to u-chains 
has long been thought to affect the physical properties and biological 
functions of IgM. Specifically, differences in the carbohydrate com­
position of cell surface and secretory IgM have been searched for to 
explain the unique cellular roles of these molecules (Melchers &
Andersson, 1973). Although it is clear that glycosylation patterns 
alone are not sufficient to distinguish surface IgM from secretory IgM, 
subcellular transport of many newly synthesised proteins, including Ig, 
is characterised by a series of specific glycosylation events (Eylar, 1965; 
Melchers, 1973; Sherr & Uhr, 1971). In this way, glycosylation
may indirectly determine the pathways which lead to either surface 
deposition or secretion of Ig. With regard to u-chain structural 
differences which may adapt sIgM to the membrane environment, it has 
been convincingly argued on the basis of thermodynamic considerations 
(Singer, 1974) that carbohydrate differences alone: are insufficient. 
However, indirect effects of carbohydrate, such as causing conformational 
changes in the sIgM molecule which would bring hydrophobic regions 
into association with the membrane, have been postulated (Vitetta &
Uhr, 1975b).
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The analysis of nonglycosylated u-chains synthesised in vivo was 
undertaken primarily to further investigate the u-chain structural 
differences previously shown to exist between surface associated and 
secretory IgM molecules. Three aspects were of particular interest. 
First, with the carbohydrate moiety removed, apparent molecular weight 
differences between the respective u-chains (see section 2.1.3) could 
be localised to either the polypeptide portion or the carbohydrate 
portion of the molecules. Second, SDS-PAGE of nonglycosylated Daudi 
and Raji U-chains may allow the resolution of two forms postulated 
from the carboxypeptidase digestion evidence, thereby testing the idea 
that unequal glycosylation of the two forms masks their resolution under 
normal circumstances (see section 2,2.5.3). Third, the processing of 
precursor segments (both putative N- and C-terminal) could be studied 
by comparative SDS-PAGE on nonglycosylated cellular chains and their 
cell-free synthesised counterparts (see sections 2,4.4 and 2.4,5).
In addition to the structural studies outlined above, possible effects 
of glycosylation in determining subcellular transport of IgM can be 
studied in tunicamycin-treated cells. Thus, it can be asked whether 
nonglycosylated p-chains are secreted or deposited in the cell membrane 
with the same efficiency as normal u-chains.
2.3.2 The Use of Tunicamycin to Inhibit Glycosylation 
To obtain nonglycosylated u-chains (and light chains) for SDS-PAGE 
analysis, the antibiotic tunicamycin was utilised. Tunicamycin has 
been shown to act by inhibiting the formation of N-acetyl-glucosamine 
lipid intermediates (Tkacz & Dampen, 1975; Bettinger & Young, 1975; 
Takatsuki et al., 1976; Lehle & Tanner, 1976) which serve as donors
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for the synthesis of the core regions of N-glycosydically linked oligo­
saccharides (Waechter & Lennarz, 1976). Thus, treatment of cells with 
tunicamycin results in the synthesis of proteins deficient in asparagine 
linked oligosaccharides (Struck & Lennarz, 1977). Since all known 
y-chain carbohydrate has been found to be asparagine linked (Shimizu 
et al., 1971; Putnam et al., 1973), treatment with tunicamycin should 
result in the synthesis of completely nonglycosylated y-chains.
2.3.3 IgM Synthesis in Tunicamycin Treated Cells; General Effects 
To investigate the biosynthesis of IgM in the presence of tunicamycin, 
cells were first preincubated with the antibiotic for either 2 hr or 
5 hr (separate experiments). For these preincubations, tunicamycin 
to a final concentration of 0.5 yg/ml was added to aliquots of log 
phase cultures without prior harvesting of the cells. After the pre­
incubation, the cells were harvested and biosynthetic labelling carried 
out (Methods, 8.1) using labelling and chase media which were also 
0.5 yg/ml with respect to tunicamycin.
In one such biosynthesis experiment, Daudi, Raji, and 1788 cells were 
first preincubated with tunicamycin for 5 hr, after which time the cells 
were allowed to incorporate 35S-methionine for 1 hr. The Daudi and Raji 
cells were then kept at 2°C while the 1788 cells were incubated under 
chase conditions (Methods, 8.1) for a further 2 hr to allow for some 
secretion of labelled IgM to occur. NP-40 cell lysates were then 
prepared. Total protein synthesis was determined by TCA precipitation 
and IgM synthesis by immunoprécipitation, using excess RAHIgM and 
S. aureus immunoabsorbent to affect complete precipitation. The synthesis 
of total protein and of IgM in tunicamycin treated cells was compared 
to the synthesis in untreated cells which had been labelled similarly.
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The results are summarised in Table 2.2,
Table 2.2 Synthesis of Total Protein and 
Treated and Untreated Cells*
IgM in Tunicamycin
Cell Line
*
Tunicamycin Treated Untreated
Protein IgM Protein IgM
Daudi 22.7 0.34 31,0 0.45
Raji 38.9 0.57 35.3 0.54
1788 (IC) 55.5 1.44 56,1 1.07
1788 (EC) 0.29
*35S-methionine counts/min ( x 
corrected for 1 x 10^ cells.
10"®), 
(IC)
1.00
intracellular, (EC) extracellular.
As can be seen from the data in Table 2,2, tunicamycin treatment 
had no measureable effect on total protein synthesis in Raji and 
1788 cells, and only a marginal inhibitory effect (27%) on protein 
synthesis in Daudi cells. This is in agreement with the findings 
of Olden et al. (1978), who reported variable but generally minor 
inhibition of protein synthesis in chick embryo fibroblasts which 
had been treated with varying concentrations of tunicamycin. It 
is not clear whether the inhibition of protein synthesis in Daudi 
cells is significant, since in other biosynthetic labellings little 
or no inhibition was found.
Tunicamycin treatment appears to have had a differential inhibitory 
effect on IgM synthesis in 1788 cells. Thus in the control (untreated) 
culture 3,6% of the total protein synthesised was precipitated with
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RAHIgM, whereas in the tunicamycin treated culture only 3.0% was 
precipitated. A closer examination of the data, however, indicates 
that the major effect of tunicamycin was the inhibition of secretion 
of IgM from 1788 cells (see section 2.3.5), Whereas approximately 
50% of the synthesised IgM in the control cultures was secreted during 
the 2 hr chase, only 20% was secreted in the tunicamycin treated cultures. 
The buildup of intracellular IgM in the treated cultures (2,6% of the 
total protein compared with 1.9% in the control) presumably reflects the 
inhibition of secretion in these cells, and may also be an indirect cause 
of the overall reduction in IgM synthesis. No differential effect of 
tunicamycin on IgM synthesis in Daudi and Raji cells was found in this 
experiment.
2.3.4 SDS-PAGE of IgM from Tunicamycin Treated Cells
SDS-PAGE profiles of reduced IgM synthesised in Daudi, Raji and 1788
cells in the presence and absence of tunicamycin are shown in Fig.2.3.
The results indicate that a 5 hr preincubation with tunicamycin (0.5 
yg/ml) completely abrogates the synthesis of normally glycosylated 
y-chains in all of the cell lines investigated. Thus the profiles 
obtained from the tunicamycin treated cultures (tracks 1-3) show no 
y-chain bands corresponding in mobility to those obtained from the 
untreated cultures (tracks 8-10). Treatment of cell cultures with 
tunicamycin (0.5 ug/ml) for 2 hr also resulted in the complete abrogation 
of normally glycosylated ychain synthesis in Daudi and Raji cells 
(see Fig. 2.6) . IgM from two hour tunicamycin treated 1788 cells has 
not been analysed by SDS-PAGE (Fig. 2.6, track 9, is a sample from 
5 hr treated 1788 cells).
The y-chains from the tunicamycin treated cells exhibited a markedly
Fig. 2.3
SDS-PAGE Analysis of Biosynthetically Labelled and Surface 
Radioiodinated IgM in Tunicamycin-Treated and Untreated Cells
Tunicamycin (1 mg/ml in DMSO) was added to a final concentration of
70.5 yg/ml to log phase cultures containing 1 x 10 cells. Parallel
7
cultures (controls) of 1 x 10 cells were also maintained. The 
cells were incubated at 37°C and, after 5 hr, cells from the tunic­
amycin- treated cultures and control cultures were harvested for bio­
synthetic labelling, 1 x 10^ cells were labelled for 1 hr in 0.2 ml 
labelling medium (with or without tunicamycin) containing lOO yCi 
35S-raethionine. Complete medium (0.8 ml, with or without tunicamycin) 
was then added and a further 2 hr incubation allowed (Methods, 8.1). 
The cells were separated from the culture medium and lysed in 0.2 ml 
NP-40 lysis buffer containing PMSF and pepstatin-A (Methods, 8.3).
After a total of 8 hr incubation, cells from the tunicamycin treated
and control cultures (Daudi and Raji only in each case) were harvested
7for radioiodination. Cell surface proteins from 1 x 10 cells were 
labelled by lactoperoxidase iodination (1-125, 1 mCi) as described in 
Methods, section 8,2, and the cells lysed in 0.5 ml NP-40 lysis buffer 
as descibred above.
Aliquots of cell lysate were removed for TCA precipitation, and then 
immunoprécipitations were carried out by addition of lO yg RAHIgM to 
the biosynthetic lysates and 1788 culture medium, or 40 yg RAHIgM to 
the radioiodinated lysates (15 min at 20°C), followed by 25 yl or 100 yl 
respectively of S. aureus immunoadsorbent (overnight at 4°C). The 
radioactivity recovered in TCA and immunoprecipitates is given for the 
biosynthetic labelling in Table 2.2, and for the surface iodination in 
Table 2.3, Washed immunoprecipitates were dissolved in reducing sample 
buffer for discontinuous SDS-PAGE on a 10% polyacrylamide slab gel 
(Methods, 11). The gel was processed for fluorography (Methods, 17.4) 
and fluorograms developed after exposures of 2-24 hr.
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faster SDS-PAGE mobility than their counterparts from the untreated 
cells, (compare for example tracks lO and 11 with tracks 12 and 13), 
consistent with a deficiency of glycosylation in the tunicamycin treated 
cells. Since tunicamycin is known to block asparagine linked glyco­
sylation, it is reasonable to assume y-chains from treated cells to be 
completely free of carbohydrate. Consistent with this assumption is 
the observation that y-chains synthesised in tunicamycin treated 1788 
cells have a slightly faster mobility on SDS-PAGE than their cell-free 
synthesised counterparts (see section 2.4.5).
2.3.5 Secretion of Nonglycosylated y-Chains from 1788 Cells 
The data given in Table 2.2 and discussed in section 2.3,3 indicated a 
significant inhibition of secretion of IgM from tunicamycin treated 
1788 cells. It was therefore of interest to determine whether the 
secreted IgM consisted of nonglycosylated y-chains or y-chains which had 
been fully or partially glycosylated even in the presence of tunica­
mycin. Fig. 2.3, tracks 11 and 13, shows the SDS-PAGE profiles of IgM 
secreted from control and.tunicamycin treated cells respectively. The 
samples used were from the same experiment described in section 2.3.3. 
Essentially all of the secreted y-chain from the treated cells comigrated 
with nonglycosylated y-chain (only an insignificant amount of label 
was detected comigrating with normal y-chains).
The foregoing results indicated that nonglycosylated y-chains can be 
secreted. However, these findings do not indicate that glycosylation 
is unnecessary for secretion. Thus, several secretory pathways for 
nonglycosylated y-chains can be envisaged. Secretion of nonglycosylated 
y-chains in monomeric form or as HgLg subunits is one possibility. 
Alternatively, nonglycosylated y-chains could be secreted in subunits
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containing one glycosylated y-chain, or in polymeric (H^L^) molecules 
containing from 1 to 10 nonglycosylated y-chains together with both 
partially and fully glycosylated 'partners'.
Since SDS-PAGE (Fig. 2.3) shows that the labelled y-chains detected by 
immunoprécipitation were nonglycosylated, it follows that only non­
glycosylated y-chains were synthesised during the labelling period. This 
does not preclude the possibility that unlabelled y-chains, fully or 
partially glycosylated were also part of the cellular y-chain pool. To 
the contrary, it would be reasonable to assume, depending on the rate of 
action of tunicamycin and the kinetics of secretion of newly synthesised 
y -chains, that a residual pool of fully and partially glycosylated y-chains 
was present before the onset of labelling. Thus, some, if not all, of 
the nonglycosylated y-chains detected in the culture medium could have been 
'carried' out as part of or molecules containing glycosylated
y-chains as well. This situation seems more likely in the case of IgM, in 
that the pentameric molecule could probably contain a few nonglycosylated 
y-chains without major conformational change. The amount of nonglycosylated 
jichain 'carried' out in this manner would depend on how strict the require­
ment for glycosylated 'partners' is, and on how many such glycosylated 
y-chains were available during the labelling and chase periods. The 
inhibition of secretion in the tunicamycin treated .cultures (20%, compared 
with 50% in the control cultures) indicates, according to this inter­
pretation, that the availability of, or the requirement for 'carrier' 
y-chains was somewhat but not completely limiting.
It is clear that the use of tunicamycin provides an excellent system in 
which to investigate the glycosylation of jy-chains, their assembly into 
subunits, the size and rate of depletion of the intracellular y-chain pool.
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and the glycosylation requirements for active secretion. For example, two 
mechanisms of IgM assembly and secretion can be proposed, based on the 
experiments with tunicamycin treated cells. Thus it was assumed in the 
preceeding discussion that glycosylated and nonglycosylated u-chains can 
pair up to form pentamers which are either rapidly secreted, slowly secreted, 
or not secreted at all, depending on their structural similarity to normal 
pentameric IgM. An alternative model would propose that glycosylated and 
nonglycosylated y-chains do not pair up, and that completely nonglycosylated 
pentamers (or monomers) can be secreted, albeit at a slower rate than normal 
pentamers.
To decide between these models it would be necessary to know the structure 
of the so-called 'carrier' units. This could be determined indirectly by 
SDS-PAGE of the unreduced (presumably pentameric) secretory IgM to resolve 
molecules containing 1,2,3,....up to 10 nonglycosylated y-chains. This 
approach would probably be feasible using refinements of the available SDS- 
PAGE techniques for the analysis of high molecular weight molecules. The 
presence of partially glycosylated y-chains in the 'carrier' units would, 
however, add another level of complexity to the analysis,
2.3.6 Lack of Surface Deposition of Nonglycosylated y-Chains 
The surface deposition of nonglycosylated y-chains was investigated as 
part of the same experiment described in section 2.3,3, The tunicamycin 
treated and control cultures, from which cells were harvested for bio­
synthesis after 5 hr preincubâtion, were also the source of cells for 
surface iodination. Daudi and Raji cells were harvested after 8 hr pre­
incubation with tunicamycin and cell surface proteins labelled by lacto- 
peroxidase iodination. Cultures of untreated Daudi and Raji cells were 
also iodinated under similar conditions. The incorporation of 125-1
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into TCA and anti-IgM precipitable material is summarised in Table 2.3
Table 2.3 Incorporation of 125-1 into Total Surface Proteins and 
sIgM in Tunicamycin Treated and Untreated Cells*
Cell Line
Daudi
Raji
Tunicamycin Treated 
Total Surface
Proteins
42.3
21.8
sIgM
1.07
0.20
Untreated
Total Surface 
Proteins
44.9
23.3
sIgM
1.31
0.35
*Counts/min ( x 10 , corrected
for 1 X 10^ cells.
No measureable inhibition of labelling of total surface proteins in 
tunicamycin treated cells was detected. In contrast, there was a slight 
inhibition of sIgM labelling after tunicamycin treatment. Thus, in the 
control cultures 3.0% of Daudi and 1.5% of Raji surface proteins were 
immunoprecipitated with RAHIgM, whereas in the tunicamycin treated cultures 
only 2.6% of Daudi and 0.9% of Raji surface proteins were immunoprecipitated, 
The significance of these differences depends on their reproducibility, 
which was not rigorously tested. Previous experience indicated, however, 
that experimental error in parallel immunoprécipitations of this sort is 
unlikely to lead to such differences.
It was of interest to determine whether the surface labelled IgM from 
tunicanycin treated cells consisted of nonglycosylated y-chains, normal 
y-chains, or both. A priori it was expected that a relatively high 
proportion of surface y-chains would be glycosylated as a result of their 
having been synthesised before tunicamycin addition. This assumes a 
slow rate of turnover for cell surface IgM, which has indeed been found
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to be the case for mouse splenocytes (Melchers & Andersson, 1973) , 
although it has not been as well documented for human lymphoma-derived 
cells. Assuming that enough time was allowed for the surface expression 
of newly synthesised y-chains, the absence of nonglycosylated y-chains 
from the cell surface would indicate that glycosylation was necessary for 
surface deposition. In the present experiment an 8 hr preincubation with 
tunicamycin was allowed (the cells were shown to be synthesising only non­
glycosylated y-chains after 5 hr preincubation). It was felt that this 
experimental design would allow at least some surface expression of newly 
synthesised y-chains to occur.
The SDS-PAGE profiles of surface IgM from tunicamycin treated and untreated 
Daudi and Raji cells are shown in Fig. 2.3(B), Both treated and untreated
Daudi cells were found to express high levels of sIgM, consisting solely of 
normally glycosylated P , p33 (see ch.3), and K-chains (see tracks 4 and 6).
To a very sensitive level of detection (i.e. compare the intensity of the 
y-chain bands from Daudi and Raji cells), no nonglycosylated or partially 
glycosylated y-chains were expressed on the Daudi cell surface. This was 
the case even though total sIgM was being raeasureably depleted from the 
Daudi cell surface, implying that normal turnover would have been replacing 
these molecules if suitable replacements were available. Thus, I believe 
this result provides strong evidence that nonglycosylated y-chains are 
effectively inhibited from surface expression in Daudi cells.
Untreated Raji cells (track 7) were found to express extremely low amounts of 
sIgM relative to Daudi cells (track 6), consistent with previous findings 
(the relative amount of sIgM on Raji cells is always vastly overestimated 
when comparing iramunoprecipitable radioactivity, as in Table 2.3). SDS-PAGE 
of the IgM precipitated from tunicamycin treated Raji cells (track 5) gives 
no detectable band of radioactivity corresponding to the mobility of
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glycosylated or nonglycosylated y-chains. This indicates, though to a 
much lesser sensitivity than with Daudi cells, that nonglycosylated y-chains 
in Raji cells are inhibited from surface expression as well. The lack of 
a normal y-chain band from the treated Raji cells suggests that these cells 
may have a faster rate of turnover of sIgM than Daudi cells. Thus, the 
tunicamycin treatment appears to have caused the modulation of sIgM from the 
Raji cell surface,
2,3.7 Nonglycosylated Daudi and Raji y-Chains Resolve into Two Forms 
by SDS-PAGE
SDS-PAGE analysis of Raji and Daudi IgM, biosynthetically labelled in the 
presence of tunicamycin (5 hr preincubation), showed the nonglycosylated 
y-chains to resolve into two forms. These forms, which differ in apparent 
molecular weight, are indicated by the arrows in Fig, 2 3, track 1, Fig.
2.6 (tracks 7 and 8) shows similar SDS-PAGE profiles obtained from 2 hr 
tunicamycin treated Daudi and Raji cells, in which the two forms of y-chain 
are moreclearly resolved, A similar exposure of the profile from tunica­
mycin treated 1788 cells (Fig. 2,6, track 9) shows the y-chain to consist 
of only a single band.
The existence of two forms of y-chain in Daudi and Raji cells was predicted 
earlier on the basis of the C-terminal analysis performed using carboxy- 
peptidase digestion (section 2.2). The resolution of these forms by SDS- 
PAGE is strong evidence in support of this earlier prediction. The ability 
to resolve the nonglycosylated but not the glycosylated y-chains is con­
sistent with the idea that variable glycosylation masks the apparent molecular 
weight difference of the polypeptide portions of the y-chains (section 2.2, 
5.3) .
As discussed earlier, if the two forms of y-chain detected have structures
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consistent with the model for secreted and cell surface molecules (the 
latter postulated to have an extra C-terminal sequence), the C-terminal 
tyrosine negative y-chain should be the higher molecular weight form.
The present findings provide indirect though strong evidence that this is 
indeed the case. This interpretation makes use of the observation from 
the carboxypeptidase digestion that Daudi cells synthesise significantly 
more of the C-terminal tyrosine negative y-chain (putative surface form), 
and conversely, less of the C-terminal tyrosine positive y-chain (secretory 
form) than Raji cells. The SDS-PAGE profiles in Figs. 2,3 and 2.6 show 
greater labelling of the higher molecular weight y-chain in the case of Daudi 
and of the lower molecular weight y-chain in the case of Raji cells. The 
higher molecular weight y-chain can therefore be equated with the C-terminal 
negative form (i.e. the putative surface form), and the lower molecular 
weight y-chain with the C-terminal tyrosine positive form (secretory form), 
as predicted from the model.
Similar results to those described above have been found from each SDS-PAGE 
analysis so far performed on y-chains from tunicamycin treated cells. These
experiments include those in which the cells were preincubated with tunic­
amycin (0.5 Pg/ml) for 2, 4, or 5 hr. In all of the experiments, the
relative labelling of the two forms of y-chain in Daudi and Raji cells was
similar to that shown in Figs. 2.3 and 2.6. This argues strongly against 
the notion that artefacts introduced during preparation or electrophoresis 
of the samples are responsible for the double banding pattern.
Several trivial explanations for the resolution of two forms of y-chain from 
Daudi and Raji cells have not been formally ruled out. Thus, the higher 
molecular weight y-chain may have on oligosaccharide subunit still present, 
which shows variable resistance in the two cell lines to inhibition by
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tunicamycin. Alternatively, the main structural difference detected may 
be at the N-terminal end, caused perhaps by unequal processing of putative 
synthetic precursors. When viewed in the light of the C-terminal analysis, 
however, these alternative explanations lose much of their appeal. One 
important test of the hypothesis that surface y-chains have an extra C- 
terminal would be to physically isolate the two forms of y-chain and 
analyse each for release of C-terminal tyrosine. This experiment has been 
done preliminarily and the results indeed indicate release of C-terminal 
tyrosine from the lower molecular weight y-chain, and not from the higher 
molecular weight y-chain.
2.3.8 Apparent Molecular Weight of Nonglycosylated 1788 y-Chains 
It was previously shown (section 2.1.4) that Daudi and Raji surface y-chains, 
radiolabelled with a short (1 hr) pulse, comigrated as single bands on SDS- 
PAGE, with a retarded mobility relative to y-chains (intracellular or 
secreted) from secretory cells such as 1788, These findings are shown in 
Fig, 2.1, and are illustrated again in Fig. 2.3 (tracks 8-10) and Fig,
2,6 (tracks 1-3).
With the use of tunican^cin, it could be asked whether additional asparagine 
linked glycosylation is responsible for this retarded mobility of Daudi and 
Raji y-chains. For such an experiment, it is appropriate to compare the 
SDS-PAGE mobility of nonglycosylated 1788 y-chain with that of the lower 
molecular weight form of Daudi and Raji y-chains. This follows from the 
evidence that it is the lower molecular weight form which most resembles 
secretory y-chain (i.e. by C-terminal analysis, see sections 2.2 and 
2.3,7) .
The SDS-PAGE profiles shown in Figs. 2.3 (tracks 1-3) and 2.6 (tracks 7-9) 
show that nonglycosylated 1788 y-chains migrate slightly faster than the
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lower molecular weight form of either Daudi or Raji y-chains.
This finding appears to indicate that these y-chains differ in their 
polypeptide portion, and not in their carbohydrate portion. Thus, 
the polypeptide portion of 1788 secretory y-chain appears to be of 
lower molecular weight than that of the putative secretory type 
y-chains from Daudi and Raji cells.
Explanations for the above finding include the possibility that Daudi 
and Raji y-chains (higher and/or lower molecular weight forms) contain 
nonasparagine linked carbohydrate which retards their SDS-PAGE 
mobility relative to 1788 y-chains. Alternatively, Daudi and Raji 
y-chains may be of a subclass different from 1788 y-chains and exhibit­
ing a mobility on SDS-PAGE distinct from 1788 y-chains. A third 
possibility is that Daudi and Raji y-chains (both forms) retain their 
N-terminal precursor piece in vivo, whereas 1788 y-chains have theirs 
removed. Evidence comparing the SDS-PAGE mobility of nonglycosylated 
in vivo-synthesised y-chains and cell-free synthesised y-chains 
(sections 2.4,4 and 2.4.5) supports this latter explanation.
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2.4 CELL-FREE SYNTHESIS OF y-CHAINS FROM CELL SURFACE AND 
SECRETORY IgM-PRODUCING CELLS: ANALYSIS OF PRECURSORS
2.4.1 Preparation of Polyribosomes
Messenger RNA capable of being efficiently translated in a wheat germ 
cell-free system was prepared by a two stage procedure. Polyribosomes 
were first prepared from detergent extracts of human lymphoid cells, 
according to the methods of either (I) Bennett, Fitzmaurice and 
Williamson (in preparation), or (II) T. Mosmann (personal communication). 
Both methods, which are modifications of published techniques, were 
developed specifically for use with mouse myeloma cells in tissue culture. 
However, both were found to be well suited for the preparation of high 
yields of undegraded polyribosomes from human lymphoid cells.
Figure 2.4 shows a typical polyribosome profile, obtained using the
method of T. Mosmann. The large proportion of rapidly sedimenting
material (i.e. high molecular weight polyribosomes), as well as the
sharp resolution of individual peaks of up to nine ribosomal subunits,
(indicated by arrows) is characteristic of an undegraded preparation.
The polyribosome yield from the human lymphoid cell lines investigated
was generally found to be lower than that from mouse myeloma cells, as
would be expected from the less active metabolic rate of the human cells
(i.e. less rough endoplasmic reticulum (RER) and less protein synthesis
as measured by incorporation of labelled amino acids). Thus, the
human cells yielded an average of approximately 2-3 mg (50-7 5 A^^^ units)
9polyribosomes per 1 x 10 log phase cells, as compared to the reported
9
values ranging from 7 5-200 Ag^^ units/10 mouse myeloma cells.
Although both methods of polyribosome preparation were suitable in most
■Fig. 2.4
Sucrose Density Gradient Centrifugation of Polyribosomes Prepared 
from Human Lymphoid Cells
Polyribosomes were prepared according to the Modified Method of
9
T, Mosmann (Methods, 9.3,2) from 5 x 10 log phase Daudi cells.
Approximately 10 A^^^ units of polyribosomes in 100 ul of O.25 M
sucrose were layered onto linear sucrose gradients (0.5 - 1.25 M
sucrose in Solution C) prepared in 12 ml polyallomer tubes to fit
a Spinco SW41 rotor. The gradients were centrifuged at 4°C for
90 min at 40,000 rpra. The A^^^ profile was generated by pumping
the gradient at 1 ml/min through a spectrophotometer flow cell of
1 mm path length, and recorded on a chart recorder set at 50/sec/cm
with a full scale absorbence of 0.2 A„_ units.
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circumstances, the method of T. Mosmann (Method II) was found to be 
preferable because of its insensitivity to the range of RER content 
encountered in the human cell lines. Thus, in Method I, the amount 
of triton X-lOO (0.04-0.1%) used in conjunction with 1 mg/ml heparin 
(included as an inhibitor of ribonuclease, but also acting as an ionic 
detergent) had to be titrated against the RER content of the cells in 
order to avoid nuclear lysis and consequent degradation of the poly­
ribosomes. In Method II, however, the initial heparin concentration 
was tenfold lower (0.1 mg/ml) and the triton X-100 (2% w/v) was therefore 
the major lysing agent. Since triton X-100 does not lyse nuclei very 
readily, no titration was necessary and nuclear lysis rarely occurred.
2,4.2 Preparation of Messenger RNA
Messenger RNA was prepared from polyribosomes by phenol extraction and
oligo dT cellulose chromatography of the resulting polysomal RNA (see
Methods, section 9.4 and 9,5), The oligo dT cellulose chromatography
was done by a three-step elution procedure, in which the eluting buffers
contained successively lower concentrations of lithium chloride (i.e.
0.5 M, 0.1 M, and none) . The method was found to be reproducible in
both the quantity and quality of the messenger (i.e. poly(A)*^) RNA
+
recovered. The poly (A) fraction (eluted in salt-free buffer) was 
consistently 1.5-2.0% (by absorbency) of the polysomal RNA applied to the 
oligo dT cellulose column. The intermediate wash (eluted with 0.1 M 
LiCl) was 3-4% of the polysomal RNA and could be demonstrated both by 
PAGE and by translation capacity to consist of approximately 20% mRNA 
and 80% ribosomal RNA (data not shown).
In general, the quality of an mRNA preparation was judged by its ability 
to direct cell-free synthesis of proteins having SDS-PAGE mobilities and
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relative labelling intensitites (i.e. sufficient labelling of high
molceular weight proteins) resembling that of their in vivo synthesised
counterparts. By this criteria, mRNA preparations were judged to be
free of interfering levels of degradation. On several occasions, RNA
labelled by in vivo incorporation of 3H-Uridine was also characterised
by PAGE in 99% formamide. A PAGE profile of 1788 poly (A)^ RNA is
shown in Fig, 2,5. The RNA migrates as a heterogeneous mixture of
molecular species, with sizes from greater than 282 to approximately 88,
There is no labelled material detected migrating faster than approximately
82, indicating that no detectable degradation has occurred. As can be
seen from the size of the peaks migrating with the 288 and 182 markers,
very little ribosomal RNA (rRNA) is present in the preparation. It
should be noted, however, that the PAGE profiles such as Fig. 2.5
necessarily give an underestimate of the rRNA present in the preparation
+
because rRNA labels to a lower specific activity than the poly (A) RNA 
under the conditions employed (i.e. 6 hr labelling, see Methods, section 
9.2). Thus, in the preparation used in Fig. 2.5, the rRNA had a specific 
activity of 17,000 cpm/yg, whereas that of the poly (A) ^  RNA was 
52,000 cpm/yg. These values were typical of the results obtained with 
other RNA preparations similarly prepared and labelled, and indicate a
*4"
probable rRNA contamination of not more than 10% of the total poly (A) 
preparation.
2.4.3 5D2-PAGE of Cell-Free Synthesised y-Chains: Detection of Two
Forms of y-Precursor from Daudi and Raji Cells
Wheat germ cell-free translation of poly (A)^ RNA resulted in the synthesis
of proteins with a heterogeneous distribution of molecular weights as
determined by 8D8-pAGE. As with cellular proteins labelled in vivo, IgM
heavy and light polypeptide chains could be immunoprecipitated from the
bulk of the labelled cell-free synthesised proteins using specific
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antiserum. For such immunoprécipitations, both anti-y antibody and 
anti-X of anti-K antiserum were utilised.
Figure 2.6 (tracks 4-6) shows the SDS-PAGE migration of Daudi, Raji and 
1788 cell-free synthesised y and light chains, Daudi and Raji 
y-chains resolved into two forms, as indicated by the arrows in tracks 
4 and 5. This was a consistent finding in every such SDS-PAGE of cell- 
free synthesised Daudi and Raji y-chains performed, including those in 
which different poly (A) RNA preparations and wheat germ extracts were 
used. This argues against the possibility that artefacts arising either 
during the preparation of the RNA, cell-free translation, or SDS-PAGE 
were involved. In contrast to the above findings, 1788 y-chain (track 6) 
and all the light chains shown in the figure (see section 2.4.5) 
migrated as single bands.
2.4.4 Daudi and Raji y-Chain Precursors (Both Forms) Comigrate with 
their Nonglycosylated in vivo Synthesised Counterparts
The finding that nonglycosylated Daudi and Raji y-chains resolve into a
lower and a higher molecular weight form by SDS-PAGE has been discussed
previously, as has the evidence that these forms probably represent
normal y-chains and y-chains with a C-terminal extra sequence respectively
(section 2.3.7). Figure 2.6 shows that the two y-chain forms synthesised
in the cell-free system from Daudi and Raji poly (A)^ RNA comigrated
with the nonglycosylated forms (compare tracks 4 and 5 with tracks 7 and
8 respectively). Moreover, the relative labelling of the two cell-free
synthesised forms (i.e. stronger labelling of the higher molecular weight
form in Daudi, and of the lower molecular weight form in Raji cells)
was similar to that of the nonglycosylated forms.
Fig. 2.6
SDS-PAGE Analysis of y-Chains and Light Chains Synthesised in vitro 
in a Wheat Germ Cell-Free System and in vivo in Tunicamycin Treated 
and Untreated. Cells
The samples shown in the figure consist of RAHIgM CIO yg) plus 
S. aureus immunoprecipitates from cell lysates or diluted wheat germ 
assays (also with anti-K or anti-X) prepared in 3p TKM lysis buffer con­
taining PMSF and pepstatin-A (Methods, 8.3 and 10.4). The washed 
imraunoprecipitates (25% of each sample) were dissolved in reducing buffer 
and applied to a 10% polyacrylamide slab gel for discontinuous SDS- 
PAGE (Methods, 11). The gel was processed for fluorography (Methods, 
17.4) and the fluorogram developed after a 3-day exposure to film.
Biosynthetic samples from normal cells (tracks 1-3) were prepared 
by a lO min incubation of 1 x 10^ cells in 0.2 ml labelling mediun 
containing 100 yCi 35S-methionine (Methods, 8,1).
Biosynthetic samples from tunicamycin treated (-CHO) cells (tracks 
7-9) were prepared by a 4 hr incubation of 1 x 10^ cells with 0.5 yg/ml 
tunicamycin followed by a 1 hr incubation in 35S-methionine-containing 
labelling medium as described above.
Wheat germ cell-free synthesised samples (tracks 4-6) were prepared 
by translation of 1 yg poly (A)^ RNA (see Methods, 9) from each cell 
line in 50 yl standard wheat germ assays (Methods, 10) containing 
approximately 30 yCi (5 yl) 35S-methionine (sp. act. 800 Ci/mmole).
The y and y (precursor, -CHO) markers were derived from the migration of 
the samples under investigation. No independent markers were used.
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2.4.5, 1788 y-Chain Precursor Migrates with a Higher Apparent
Molecular Weight that its Nonglycosylated in vivo 
Synthesised Counterpart
1788 y-chain synthesised in the wheat germ cell-free system had a
detectably slower SDS-PAGE mobility than nonglycosylated y-chain from
tunicamycin treated 1788 cells (Fig. 2.6, tracks 6 and 9). This can
best be seen using the doublet bands from Daudi and Raji y-chains
(tracks 7 and 8) for comparison. Thus, 1788 y-chain from the cell-
free system (track 6) migrated approximately midway between the doublet
bands, whereas nonglycosylated 1788 y-chain (track 9) migrated faster
than the fastest migrating member of the doublet. This finding is
consistent with the presence of an N-terminal precursor piece on cell-
free synthesised 1788 y-chain. In support of this conclusion, H.Singer
& Williamson (in preparation) have demonstrated by amino acid sequencing
the existence of a 19 amino acid precursor piece on cell-free synthesised
mouse y2a. myeloma protein) heavy chain, and have further shown
that this molecular weight difference is reflected in the slower SDS-
PAGE mobility of the cell-free product compared with the nonglycosylated
in vivo synthesised product.
The implications of the above findings (sections 2.4.3 - 2.4.5), con­
cerning the comparative SDS-PAGE of normal, nonglycosylated and cell- 
free synthesised y-chains, are discussed further in section 2.4.7.
2.4.6 SDS-PAGE Mobilities of Light Chains; Comparison of Precursors, 
Nonglycosylated and Glycosylated Products
Figure 2.6 shows the relative mobilities of Daudi, Raji and 1788 light
chains synthesised in the cell-free system or in vivo in the presence or
absence of tunicamycin (the locations of Daudi and 1788 light chains in
tracks 1, 3 and 9 were determined from other SDS-PAGE analyses, and are
shown here to facilitate comparison). From the mobilities of these
light chains it is possible to deduce certain information concerning
“ 17 0 “
their biosynthesis. Thus, Daudi and Raji K-chains synthesised in the 
cell-free system (tracks 4 and 5) were found to comigrate by SDS-PAGE. 
Daudi K-chain synthesised in the presence of tunicamycin (track 7) 
migrated faster than the cell-free product, consistent with the presence 
of an N-terminal precursor piece on the cell-free product which is cleaved 
off in vivo. Daudi K-chain synthesised in the absence of tunicamycin 
(track 1) migrated slower than the nonglycosylated product, indicating 
the presence of asparagine linked carbohydrate.
Raji K-chain synthesised in the presence of tunicamycin migrated slightly 
slower than the cell-free synthesised product, consistent with either 
(1) non-asparagine linked carbohydrate, or (2) non-asparagine linked 
carbohydrate and retention of a putative N-terminal precursor piece on 
Raji K-chain. Retention of a precursor alone, without the presence of 
carbohydrate, is ruled out because the product from the tunicamycin 
treated cells appeared by SDS-PAGE to be larger and not identical in 
molecular weight to the cell-free product. Thus, Raji K-chain has 
attached a small complement of non-asparagine linked carbohydrate. Raji 
K-chain synthesised in the absence of tunicamycin (track 2) comigrated 
with its counterpart from tunicamycin treated cells indicating that all 
and not just part of the Raji K-chain carbohydrate moiety is non- 
asparagine linked.
1788 X-chain synthesised in the cell-free system (track 6) migrated 
markedly slower than cell-free synthesised Daudi and Raji K-chains.
The observation that Daudi and Raji K-chain precursors comigrated argues 
against the hypothesis that amino acid composition differences alone are 
detected by Laemmli SDS-PAGE, and instead supports the hypothesis that 
only gross molecular weight differences (i.e. those contributed by extra
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carbohydrate or extra polypeptide chain length) are detected. Thus 
there appears to be such a gross molecular weight difference between 
the K and A precursors investigated (and possibly between the cellular 
products; see Ch. 1, section 1.3.5). 1788 A-chains synthesised in vivo
in the presence or absence of tunicamycin (tracks 9 and 3) were found to 
comigrate, indicating either the absence of carbohydrate or, as in the 
case of Raji K-chain, the presence of non-asparagine linked carbohydrate. 
The double banding pattern shown in the figure was an anomalous finding 
in one labelling experiment (see Fig. 2.3) which, however, does not 
alter the present interpretation of the results (in previous experiments 
it was the lower band which was detected),
In vivo synthesised A-chain was also found to migrate faster than the 
cell-free product, again consistent with the presence of an N-terminal 
precursor piece on the cell-free product which is cleaved off in vivo.
This putative A precursor piece appears to be longer than the k precursor 
piece. This conclusion is based on the smaller apparent molecular weight 
difference between the Daudi tc precursor and nonglycosylated product than 
that between the 1788 A precursor and nonglycosylated product (compare 
the mobility difference in tracks 4 and 7 to that in tracks 6 and 9) ,
However, this conclusion assumes that the Daudi K-chain from the tunic­
amycin treated cells is completely free of carbohydrate. If, instead, 
these K-chains have tunicamycin-insensitive carbohydrate attached, this 
would lead to an underestimate of the size of the precursor piece.
The findings and implications discussed above can be summarised as follows, 
(1) Both K and A chains from human lymphoma and lymphoblastoid cells 
are probably synthesised with N-terminal precursor pieces, which are 
cleaved off in vivo. (2) Assuming that the light chains shown in
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tracks 7-9 (from tunicamycin treated cells) are completely free of 
carbohydrate, and further assuming that the mobilities of the non­
glycosylated K and A chains and their precursors shown in Fig. 2.6 are 
the same for all such k and A chains, it appears that both the mature 
polypeptide chain and the precursor piece from A chains are probably 
larger than those from K-chains. (3) Kappa chains from Daudi and 
Raji cells each contain carbohydrate; Daudi k having a larger amount 
of asparagine linked moieties, and Raji k having a smaller amount of non­
asparagine linked moieties.
2.4.7 Conclusion; Aspects of p-Chain Processing in Lymphoma and 
Lymphoblastoid Cells
The above analysis of p-chains translated in vitro and in vivo in the
presence and absence of tunicamycin reveals striking differences in
y-chain expression between the lymphoma-derived and lymphoblastoid cells,
as well as offering insight into the nature of these differences. Two
particular features of y-chain processing have emerged from the data.
These features are discussed below,
(i) The two forms of Daudi and Raji y-chain are differentiated at 
the mRNA level. This conclusion is based on the observaton that cell- 
free translation of Daudi and Raji mRNA yielded both forms of y-chain in 
the same relative amounts as the nonglycosylated in vivo synthesised 
products. This reproduction in vitro of such an in vivo labelling 
pattern cannot be adequately explained by artefactual effects such as 
processing or nonspecific proteolysis in the wheat germ system. Likewise, 
it is unlikely that artefacts arising during SDS-PAGE could account for 
the labelling pattern observed. Thus, the most compelling explanation 
is that the information for the synthesis of the two forms in their 
proper relative amounts (i.e. as in the cell) is contained in the cellular 
mRNA, and is not dependent on cellular translation mechanisms. The
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most straightforward mechanism would be that each form of y-chain is 
encoded by a separate mRNA species? however, other mechanisms are not 
ruled out.
(ii) Daudi and Raji y-chain precursors (both forms) are apparently 
not processed in vivo, whereas 1788 y-chain precursor is processed to 
a lower molecular weight form. This conclusion is based on the comigration 
of cell-free synthesised Daudi and Raji y-chains with their nonglyco­
sylated counterparts, and in contrast, the retarded mobility of cell- 
free synthesised 1788 y-chain relative to its nonglycosylated counter­
part. Two possibilities can be envisaged to explain the apparent lack 
of processing in Daudi and Raji cells. Thus, both forms of y-chain 
could be synthesised without N-terminal precursor sequences, therefore 
requiring no processing to produce the normal cellular products. Alter­
natively, the y-chains could be translated with N-terminal precursor 
sequences which are then left intact in the normal cellular products. 
Although the data discussed above is not sufficient to distinguish between 
these possibilities, in either case a fundamental difference in y-chain 
processing would be involved. Amino-terminal sequencing of cellular 
Daudi and Raji y-chains is presently being carried out in collaboration 
with D. Capra and his coworkers, and from such analysis it should be 
possible to determine whether these y-chains have precursor-like or 
V region-like amino terminal sequences.
2.5. MOLECULAR EVENTS IN THE BIOSYNTHESIS OF CELL SURFACE AND 
SECRETORY IgM: A MODEL
The results described in this section suggest several novel features 
in the biosynthetic pathways of cell surface and secretory IgM in 
human lymphoid cell lines. It is expected that these features will
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in general be similar to those involved in the in vivo surface deposition 
and secretion of IgM by lymphocytes. The essential features are 
presented below in the form of a model for IgM expression.
2.5.1. Integral Membrane Binding of Cell Surface IgM 
Previous reports have determined that cell surface y-chains are of 
higher molecular weight, bind more detergent, are less soluble in 
aqueous media, and have a modified carboxy-terminus relative to secretory 
y-chains (reviewed in Introduction, section 2). The implication is 
that the y-chain from sIgM has an hydrophobic carboxy-terminal peptide 
capable of insertion into the membrane lipid bilayer. The results 
presented in this section have shown that single cell lines can 
synthesise both normal y-chains and y-chains of a higher apparent 
molecular weight. The presence of the higher molecular weight form 
correlates with the cellular expression of sIgM. A modified carboxy- 
terminus has been detected specifically on the higher molecular weight 
species in two such cell lines —  a prerequisite for the concept of an 
extra C-terminal peptide on surface y-chains.
Thus, it appears that cell surface IgM is an integral membrane protein 
attached to the lipid bilayer by means of a C-terminal hydrophobic 
'tail'. It would be of considerable interest to determine what type 
of integral membrane binding is exhibited by sIgM molecules. In a 
recent article. Singer (1977) has identified four classes of integral 
membrane protein —  1) internally (cytoplasmic) facing, partially 
embedded, 2) externally-facing, partially embedded, 3) trans-membrane 
and 4) subunit aggregates forming a transmembrane aqueous channel or 
'pore'. Classes 1 and 3 are represented by cytochrome b^ and glycophorin.
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respectively. According to Singer (197 7), it is not yet clear whether 
class 2 proteins exist. It may be that slgM is such an integral 
membrane protein. Thus, the reported SDS-PAGE mobility difference 
between putative surface and secretory y-chains (Melcher & Uhr, 1976; 
this thesis) are consistent with a 'tail' of around 15-20 amino acids 
in length. A tail of this size would be capable of embedding itself 
in the lipid bilayer, but possibly not spanning it. The finding of 
Walsh & Crumpton (1977) that IgM could not be radioiodinated from the 
cytoplasmic side of the surface membrane (using inside-out vessicles) 
supports this idea.
2.5.2. The Separation of sIgM and Secretory IgM Biosynthetic 
Pathways ; Production of Distinct mRNA Species
Previous models support the idea that the biosynthetic pathways for
sIgM and secretory IgM diverge only at a late stage in the intracellular
transport of the molecules. Thus Uhr (1970) and Uhr & Vitetta (1973)
have proposed that both forms of IgM are initially bound to microsomal
membranes by their C-terminal ends. This binding is thought to
facilitate glycosylation by membrane bound glycosyl transferases in
the smooth ER and Golgi complex. According to their model, the
newly synthesised IgM passes from the Golgi complex and into post-
Golgi vessicles, where a signal is read which results in release from
the membrane, by specific proteolytic cleavage, of those molecules
destined for secretion. Secretion (or surface deposition, in the
case of those molecules which remain membrane-bound) is accomplished
by fusion of the vessicle with the plasma membrane and reverse pino-
cytosis.
The results presented in this thesis section suggest an alternative 
model. According to this model, synthesis of the y-chain of cell
— 17 6 —
surface IgM is directed by an mRNA molecule distinct from that coding 
for secretory IgM y-chain. Thus, it is proposed that the sIgM y-chain 
messenger contains the sequence coding for the putative C-terminal 
hydrophobic peptide whereas secretory IgM y-chain messengers do not 
contain such a coding sequence. The basis for this conclusion is the 
finding that a wheat germ cell-free system directs the in vitro synthesis 
of both forms of y-chain (surface and secretory), under circumstances 
which preclude protein processing as a plausible explanation.
The production of distinct messenger RNA species for surface and 
secretory y-chains implies either 1) the existence of different genes 
for these polypeptides or 2) different transcriptional or post-trascript- 
ional processing of primary gene transcripts. Because of the increasing 
evidence for post-transcriptional processing of primary gene transcripts, 
I tend to favor alternative 2. Thus it can be envisaged that the coding 
sequences for y-chain V, C, and hydrophobic 'tail' regions are all con­
tained within the sequence of nucleotides comprising the y-chain gene.
As has recently become evident from the work of many investigators, genes 
need not be continuous. ' Thus, the y-chain gene may be found to be 
interrupted by one or several non-coding sequences. The primary RNA 
transcript for both surface and secretory y-chains may either contain 
or not contain the 'tail' region coding sequence. If the latter alter­
native is correct, then direct transcriptional control on the y-chain 
gene would be involved. If the first alternative is correct, then 
removal of the 'tail' region coding sequence from secretory y-chain 
messengers would presumably occur during post-transcriptional processing. 
The existence of large-sized heterogeneous nuclear RNA in all eucaryotic 
cells is generally considered as strong evidence that such post-trans­
criptional processing occurs. This processing is undoubtedly capable of
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a high degree of specificity, however the mechanisms involved are not 
yet known.
Both the control of cell surface vs. secretory Ig expression, and the 
control of Ig isotype expression are intimately connected with B-cell 
maturation. A minimal hypothesis would be that the control mechanisms 
involved in these processes operate at the same cellular level. Ig 
isotype switch is clearly controlled directly at the level of the Ig 
H-chain genes. A minimal model would therefore propose the same direct 
control of surface vs. secretory Ig expression. The model proposed here 
is such a minimal model. Alternative concepts require that surface vs. 
secretory Ig expression be controlled through various complex intermediate 
pathways —  such as the coordinated action of specific glycosylases and 
proteases to identify and cleave membrane bound sIgM destined for secretion; 
or the regulation of quantity or sIgM-binding affinity of putative 'anchor' 
proteins.
2.5.3. Amino Terminal Precursors
It is reasonably well established that most, if not all, proteins destined 
for vectorial release into the rough ER cisternae are synthesised with 
amino terminal precursor peptides. This has been shown to be the case 
for all of the several L-chain and both of the two H-chain precursors 
examined (see Introduction, section 3). In addition, the SDS-PAGE 
analysis of nonglycosylated and cell-free 1788 y-chain suggests that it 
too is synthesised as a precursor. Thus it is likely that both forms of 
Daudi and Raji y-chains (surface and secretory) are synthesised as 
precursors. One working hypothesis during the course of these investi­
gations was that retention of the amino terminal precursor peptide might 
be a mechanism for membrane binding of sIgM. However, the evidence for
- 1 / ü -
a carboxy terminal extra peptide removed the immediate need to postulate 
a role for the amino terminal precursor peptide. The comparitive SDS- 
PAGE analysis suggested that both the putative surface and secretory 
forms of y-chain may retain their amino terminal precursors, which was 
difficult to reconcile with a specific role for the sIgM precursor. To 
test this idea directly, samples of labelled y-chain from Daudi and Raji 
cells were prepared for radioactive microsequencing of the amino terminus. 
This sequencing work was done in collaboration with Dr. Donald Capra and 
his coworkers. The results revealed that both Daudi and Raji y-chains 
have leucine at positions 4, 11, 18 and 20, and valines at positions 2,
5 and 12 —  consistent with both of these being unblocked (V^ III) y-chains 
Since a significant portion of intracellular y-chains from Daudi cells 
was always found to be of the surface form, it can be concluded that 
amino terminal precursor peptides are not involved in the binding of sIgM 
to the plasma membrane in these cells. Instead, the above data from SDS- 
PAGE analysis can be interpreted to indicate that precursor processing in 
Daudi and Raji cells is either 1) less efficient than in secretory (i.e. 
1788) cells, or 2) more sensitive to tunicamycin than in secretory cells.
2.5.4. Intracellular Transport of sIgM as an Integral Membrane Protein 
If cell surface IgM y-chains are synthesised as integral membrane proteins 
of the class 2 type —  i.e. partially embedded in the lipid bilayer and 
facing into the microsomal compartment, it is relevant to ask how it 
attains its final membrane bound position. Singer (1977) has proposed 
that cytoplasmic-facing partially embedded membrane proteins, such as 
cytochrome b^, must insert into the membrane after completion of syn­
thesis —  without being vectorially transferred across any intracellular 
membranes. It is also reasoned in this article that integral membrane 
proteins which are vectorially transferred, but which are also of the
-l/y-
partially embedded type (as postulated for sIgM) may be free to reattach 
themselves to other areas of the intra-microsomal membrane. Provided 
that further evidence bears out that sIgM is a partially embedded 
integral membrane protein, it would be of considerable interest to 
determine if it is capable of detaching from and reattaching to membrane 
sites. Such a property of sIgM would be important for intracellular 
transport as well as for its putative functions in immune system 
interactions at the cellular level.
The apparent progression of newly synthesised cell surface and secretory 
Ig through the cellular compartments leading to the plasma membrane has 
been well documented (Introduction, sections 3 & 4) . What is not completely 
clear, however, is whether the cellular compartments for sig and 
secretory Ig are the same or independent. The findings presented in 
this thesis that nonglycosylated y-chains are not deposited on the cell 
surface, but are secreted in significant quantities, leads to the tentative 
conclusion that these molecules are compartmentalised independently. The 
alternative view is that the two y-chain types are compartmentalised 
together in post-Golgi vessicles. However, if this were the case, 
fusion and reverse pinocytosis which releases nonglycosylated y-chains 
should also result in some surface deposition of nonglycosylated y-chains. 
Clearly other explanations of the data are possible, however. One such 
explanation would be that nonglycosylated membrane bound y-chains are 
specifically degraded within the post-Goigi vessicle. Further exper­
iments are required to decide between the possible interpretations.
CHAPTER III
CHARACTERIZATION OF A POLYPEPTIDE (p33) IN A NOVEL 
COVALENT ASSOCIATION WITH DAUDI CELL SURFACE IgM
— 180—
3.1. INITIAL DETECTION OF P33
3.1.1. SDS-PAGE of Daudi Surface IgM (sIgM)
Daudi surface protein p33 was first detected during a screening 
experiment designed to determine the cell surface Ig(slg) expression 
of several lymphoma and lymphoblastoid cell lines. Cell surface 
proteins were labelled by lactoperoxidase catalysed radioiodination 
and sIg isolated from NP-40 cell lysates by immunoprécipitation with 
anti-IgM antiserum (y-specific). The immunoprecipitates were reduced 
and alkylated and analysed by SDS-PAGE on 6% polyacrylamide gels.
The SDS-PAGE profile obtained from reduced Daudi sig is shown in 
Fig.3.1(A). The label was resolved into a peak which comigrated 
with y-chain, an unusually large peak of about 33,000 molecular weight 
(section 3.3), and a partially resolved small peak which was coincident 
in mobility with L-chain. The results confirmed the findings of 
Klein et al. (1968) that Daudi sig was of the IgM class. These 
workers also characterised Daudi L-chain as being of the K-type.
3.1.2. Nature of 33,000 Molecular Weight Peak
The nature of the SDS-PAGE profile in the L-chain region of the gel 
was unusual, and presented a dilemma. If the small peak of L-chain 
mobility represents Daudi K-chain then the 33,000 molecular weight 
peak would appear to be an 'extra' component of Daudi sIgM. Alter­
natively, if the small peak is spurious then the 33,000 molecular 
weight peak would likely represent either a normal K-chain of anomalous 
SDS-PAGE mobility or an abnormally large K-chain. While it is 
generally accepted that spurious peaks and anomalous migration of
Fig. 3.1
SDS-PAGE Profiles of Daudi Cell Surface and Int-racellular IgM 
Showing Presence of p33 Peak
7
Cell surface proteins from 1 x 10 cells were labelled by lacto­
peroxidase iodination (1-125, 0.25 mCi) as described in Methods, 
section 8.2, and the cells lysed in 1 ml NP-40 lysis buffer con­
taining PMSF and iodoacetate (Methods, 8.3). Immunoprécipitation 
from the lysate was carried out by addition of 2 yl anti-IgM (15 min 
at 4°C) followed by 100 yg GARIgG (15 min at 4°C).
For biosynthetic labelling, 5 x 10^ cells from log phase cultures 
were incubated for 6 hr in 1 ml labelling medium containing 62.5 
yCi 3H-leucine (Methods, 8.1). The cells were separated from the 
culture medium. Cell lysis and immunoprécipitation were carried out 
as described above.
Washed immunoprecipitates were dissolved in 75 yl SDS-PAGE sample 
buffer and half removed for reduction and alkylation (Methods, 12.4). 
Electrophoresis was in phosphate-buffered tube gels of either 6% 
polyacrylamide for the radioiodinated sample, or 10% polyacrylamide 
(DATD-crosslinked) for the biosynthetic sample (Methods, 12). Radio­
activity in individual gel slices was determined for the biosynthetic 
samples by scintillation counting of the periodic acid solubilised 
slices (Methods, 17,2), or for the radioiodinated samples by gamma 
counting. Molecular weight marker y , y, and light chains were 
electrophoresed in separate 6% or 10% polyacrylamide tube gels.
(A) Cell Surface IgM (Radioiodinated)
(B) Intracellular IgM (Biosynthetic)
Inset Kennel, 1974. Anti-y precipitate from purified membranes 
of surface iodinated Daudi cells, SDS-PAGE was in a 6% polyacrylamide 
tube gel.
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proteins occur in SDS-PAGE profiles of immunoprecipitates, several 
arguments against this trivial explanation were apparent from the 
experimental observations. These arguments were:-
(i) The p33 peak was very highly labelled relative to 
Daudi p-chain, whereas lactoperoxidase iodination 
is known to label y-chains of sIgM preferentially 
over L-chains (Vitetta et al, 1971; personal 
observation).
Cii) The small peak exactly comigrated with the «-chain 
marker and, in addition, the lesser label in this 
peak relative to the -y-chain peak was consistent 
with it being Daudi «-chain,
(iii) No spurious peaks were seen in the SDS-PAGE profiles 
from the nine other cell sigs investigated in this 
experiment,
(iv) Biosynthetic labelling also showed Daudi cells to have 
well resolved p33 and «-chain peaks in the SDS-PAGE 
profile of its reduced sIgM (Section 3,2 and Fig, 3.1(B)),
These observations supported in two ways the interpretation that the 
p33 peak was indeed an 'extra' component of Daudi sIgM. First, it 
was unnecessary to identify p33 as the Daudi «-chain because the 
SDS-PAGE profile contained a small peak representing an apparently 
normal «-chain. Equally, it was unlikely that p33 was an abnormally 
large K-chain because of its unusually high degree of labelling,
3,1,3, Comparison to Findings of Kennel (1974)
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The published findings of Kennel (1974) are interesting with regard 
to this dilemma. He also investigated the sIgM of Daudi cells by 
lactoperoxidase iodination, immunoprécipitation, and SDS-PAGE of the 
reduced immunoprecipitates. The SDS-PAGE profile Kennel obtained 
of reduced Daudi sIgM isolated from pre-purified plasma membranes 
(Fig. 3.1(A), inset) is virtually identical to the profile I obtained. 
Kennel did not comment, however, on the presence of the small «-chain 
peak or on the unusual labelling pattern of the 33,000 molecular weight 
peak, and may have overlooked the significance of these observations.
In the event, he came to the erroneous conclusion that the p33 peak 
represented an abnormally large «-chain.
3,2.- BIOSYNTHETIC LABELLING OF p33
3.2,1, SDS-PAGE Analysis
As part of the screening experiment described in the previous section 
(3,1,1 ), cellular proteins were labelled by biosynthetic incorporation 
of 3H-leucine for 6 hr. Labelled cellular Ig was analysed by immuno­
précipitation and SDS-PAGE on 10% polyacrylamide gels.
The SDS-PAGE profile of the reduced Daudi anti-IgM (y-specific)
imraunoprecipitate (Fig, 3,1 (B)) shows the presence of three peaks of
radioactivity. Besides y-chain and «-chain peaks, a third small peak 
was resolved. This peak was assumed to be the 3H-leucine labelled 
analogue of the p33 peak which was detected by surface iodination.
This assumption was based on the similarity of the three-peak profiles 
obtained for Daudi sIgM by both labelling methods. In contrast, none
of the other cell lines investigated showed such a profile.
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The coincident migration of biosynthetically labelled and iodinated 
p33 has also been confirmed by SDS-PAGE on high resolution slab gels 
using 35S-methionine as the incorporated label (data not shown).
3.2.2. Synthesis of p33 by Daudi Cells
The biosynthetic labelling result confirmed p33 to be an actual pro­
duct of Daudi cells, and not merely a serum protein from the culture 
medium which had become attached to the cell surface. This dis­
tinction cannot be made using lactoperoxidase catalysed iodination, 
although it is generally accepted that cells in long, terra tissue 
culture do not display foreign proteins on their surfaces.
3.2.3. Characteristics of Amino Acid Incorporation
In general, biosynthetic labelling of p33 was inefficient when 
compared with lactoperoxidase iodination. Fig. 3.1 (B) shows the 
amount of label incorporated into p33 to be similar to that for the 
K-chain, and very much less than the label incorporated into the y- 
chain of Daudi cells. This contrasts sharply with the pattern of 
iodinated Daudi sIgM polypeptide chains (compare Figs. 3.1 (A) and
3.1 (B)). Often in biosynthetic labelling p33 could not be detected
at all by SDS-PAGE analysis on slab gels, or could be detected only 
with very long-exposure autoradiography. This phenomenon appears to 
reflect the rate of synthesis and turnover of p33, in that it was 
related to the labelling conditions used. Thus, incorporation of 
labelled amino acids for 1-3 hr was found to be better than a similar 
incorporation period followed by a long (6-18 lir) chase with non­
labelled amino acids. This labelling pattern is consistent with that 
found in general for y-chains and L-chains of sIgM and implies but 
does not prove that in human lymphoma cells these surface molecules
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have a rather more rapid rate of turnover than that suggested by the 
work on mouse splenocytes (Melchers & Andersson, 1973). It has not 
proved possible, however, to obtain more quantitative information on the 
rate of synthesis and turnover of Daudi p33, principally because of its 
extremely low labelling efficiency.
3.3. MOLECULAR WEIGHT ESTIMATION OF p33
3.3.1. Previously Reported Value
+
A molecular weight estimation of 32,4000 to 34,000 - 2,000 was given 
for Daudi p33 by Kennel (1974) , based on SDS-PAGE on gels of 6% to 
12.5% polyacrylamide and using four non-glycoprotein standards. This 
represents the only published information available.
3.3.2. Determination Based on SDS-PAGE Analysis
Estimates of the molecular weight of p33 which I have obtained from 
my own data were made from plots of log molecular weight versus 
migration (Pig. 3.2), based on the SDS-PAGE profiles shown in Fig. 3.1 
and using y, y, and L-chains as standards. The molecular weights used 
for Y and L-chains were 55,000 and 23,000 respectively. For secretory 
y-chains an apparent molecular weight of 83,000 was determined by 
separate SDS-PAGE analysis (Fig. 3.2, inset) using the a, and a-chains 
of RNA polymerase (Coggins et al., 1977), IgG Y'Chains, and actin as 
standards. This determination was necessary because the glycoprotein 
nature of the immunoglobulin y-chain causes its SDS-PAGE mobility to be 
anomalously slower than expected from its known molecular weight. Using 
the above method, and averaging the values (32,000 and 35,000) 
obtained from each SDS-PAGE profile, a molecular weight of 33,500 was 
determined for p33.
Fig. 3.2
Serai Log Plot for Molecular Weight Determination of p33
The SDS-PAGE mobilities of the marker y, y , and light chains from 
Pig. 3.1 are plotted versus their molecular weights of 83,000,
55,000, and 23,000 respectively on a log scale.
(A A) from Fig. 3.1 (A)
(O O) from Pig. 3.1 (B)
The broken lines show the SDS-PAGE mobility and apparent molecular
weight of p33 from each SDS-PAGE profile, as determined from these 
plots.
Inset For determination of y-chain molecular weight.
The SDS-PAGE mobilities of the marker proteins RNA pol a, IgG y-r 
chain, actin, and RNA pol a are plotted versus their molecular weights 
of 90,000, 55,000, 43,000 and 40,000 respectively on a log scale.
The broken line shows the SDS-PAGE mobility and apparent molecular
weight of secretory y-chain as determined from this plot. All 
mobilities were plotted frcxn the SDS-PAGE profile shown above 
obtained on a discontinuous Tris-glycine buffered slab gel of 12.5% 
polyacrylamide. The actin and IgG y-chain bands are not shown.
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3.3.3. Sources of Errors
The above results indicate a significant disparity in the values from 
the two SDS-PAGE profiles. While no clear explanation for this dis­
parity can be given, several significant sources of error in this 
molecular weight determination deserve comment:-
(i) The marker y, y, and L-chains were, in both cases, electro­
phoresed on separate gels run in parallel with those 
loaded with the Daudi sIgM immunoprecipitates. Under 
these circumstances, mobility comparisons were found to 
be accurate to only ^ 1 mm.
(ii) Molecular weight estimations of glycoproteins from SDS- 
PAGE on gels of different percentage acrylamide can vary 
considerably - higher percentage gels giving lower 
apparent molecular weights. This effect has been shown 
to be particularly pronounced in the case of y-chains 
(Melcher & Uhr, 1976).
Because of the above considerations, this estimation of the molecular 
weight of p33 must be regarded as only approximate. However, the 
average value of 33,500 is in good agreement with the average of 
33,000 which is reported by Kennel (1974) and so this latter value will 
be used for the purpose of further discussion.
3.4. RESOLUTION OF p33 BY DISCONTINUOUS SDS-PAGE ON SLAB GELS
Discontinuous pH tris-glycine slab gels proved to be vastly superior to 
the continuous phosphate-buffered cylindrical gels for the SDS-PAGE 
analysis of cell surface Ig. The discontinuous SDS-PAGE system gave 
the high resolution necessary to detect subtle mobility differences in
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y-chains isolated from different cell lines (Chapter 2, Section 2,1) 
and also resolved L-chains of sig as fine bands of characteristic 
mobilities (Chapter 1, Section 1.3.5).
Tris-glycine SDS-PAGE resolved Daudi p33 as a diffuse band of radio­
activity, quite distinct however from the Daudi K-chain band
(Fig. 3.3,track 6). This clear separation of the two bands, as well
as their characteristic shapes on electrophoresis (p33 diffuse and 
K-chain sharp) was considered to be strong evidence that p33 was a 
unique 'extra' component of Daudi slgM. The p33 band was similarly 
seen in all subsequent experiments involving the SDS-PAGE analysis of 
Daudi sIgM.
3.5. TEST FOR NONSPECIFIC BINDING OF p33 TO IMMUNOPRECIPITATES
Having established that p33 was a unique component of the Daudi sIgM 
immunoprecipitate, it was of interest to determine if it was an integral 
part of Daudi sIgM or alternatively, if its presence was the result of 
non-antigenic binding to the immunoprecipitate.
Non-antigenic binding to immunoprecipitates was considered not merely
as a spurious effect, but also as one with possible functional sig­
nificance. The B-lymphocyte F^ receptor, for example, is known to 
bind to antigen-antibody complexes very similar to those formed during 
indirect immunoprécipitation. In another context, it has been suggested 
(Premkumar et al., 1975a, 1975b) that a type of non-antigenic binding 
to immunoprecipitates may also detect 'anchor' proteins which have 
been postulated to bind the hydrophilic C-termini of sIgs into the 
hydrophobic cell membrane.
Fig. 3.3
SDS-PAGE Analysis Showing p33 in Daudi Total Surface Proteins 
and the Specificity of p33 Immunoprécipitation
7
Cell surface proteins from 1 x 10 cells were labelled by lacto­
peroxidase iodination (1-131, 2 mCi) as described in Methods, 
section 8.2, and the cells lysed in 0.5 ml NP-40 lysis buffer con­
taining PMSF (Methods, 8.3).. Aliquots of lysate were removed 
for acetone precipitation (Methods, 8.4,1) or immunoprécipitation 
as follows:-
Sample Amount of Lysate Counts/min
Total Surface Proteins
*BJAB 5 yl (1%) 202,000
Daudi " " 197,000
*Raji " " 139,000
Anti-y Precipitates
*Raji 25 yl (5%) 5,000
Daudi " " 34,000
BJAB " " 35,000
Daudi Non-Specific 
Precipitates
NRS 25 yl (5%) 1,250
Anti-IgD " ” 1,400
Anti-A ■ " " 1,100
Anti-5563 (Mouse " " .1,550
Immunoprécipitations were carried out by addition of either 5 yg 
RAHIgM or 0.5 yl antiserum (15 min at 20°C) followed by 25 yg GARIgG 
(1 hr at 20°C, or overnight at 4°C). Washed acetone and immune 
precipitates were dissolved in reducing sample buffer for discontinuous 
SDS-PAGE in a 12.5% polyacrylamide slab gel (Methods 11). The gel 
was processed for fluorography (Methods 17.4) and the fluorogram 
developed after an exposure of 8 hr.
*These tracks were printed at higher sensitivity.
oo
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In order to test the affinity of p33 for antigen-antibody complexes, 
NP-40 lysates of Daudi cells labelled by lactoperoxidase iodination 
were subjected to indirect immunoprécipitation using either non- 
iraraune rabbit serum, or non-crossreacting rabbit antisera to human 
IgD, Bence-Jones lambda, or mouse IgGg^ myeloma protein. The 
results (Pig. 3.3, tracks 11-14) showed that no p33 was precipitated 
in these immunoprecipitates. In contrast, antibody directed against 
Daudi sIgMK (y or «-specific) always precipitated p33 along with the 
y and «-chains (Fig. 3.3, track 5). It was possible to conclude from 
this data that p33 was not a nonspecific component of Daudi immuno­
precipitates. Moreover, the effectiveness of both y and «-specific 
antisera strongly suggested that p33 was an integral part of the sIgM
^2^2 and not a separate antigenically related protein or
fragment,
3.6. EXPRESSION OF p33 RESTRICTED TO DAUDI CELLS
3.6.1. Analysis of Total Surface Proteins from Several Lymphoma Cells
In order to determine whether p33 expression on the cell surface was 
unique to Daudi cells, or if only the association of p33 with Daudi 
sIgM was unique, total surface proteins from several lymphoma cell 
lines were compared.
Cell Surface proteins were labelled by lactoperoxidase iodination 
and isolated from NP-40 cell lysates by precipitation with acetone.
The labelled surface proteins were reduced and analysed by SDS-PAGE 
on Tris-glycine buffered slab gels of 12.5% polyacrylamide.
The SDS-PAGE profiles obtained in one such experiment from BJAB, Daudi,
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and Raji-ATG cells are shown in Fig, 3.3, tracks 1-3. A comparison 
of these profiles with that obtained from immunopr e c ipi ta ted Daudi 
sIgM (track 6) unambiguously identifies the p33 band amongst the total 
surface proteins of Daudi cells. In contrast, the profiles of Raji-
ATG and BJAB surface proteins show no band of equal intensity. This
observation (i.e. lack of p33) has also been extended to the U698M 
and Namalwa cell lines.
3.6.2. Implications of Findings
Several explanations are consistent with the above result:-
(i) p33 is unique to Daudi cells, of those cell lines tested,
(ii) p33 is expressed on the surface of other lymphoid cells
but at much lower levels than on Daudi cells.
(iii) p33 is expressed on the surface of other lymphoid cells
but is only exposed to surface radioiodation on Daudi
cells,
Of course, alternatives (ii) and (iii) are not mutually exclusive. 
However, we know of no evidence to suggest that exposure to surface 
radioiodination is particularly variable, and therefore possibility
(iii) is not considered likely. Further experiments are currently 
underway to prepare anti-p33 antiserum for the purpose of looking in 
a more sensitive way for p33 on the surface of other lymphoid cells.
3.7. INSENSITIVITY OF p33 TO CELLULAR PROTEASES
3.7.1. Rationale for Investigation of Proteolysis
The sensitivity of p33 to cellular proteases was investigated to test
the hypothesis that p33 might be the result of proteolytic cleavage 
of Daudi sIgM y-chains. This hypothesis would be consistent with the 
available data if it was postulated that some of the y -chains within
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the structure were cleaved, but in such a way that the integrity
of the structure itself was undamaged. This would specifically
explain the serological data which showed both' anti-y and anti-K 
antisera to precipitate p33 equally well. In one possible mechanism, 
where the cleavage is postulated to occur at the Daudi y-chain "hinge" 
region, two fragments of approximately p33 size could result. Upon 
reduction and SDS-PAGE analysis, these fragments might be expected 
to coelectrophorese as a broad band of radioactivity identical to the 
p33 band.
The recent findings that -chains of murine sIgD are highly sensitive 
to cleavage by papain (Vitetta & Uhr, 1976; Cambier et al., 1977) 
added impetus to the above hypothesis. Goyert et al. (1977) have 
also demonstrated spontaneous cleavage of human serum IgD. It has 
been postulated (Vitetta & Uhr, 1976) that specific proteolytic 
cleavage of sIgD may have a functional role in antigen-triggered 
lymphocyte activation. Although y-chains are not reported to be 
similarly sensitive,, the possibility that Daudi y-chains were 
exceptional in this respect could not be ruled out a priori.
3.7.2. Experimental Observations and Conclusions 
If Daudi sIgM y-chains were sensitive to proteolytic cleavage 
giving rise to p33, it may be expected that inhibition of proteolysis 
during cell lysis and immunoprécipitation would result in decreased 
detection of the p33 band on SDS-PAGE analysis. Indeed, more 
efficient detection of sIgD in mouse spleenocytes has been reported 
when proteolysis was inhibited by a combination of rapid handling of 
cell lysates of 4°C and the use of the protease inhibitors PMSF and
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iodoacetamide (Abney et al., 1976), In order to test this idea with 
respect to p33, data from several experiments in which iodinated 
Daudi sIgM was isolated under various conditions were compared.
TABLE 3.1. EFFECT OF PROTEOLYSIS ON p33 DETECTION
Experiment Figure
I 3.1(A)
II 3.3, track 6
III
IV 1.3, track 2
Incubation
Conditions
30 min at 4°C
70 min at 20°C 
o/n at 4°C
1.2, track 8 60 min at 20 C
o/n at 4 C
75 min at 20 C 
o/n at 4°C
Protease
Inhibitors
PMSF, IAM
PMSF
PMSF
PMSF
Ratio
P ? J } \ L
*2.7
2.5
2.7
2.4
*Estimated from peak heights
Table 3.1 summarizes the conditions used for the isolation of Daudi sIgM 
in four separate experiments. A visual comparison of the relevant 
figures for each experiment shows that no detectable change in the SDS- 
PAGE profile with regard to p33 resulted from short incubations on ice. 
Moreover, the addition of the protease inhibitors PMSF and iodo- 
acetamide also had no observable effect.
In a more sensitive analysis of these SDS-PAGE profiles, the ratio 
of radioactivity in the y-chains and p33 bands was compared. The 
radioactivity in each band was determined by direct gamma counting, 
and the data are shown in the last column of Table 3.1. In con­
firmation of the visual comparison, the ratio of the counts in the 
y-chain and p33 bands shows no appreciable variation with the 
conditions of isolation employed.
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By analogy to the situation with sIgD, where the sensitivity of the 
6 -chain to proteolytic cleavage results in observable degradation 
during isolation, the above data argue against such a cleavage of 
sIgM being responsible for p33. However, since the above analysis 
applies only to cleavage during cell lysis and immunoprécipitation, 
the possibility of such a cleavage occurring before cell lysis was 
not formally excluded.
3.8. NATURE OF DAUDI sIgM - p33 ASSOCIATION
3.8.1. SDS-PAGE Analysis of Unreduced Daudi sIgM
To further the investigation of p33, it was of interest to determine 
whether its association with Daudi sIgM involved disulfide linkage.
To this end, iodinated Daudi sIgM isolated by immunoprécipitation was 
subjected to SDS-PAGE analysis without prior reduction. To insure 
complete dissociation of non-covalent bonds, the sIgM-containing 
immunopr ecipitate was heated at 100° for 10 min in 2% SDS-6M urea before 
application to the gel. Fig. 3.4(A) shows the SDS-PAGE profile 
obtained on a 3% polyacrylamide-0.5% agarose gel. Two peaks of radio­
activity were detected - a major peak of approximately lOS (Peak I) 
and a minor peak of approximately 6S (Peak II) . The migration of these 
two peaks was consistent with them being sIgM H^L^ and HL molecules 
respectively (Kennel & Lerner, 1973, have previously reported the 
presence of both H^L^ and HL molecules in unreduced sIgM-containing 
immunoprecipitates from the Wil-2 lymphoid cell line). In Fig. 3.4(A) 
no peak corresponding to 33,000 molecular weight was seen, indicating 
that the p33 was migrating covalently bound to either the Daudi sIgM 
H^L^ or HL peak.
Fig. 3.4
SDS-PAGE Profiles of Unreduced Daudi sIgM Demonstrating the 
Presence of Disulphide Bonded p33
(A) Daudi sIqM (Unreduced)
7
Cell surface proteins from 1 x 10 cells were labelled by lacto­
peroxidase iodination (1-125, 0,25 mCi) as described in Methods, 
section 8.2, and the cells lysed in 1 ml NP-40 lysis buffer con­
taining PMSF and iodoacetate (Methods, 8.3). Immunoprécipitation 
from the lysate was carried out by addition of 2 yl anti-IgM 
(15 min at 4°C) followed by 100 yg GARIgG (15 min at 4°C). The 
washed immunoprecipitate was dissolved in 75 y 1 SDS-PAGE sample 
buffer, and half removed for electrophoresis in a phosphate- 
buffered tube gel of 3% polyacrylamide-O.5% agarose (Methods, 12). 
The radioactivity in individual gel slices was determined by gamma 
counting.
(B) Peak I (Reduced)
(C) Peak II (Reduced)
Gel slices 25 and 33 (Peak I and Peak II) shown in (A) were dried 
and rehydrated with SDS-PAGE sample buffer containing 50 mM DTT, 
and incubated in a humid chamber (30 min at 37°C). lodoacetamide 
was then added to a final concentration of 125 mM (30 min at 20°C). 
The gel slices were then placed on top of phosphate-buffered tube 
gels of 6% polyacrylamide and electrophoresed (Methods, 12).
The radioactivity in individual gel slices was determined by gamma 
counting.
Molecular weight markers 195 IgM, 75 IgG, y , y, and light chains 
were electrophoresed in separate tube gels.
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3.8,2, SDS-PAGE of Reduced Daudi sIgM and HL Peaks
To confirm the presence of p33 in these peaks, the following 
experiment was performed. The slices of the gel shown in Fig, 3.4(A) 
corresponding to each of the two peaks (Nos, 25 and 33) were saved 
and the labelled material reduced and alkylated in situ. The slices 
were then placed on top of cylindrical gels of 6% polyacrylamide and 
electrophoresed. Figs, 3,4 . (B) and (C) show the results of the 
electrophoresis of reduced material from peaks I and II respectively. 
Peak I appears to be composed of p-chain, p33, and K-chain in approx­
imately the same proportions as seen in the fully reduced immuno- 
precipitate. This result confirmed that disulfide linkage was involved 
in the association of p33 with Daudi sIgM molecules. Peak II
also appears to be composed of y-chain, p33, and K-chain, suggesting 
that this peak represents a complex of Daudi HL plus p33. However, 
from this data it was not possible to characterise peak II with 
certainty.
3,9, MOLECULAR WEIGHT OF DAUDI sIgM-p33 COMPLEX; STOICHIOMETRY 
OF p33 BINDING
3,9,1. Rationale for Investigation of Molecular Weight 
Previous results had established that p33 was covalently associated 
with Daudi sIgM HgL^, and also probably HL molecules, on the cell 
surface. If p33 was an additional component of these sIgM molecules 
(and not, for instance, a fragment of y-chain), it would be expected 
to confer a higher molecular weight on the unreduced Daudi sIgM, and 
thus a slower SDS-PAGE mobility. Moreover, the extent of difference 
in apparent molecular weight between Daudi sIgM and other cell sIgMs 
would indicate the stoichiometry of p33 binding.
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3.9.2. 5DS-PAGE Analysis
To determine the apparent molecular weight of Daudi sIgM molecules in 
comparison with those of other cell lines, continuous phosphate 
buffered SDS-PAGE analysis was performed on the unreduced sig molecules 
of cell lines Bec-11 (sIgG), BJAB (sIgM), U598M (sIgM), and Daudi (sIgM), 
Electrophoresis was carried out on a slab gel for accurate comparison 
of the bands; and polymerised BSA was used to provide molecular weight
calibration in the desired range of 200,000 to 300,000 daltons.
The results of this SDS-PAGE analysis are shown in Fig. 3.5. The 
sIgM of cell lines BJAB, and U698M migrates as two distinct bands, 
suggesting and HL structures respectively. Significantly, the
corresponding Daudi molecules migrate with higher apparent molecular 
weights, which was consistent with an additional contribution to 
Daudi sIgM by covalently associated p33. This result was also seen 
in a similar SDS-PAGE analysis where the mobility of Daudi sIgM was 
compared with that of BJAB sIgM (data not shown).
3.9.3. Semi-Log Plot for Molecular Weight Determination 
Molecular weight estimations for the sIgM molecules have been obtained 
from a semi-log plot of molecular weight versus migration, using the 
polymerised BSA as a standard (Fig. 3.6 ). BJAB and U698M ^2^2 ^L
molecules have apparent molecular weights of 260,000 and 142,000 
respectively. These values are in close agreement with those reported 
by Kennel & Lerner (1973) for Wil-2 lymphoid cell sIgM.
In contrast to the above values, the Daudi sIgM molecules have apparent
molecular weights of 292,000 and 165,000. These values represent an 
increase in molecular weight over the normal (BJAB and U698M) ^2^2
Fig. 3.5
SDS-PAGE Mobilities of the Daudi y^K^-p33 Complex and Other 
Cell Surface PgKg Molecules
7
Cell surface proteins from 2 x 10 cells were labelled by lacto- 
peroxidase iodination (I-131> 1 mCi) as described in Methods, 
section 8.2, and the cells lysed in 0.5 ml NP-40 lysis buffer con­
taining PMSF (Methods, 8.3). Immunoprécipitations were carried 
out by addition of 10 pg RAHIgM to 40% of each lysate, or 10 yg 
RAHIgG to 40% of the Bec-11 lysate (15 min at 20°C) followed by 
50 yg GARIgG (1 hr at 20°C, overnight at 4°C). Washed immuno- 
precipitates were dissolved in 9 M urea and aliquots (one-eighth) 
precipitated with acetone and redissolved in SDS-PAGE sample buffer 
for electrophoresis in a phosphate-buffered 5% polyacrylamide slab 
gel (Methods, 12). The gel was stained in a solution of 0,1% w/v 
Coomassie Blue Dye in methanol:water : acetic acid (45:45:10), 
processed for autoradiography (Methods, 17.3), and the autoradio­
gram developed after an exposure of 8 days. The marker proteins 
(poly BSA) were a kind gift from Dr. Keith Whaley, Pathology, 
Western Infirmary, Glasgow,
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Fig. 3.6
Semi Log Plot for Molecular Weight Determination of Cell Surface
^2 ^ 2  and Moieties
The SDS-PAGE mobilities of the poly BSA marker proteins from 
Fig. 3.5 are plotted versus their molecular weights (BSA=67,000) 
on a log scale. The arrows indicate the mobilities and cor­
responding molecular weights of the unreduced surface Ig moieties, 
as determined from this plot.
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HL molecules of 32,000 and 23,000 respectively. This data can serve 
as a basis for determining the stoichiometry of p33 binding, with the 
following assumptions :
(i) p33 is the only additional component of the Daudi
H^Lg and HL molecules.
(ii) The molecular weight contribution of p33 to the H^L^ 
and HL molecules is equal, within experimental error, 
to its own molecular weight of 33,000.
(iii) The molecular weight difference contributed to the
complexes by differences in ]X and K-chains mobilities 
is insignificant compared with that contributed by 
p33. In this regard, it should be noted that Daudi 
y and K-chains are of slightly higher apparent 
molecular weight than those from BJAB and U698M cells 
(chapter 1, Sections 1.3,4 & 1,3.6)
3.9.4, Interpretation of Results
Based on the above assumptions the data are consistent with a sto­
ichiometry of one p33 molecule associated with both the Daudi ^2^2 
and HL bands. In the case of the HL band the calculated variance 
of 23,000, rather than the expected value of 33,000, can be attributed 
to inaccuracy in molecular weight determination. Other features of 
this result require comment, however. If the HL band seen on SDS- 
PAGE analysis arose from cleavage of H2L2, then the above interpretation 
would also predict the presence of an HL band without p33. There is 
no such band apparent in Fig. 3,5, although the expected low radio­
activity in this band (due to the absence of highly labelled p33) may 
be below the limit of autoradiographic detection in this experiment.
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If, on the other hand, HL-p33 exists independently on the Daudi cell 
surface, no further explanation is required for the absence of an HL 
band. The presence of HL bands in unreduced sIgM has been reported 
previously (Kennel & Lerner, 1973), although it is not known whether 
the HL molecules exist on the cell surface or are merely artefacts 
o:^  isolation.
An alternative interpretation of the data presented in Pigs. 3.5 and 
3.6 is possible if assumption (ii) above is incorrect. Thus, if 
one p33 molecule does not contribute 33,000 daltons to the H^L^ and 
HL apparent molecular weights, the data are consistent with two p33 
molecules associated with the H2L2 and one with the HL. This possibility 
can be envisaged as follows. Due to constraints on the conformation 
of the HL complex caused by disulfide bonding of the chains, the 
addition of p33 causes a non-linear increase in the apparent mole­
cular weight of the complex. Thus, the molecular weight contribution 
of p33 to the HL-p33 complex could be only 23,000 daltons. The same 
situation would apply to the H2L2 complex but because it is more 
constrained by disulfide bonding the effect would be greater. Thus, 
two p33 molecules could add only 32,000 daltons to the H2L2 molecular 
weight. This hypothesis is supported by the non-linear relationship 
of the apparent molecular weights of the normal HL and H2L2 moieties - 
the H2L2 being less than twice the apparent molecular weight of the HL,
The above interpretations could be resolved by a further SDS-PAGE of 
unreduced Daudi sIgM; after which the H2L2 and HL bands are sliced 
out of the gel, reduced and re-electrophoresed. The radioactivity 
in the y and p33 bands from this second gel could then be determined 
by direct gamma counting. If there is one p33 in both the H2L2 and HL
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moieties {first interpretation), then the p33:y ratio in the HL band 
should be twice that in the H^L^ band. If, however, there is one p33 
in the HL moiety and two in the H^L^, then the ratios should be 
identical. This experiment is presently in progress.
3,10. ISOELECTRIC FOCUSING SPECTRUM AND CYSTEINE CONTENT OF p33
3.10.1. Charge-Shift Titration Experiment
Because of the discovery of its disulphide linkage to Daudi sIgM, it 
was of interest to determine the cysteine content of p33. It has been 
shown (Feinstein, 1966; Stott & Feinstein, 1973) that this determination 
can be done on a micro scale using the method of charge-shift titration 
on isoelectric focusing gels. It was felt that this technique could be 
adapted to the analysis of p33, and would be a useful way of further 
characterising the molecule. Accordingly, the following experiment 
was performed.
Daudi sIgM was labelled by lactoperoxidase iodination, isolated by 
immunoprécipitation, reduced but not alkylated, and analysed by SDS- 
PAGE on a Tris-glycine buffered slab gel. The profile obtained was 
identical to that shown in Fig. 3.3, track 6. The p33 band was then 
sliced out of the gel and eluted in the reduced form in buffer con­
taining DTT and SDS. The material was then either amidomethylated or 
carboxymethylated as indicated in the legend to Fig. 3.7, and focused 
in thin polyacrylamide slab gels. Amidomethylated cysteines add no 
net charge, whereas carboxymethylated cysteines each add exactly 
one negative charge to the p33 protein. On isoelectric focusing, 
each negative charge added shifts the focusing spectrum one 'step' 
towards the anode. By counting the number of steps of shift, the
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number of cysteines in the p33 protein could be directly read off.
For the purpose of measuring the steps, a 'ladder' is generated.
That is, all the intermediate steps of charge shift are produced by 
using mixtures of the carboxy- and amidomethylating agents. The 
results of the isoelectric focusing (Fig, 3.7) show p33 to contain three 
cysteine residues, as determined by the three 'steps' between homo­
logous bands (indicated by the arrows) of the amidomethylated and car­
boxymethylated species. This result also rules out the hypothesis 
that p33 is a fragment of immunoglobulin or any Ig-like molecule, 
because an Ig-like molecule the size of p33 would necessarily contain 
two full domains and therefore at least four cysteines. Homology 
does exist, however, between p33 and one other known lymphocyte surface 
antigen. Thus, the heavy chain of human la antigen (p34) has also 
been shown to contain three cysteine residues (Snary et al., 1976; 
Springer et al., 1976), The possibility of a connection between p33 
and human la-antigens will be discussed later.
3.10.2. Isoelectric Focusing Spectrum
The isoelectric spectrum of amidomethylated p33 consists of a regular 
pattern of five bands ranging in isoelectric points from 6.6 to 5.6.
This spectrotype is consistent with the pattern of post-translational 
microheterogeneity resulting either from loss of amides from asparagine 
or glutamine side chains or the presence of variable numbers of sialic 
acid residues. Two observations favour the amide-loss hypothesis: i) 
The single charge steps introduced by carboxymethylation correspond 
exactly with the steps in the spectrotype of amidomethylated p33, 
showing that charge groups of a similar pK are involved and ii) the 
single charge steps between adjacent components diminish from 0.3 pH
Fig. 3.7
Isoelectric Focusing Spectrum and Charge-Shift Analysis of p33
Labelled Daudi cell surface IgM was prepared as described in the 
legend to Fig. 3.3 and dissolved in reducing sample buffer for 
discontinuous SDS-PAGE in a 12,5% polyacrylamide slab gel (Methods, 11). 
The gel was processed for fluorography (Methods 17.4) and the 
fluorograra developed after an exposure of 8 hr. A profile indis­
tinguishable from that shown in Fig. 3.3 (Daudi anti-y) was 
obtained. The fluorogram was placed over the dried gel, aligned 
carefully, and the area of gel underlying the p33 band sliced out. 
(Methods, 15.1). Labelled p33 was eluted from the slice under 
reducing conditions (Methods 15.2) and the total recovered sample 
(29,000 counts/min p33, 50 yg carrier NoRIgG) divided into five 
tubes containing iodoacetamide and iodoacetate to yield the follow­
ing final concentrations:
Iodoacetamide (mM)
1
50
2
45
2
35
1
20
2
*0
Iodoacetate (mM) 0 5 15 30 50
Alkylation was carried out for 30 min at 20°C, and the samples 
were then prepared for isoelectric focusing by repeated acetone pre­
cipitation and dissolution in 9 M urea (Methods, 15.4). Iso­
electric focusing in a thin-layer 7.5% polyacrylamide slab gel 
was as described in Methods, section 14, using pH 3.5-10 Ampholine 
carrier ampholytes. The gel was processed for fluorography 
(Methods 17.4) and the fluorogram developed after an exposure of 
6 days.
— 204 —
w
5.0-
5.5-
■4—
6.0“
c«
1
c5 6.5-
XQ.
7.0“
(-)
1/2 3
100% cys-CH^CONH^
100% çys-CH^COO
#  # * e
-205-
units between the two most basic components to 0.15 pH units between 
the two most acidic components ; the charge groups contributing to the 
microheterogeneity of p33 are thus being titrated over the same pH 
range as the carboxyraethyl groups, as would be expected for aspartic or 
glutamic acid side chains but contrary to expectation for sialic acid 
carboxyl groups. The extensive microheterogeneity seen in the p33 
spectrum is consistent with this protein being a long-lived surface 
protein and with the fact that both old and new molecules would be 
labelled by surface iodination.
3.11. ^DISCUSSION
The results described in this section have identified and partially 
characterised a surface polypeptide chain of 33,000 molecular weight 
(p33) which is in a unique covalent association with the sIgM of 
Daudi cells. Earlier results from other laboratories had also 
suggested the presence of this component, and one specific report 
claimed it to be an abnormally large L-chain (Kennel, 1974). The 
present investigation has clarified these earlier observations. The 
cysteine content, size, radioiodination characteristics, SDS-PAGE 
behaviour, and molecular weight contribution of p33 to the Daudi 
^2^2 sIgM all argue that p33 is distinct from any Ig L-chain, H-chain 
or fragment. In addition, the actual Daudi K-chain has been resolved 
and characterised in its mature, carbohydrate-free, and precursor 
forms, and it appears to be normal.
The earlier findings of Kennel (1974) indicated that the p33 component 
could be labelled with radioactive galactose. Thus, p33 is a glyco­
protein. The observation in the studies described here, that p33
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appears as a diffuse band on discontinuous SDS-PAGE, suggests a hetero­
geneous nature of the p33 carbohydrate moieties. Microanalytical 
methods which can give a rough indication of the extent of polypeptide 
chain glycosylation (i.e. SDS-PAGE comparison of cell-free precursors 
and mature cellular products) can in theory be applied to the analysis 
of p33. However, this approach depends on the availability of a 
specific antiserum which will react both with the cellular and in vitro 
synthesised p33 polypeptide.
Other microanalytical techniques, which require only that the surface 
iodinated complex (p33-sIgM) be isolated and resolved into its poly­
peptide chain components, have been used to determine the cysteine 
content of the p33. The results indicated the presence of three 
cysteine residues, consistent with an intrachain disulphide loop and 
a single disulphide linkage to the sIgM. This particular configuration 
of disulphide linkages has not been demonstrated, however. The attach­
ment of p33 to the sIgM of Daudi cells is most likely to a y-chain, 
since y-chains have been shown to have two free -SH groups when in 
intracellular subunits (Stott & Feinstein, 1973) whereas L-chains
normally have no free -SH groups. Cysteine 575, which normally forms 
an intrasubunit disulphide bond, and cysteine 414 which forms the 
inter subunit bond in 198 IgM, are likely sites of p33 attachment.
It cannot be stated with certainty whether one br two p33 molecules 
are associated with Daudi cell surface arguments for both
interpretations of the data have been presented. Thus, although the 
measured molecular weight contribution of p33 to the Daudi y^L^ 
suggests the presence of only one p33 chain, caution may be necessary 
in interpreting molecular weights determined for covalently associated 
glycoproteins by SDS-PAGE.
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It is tempting to consider the possibility that p33 is related to a 
Daudi la antigen heavy chain. The la antigens of human lymphocytes 
are composed of two polypeptide chains of molecular weights 33,000 and 
28,000 linked non-covalently as a dimer (Snary et al., 1976; Springer 
et al., 1976). Thus, Daudi p33 is of similar molecular weight to 
la antigen heavy chain. In addition, the two polypeptides are both 
glycoproteins, they have the same number of cysteine residues, and 
they share similar isoelectric properties. With regard to this latter 
point, human la antigen heavy chain (carboxymethylated) has been 
characterised by isoelectric focusing as a poorly defined streak with 
its centre at about pH 5,1 (Springer et al., 1976). Another report 
describes a focusing spectrum for human la antigen heavy chain which 
resolves into 4 spots. Similarly, the results described in this section 
show p33 to resolve into 4 or 5 components, of pi 5.3 - 5.8.
Recent serological and functional evidence lends strong support to the 
idea that p33 may be a Daudi la antigen heavy chain. A xenogeneic 
antiserum raised against Daudi cell membranes and absorbed extensively 
with T-cells and EB^ cells (a B-lymphoma cell line which fails to 
stimulate in mixed lymphocyte reaction (MLR)) has been found to block 
MLR stimulation at a dilution of 1:1000 (Steele, M., personal communic­
ation) . The implication of this finding is that the antiserum has 
activity against Daudi la antigens. This antiserum was further 
absorbed with human IgM and whole human serum, in our laboratory, and 
then used to immunoprecipitate surface iodinated proteins from cell 
lysates of a number of sIgM synthesising lymphoma cell lines. It was 
found that only the Daudi cell lysate showed reactivity. Moreover, 
when the Daudi immunoprecipitate was analysed by SDS-PAGE, it was 
shown to consist of h, K, and p33 bands (Cushley, Singer & Williamson, 
unpublished).
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The absence of p33 attached to the surface immunoglobulin of other 
Burkitt lymphoma cells rules out the idea that the complex is character­
istic of the Burkitt lymphoma syndrome. It is possible that the 
p33-IgM complex on Daudi is related to some other unique feature of 
Daudi cells. Daudi cells are unusual in their failure to express 
products of the HL-A A, B and C loci (Fellous et al., 1975). This 
lack of expression has been attributed to a defect in the production 
by Daudi cells of B2 microglobulin (Evrin & Nilsson, 1974) which is 
normally found associated with the products of the HL-A A, B and C 
loci. This suggests the hypothesis that the expression of the heavy 
chain of la antigen is normally linked in a balanced way with the 
expression of the light chain of la antigen, and that in Daudi cells 
an imbalance has arisen. Thus the p33 chain found linked to IgM on 
Daudi cells may represent an excess production of the Daudi la heavy 
chain relative to the light chain, leaving the excess heavy chain free 
to interact with the surface IgM.
Several speculations are possible as to the functional significance 
to the p33-IgM interaction. The significance of each possibility is 
enhanced if p33 is the heavy chain of a Daudi la antigen. One possibil­
ity is that the p33-IgM complex is characteristic of a particular 
stage of the differentiation of human lymphocytes. An alternative 
possibility is that the interaction of Daudi p33 with IgM is a unique 
function of the particular alloantigenic form of p33 existing on 
Daudi cells, and possibly of the particular antibody specificity of 
Daudi IgM. A third possibility is that the Daudi p33-IgM complex 
is indicative that a functional complex of similar nature plays a 
part elsewhere in antibody formation.
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Viewing these functional possibilities in the light of the hypothesis 
that p33 is the heavy chain of Daudi la antigen suggests functional 
complementarity between the la heavy chains and a specific constant 
region domain of immunoglobulin, or alternatively, the complementarity 
may be between la heavy chain and a variable region domain of immuno­
globulin. In either case the function of the interaction may be 
related to the role of I-region products in restricting cell-cell 
interactions in immune responses and in regulating responsiveness 
to particular antigens. Functional interaction between la heavy chain 
and immunoglobulin may normally occur not on the lymphocyte surface 
but on the surface of another cell type, possibly the macrophage, or in 
cell-cell interaction.
Further studies of the nature and function of p33 on Daudi cells and 
on the possibility of similar interactions occurring elsewhere should 
help differentiate between the various possibilities discussed above.
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